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Abstract  
DNA methylation or 5-methylcytosine (5mC) is an important epigenetic mark integral to 
appropriate genomic imprinting, X chromosome inactivation and in the silencing of 
developmentally important genes. There remains to be a lot unknown about how DNA 
methylation is programmed and reprogrammed once lost particulary in early mammalian 
development. In untransformed hTERTs and in mouse embryonic stem cells (mESCs) we were 
able to investigate how methylation can or cannot be recovered following the removal and 
reintroduction of key methyltransferases, by using a range of wet-lab and bioinformatic 
approaches to assay methylation at individual CpG sites. Indeed, this thesis has shown that 
methylation, once lost is able to be recovered in nearly all of the known and putative imprints 
assayed in the mESCs through rescue with DNMT3A2. Not only does the de novo 
methyltransferase-3a assist with the recovery of methylation but it also plays a role in 
maintenance methylation.  
A reduction of methylation through a stable loss of DNMT1 in the hTERTs however 
highlighted enriched groups of hypomethylated genes such as the Cancer Testis Antigen (CTA) 
genes and the Protocadherins (PCDH) that are sentistive to this loss, and in some instances 
associated with polycomb marks. Interestingly a transient loss of methylation however in the 
same system with pharmacological 5-aza-2dC (Aza) showed not only widespread methylation, 
but also some gains of methylation at selected loci such as the the GPCRs known to act as 
oncogenes and tumour supressors. In conclusion, through examining the effects of the loss of 
DNA methylation in both human and mouse model systems, this thesis has successfully 
identified gene classes sensitive to a transient and stable loss of DNA methylation and 
identified where this methylation can be recovered.  
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General Introduction  
DNA methylation  
DNA methylation involves the transfer of a methyl group from 5-adenosylmethionine to the 
5’carbon of a cytosine residue within CpG dinucleotides, converting it to 5- methylcytosine 
(5mC) (Gibney and Nolan, 2010). DNA methylation is essential for differentiation and normal 
development, due to its effects on long-term stable gene repression (Cedar and Bergman, 2009, 
Lindroth et al., 2001). 5mC is the most prevalent covalent epigenetic mechanism of genomic 
DNA in eukaryotic cells and it is responsible for tightly regulating gene expression (Zingg and 
Jones, 1997) especially in CG dense regions i.e. at CpG dinucleotides. Stirzaker et al (2014) 
suggests that there are close to 28 million CpG dinucleotides in the human genome. These 
CpGs are not distributed evenly throughout the mammalian genome; they cluster in fact as 
CpG Islands (CGI). Housekeeping genes usually have CGI present at their promoter regions 
(Zhu et al., 2008) that remain unmethylated and are often associated with active gene 
expression, particularly in development (Messerschmidt et al., 2014). Conversely, methylated 
CGI located at promoters of such genes are associated with gene repression (Jeziorska et al., 
2017). DNA methylation is present at not only CGI but across less dense regions of CG such 
as intragenic regions and gene bodies themselves. Unlike CGI promoters, methylation at these 
regions is usually associated with active gene expression. 
It is thought that 5mC DNA methylation is the form of methylation transmitted inter-
generationally. The DNA methyltransferase (DNMT) family of enzymes are responsible for 
the maintenance of this methylation, which can in turn be removed in both an active and passive 
manner (Gibney and Nolan, 2010). 
5mC is a widely documented mechanism for transcriptional silencing, important for the 
regulation of germline-specific genes, imprinted genes, of DNA repeat elements and genes on 
the inactive X chromosome (Smith & Meissner, 2013). Exactly how DNA methylation changes 
as cells differentiate (Meissner, 2011), and its co-operative action with other chromatin 
modifiers remains unclear. 
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Main functions of DNA methylation  
DNA methylation is one of the predominant epigenetic players in the regulation of gene 
expression, doing so without causing any changes to the underlying DNA sequence. DNA 
methylation is an essential control mechanism particularly during mammalian embryonic 
development helping to direct cells towards their future lineages (Messerschmidt et al., 2014). 
Acting as an epigenetic barrier DNA methylation can also restrict differentiation (and reversal 
to an undifferentiated state) as originally postulated by Riggs (1975) and Holliday & Pugh 
(1975). This epigenetic regulator also plays an essential role in sex chromosome dosage 
compensation, protection against selfish elements such as transposons, and the appropriate 
expression of the imprints (Subramaniam et al., 2014). Methylation of DNA is catalysed by the 
DNA methyltransferase enzymes through the attachment of a –CH3 group that has been donated 
by SAM (S-adenosyl methionine) to the 5' position of a cytosine base (preceding a guanine) at 
CG dinucleotides helping to ensure the faithful propagation of DNA methylation patterns 
between mitotic cellular divisions.  Four DNA methyltransferases have been identified so far- 
the maintenance methyltransferase DNMT1 and the de novo methyltransferases, DNMT3A, 
DNMT3B and DNMT3C, as well as the catalytically inactive cofactor DNMT3L (Hata et al., 
2002; Kaneda et al., 2004). 
 
CpG islands - protection from DNA methylation 
In mammalian genomes DNA methylation is frequently found at CG dinucleotides or CpGs 
where Cytosine (C) is followed by Guanine (G) with an intermediary phosphate (denoted by 
the 'p,' Ziller et al., 2011). The current human genome assembly (hg38) has ~3 × 107 CpG 
dinucleotides (Edwards et al., 2017). CGI are dense clusters of CG dinucleotides found at 70% 
of gene promoters- (namely of housekeeping genes and those important for development) 
(Saxonov et al., 2006), they are generally GC-rich in nature (50% or higher) and are 1000bp in 
length. CGI encompass 1% of the human genome (Ehrlich et al., 1982). 
These CGI frequently have unmethylated cytosines unlike the bulk of chromosomal DNA, and 
as such have a level of protection against epigenetic reprogramming. This is in part due to 
interaction with histones and a range of transcription factors including CTCF (CCCTC-binding 
factor). The CGI are responsible for regulating and initiating transcription through the selective 
binding of transcription factors that affect the chromatin structure and ultimately influence the 
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genomic structure where they are localised to further regulate gene activity (Deaton and Bird, 
2011). A class of CGI promoters have unique protection from de novo methylation by 
FBXL10- bound by the polycomb repressive complexes PRC1 and -2 (Boulard et al., 2015). 
Originally there was thought to be little homology between the number of CGIs between mouse 
and human, with the mouse genome considered to have fewer CGI (Gardiner-Garden and 
Frommer, 1987). The additional 'orphan' CGI in the human genome however frequently occupy 
additional intergenic and intragenic regions (Smith and Meissner, 2013; Deaton and Bird, 
2011). 
Methylated cytosines can be found outside of the CGI in areas called shores, shelves, open sea, 
UTR and gene bodies. Shores are usually depicted as the region from 0kb to2kb away from 
CGI (Figure 1), shelves from 2-4kb away from the CGI and open sea (Sandoval et al., 2011) 
are outside these dimensions usually with isolated CpGs (Rechache et al., 2012). 
 
Figure 1. Distribution of CpG dinucleotide methylation and the effect on regulation across the 
genomes of both healthy and cancerous cells.  A) In a healthy cell when the CGI shore and promoter 
are unmethylated (as represented by the empty circles) there is transcription, and the converse is true 
when the promoter is methylated (depicted by black filled circles). However, in a cancerous cell B) 
hypermethylation of the CGI leads to aberrant gene silencing, inappropriate gene expression and the 
silencing of enhancer elements. Adapted and redrawn from Stirzaker et al (2014). Copyright Clearance 
Centre license number 4270160962178. 
 
 
15 
 
 
 
 
Additional cytosine modifications  
As well as 5mC, there is an additional cytosine modification called 5-hydroxymethylcytosine 
(5hmC). 5hmC is the first oxidative product generated when 5mC undergoes active 
demethylation (Kohli and Zhang, 2013), and it was first discovered in 1952 by Wyatt & Cohen 
in a T-even bacteriophage (Wyatt & Cohen, 1952) before discovery in mammalian DNA in 
1972 (Penn et al.,). This base was also rediscovered in extracts from brain tissue, where it is 
most abundant (Tahiliani et al., 2009). More robust experimental validation however was 
achieved in recent experiments in mouse embryonic stem cells (mESCs) (Tahiliani et al., 
2009), demonstrated that 5hmC is an intermediate in the demethylation of 5mC (Tahiliani et 
al., 2009), supported by low levels in the mESC genome at around 10% 5mC and 0.4% of all 
the cytosine residues (Branco et al., 2011).  
 
Non-cytosine methylation 
Methylated cytosines are not only found at CpG dinucleotides, but can also be found at CpA, 
-T and -C sites in the human genome inclusive of repetitive sequences and gene bodies. This 
non-CpG methylation was originally documented in the plant genome (Lindroth et al., 2001). 
Non-cytosine methylation is enriched in particular cell types in the human genome such as the 
oocytes (Guo et al., 2014), neurons (Lister et al., 2013) and pluripotent stem cells (Lister et al., 
2011). CpH (H= A/C/T nucleotides) methylation is crucial for both cellular differentiation and 
development and in adult somatic cells, whilst only accounting for 0.02% of the overall 5mCs 
(Jang et al., 2017). 
The mechanisms of non-CpG methylation are still poorly understood but it is widely accepted 
that this form of methylation is catalysed by the de novo methyltransferases DNMT3A and -
3B. However, both the maintenance methyltransferase DNMT1 and the de novo 
methyltransferase DNMT3A and -3B have been shown in vitro to actively methylate non-CpG 
dinucleotides.  CpH methylation is established in a de novo manner and DNMT3A is thought 
to play a role in the maintenance of these CpH methylation patterns however the exact 
mechanisms responsible are still poorly elucidated (Jang et al., 2017). 
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Maintenance methylation- DNMT1 
The heritability of DNA methylation patterns provides an epigenetic marking of the genome 
that is stable through multiple cell divisions. Originally discovered in 1988 by Bestor and 
colleagues (Bestor et al., 1988), through cloning and sequencing the cDNA encoding DNMT1 
in mouse cells, DNMT1 was reported to have a strong resemblance to the bacterial cytosine 
methyltransferase, in particular the catalytic and DNA binding domain. These regions are 
highly conserved between human and mouse, with 80% homology between proteins in the 
mammals (Yen et al., 1992).  
DNMT1 was the first mammalian DNA methyltransferase identified to faithfully maintain and 
propagate DNA methylation marks to daughter strands post-replication (Chuang et al., 1997). 
The DNA methylation marks were originally set during embryonic development by the de novo 
methyltransferase 3A and 3B. The maintenance methyltransferase DNMT1 therefore drives a 
mechanism that is responsible for securing a stable epigenetic marking of the genome and in 
doing so creating a cellular memory that is stable through multiple divisions. Incorrect 
maintenance of DNA methylation has serious implications for the imprints especially (biallelic 
expression of imprints), X-inactivation on both copies of the X chromosome and activation of 
selfish elements (Walsh et al., 1998). 
The expression of Dnmt1 is known to be activated by cell cycle dependent transcription factors 
in the 'S phase' of cell division and as such it is highly expressed in mitotic cells (Kishikawa et 
al., 2003).  DNMT1 is located close to the replication foci (Leonhardt et al., 1992), attracted 
by its PCNA (Proliferating Cell Nuclear Antigen) binding partner NP95 (Messerschmidt et al., 
2014) where it preferentially binds to hemi methylated DNA as shown later in 1997 (Yoder et 
al.,) where it restores methylation (Leonhardt et al., 1992). NP95 has been shown to specifically 
direct DNMT1 to the parental, methylated strand, where DNMT1 is orientated in such a way 
that its activity is directed towards the newly synthesised unmethylated daughter strand (Sharif 
et al., 2007). 
In mice, Dnmt1-/- is embryonically lethal and as such the null embryos fail to survive post 
gastrulation due to the consequences of global hypomethylation (Yoder et al., 1997; Arand et 
al., 2012) and die from e9.5 (Li et al., 2004). However, in mESCS such a deletion of Dnmt1 
causes a widespread hypomethylation but not comparable to the low levels observed in the null 
embryos. Interestingly, the proliferation and morphology in the mESCs shows negligible 
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changes, however there is an impaired functionality with respect to differentiation and such 
cells were observed to undergo apoptosis (Jackson-Grusby et al., 2001) including cells in 
tissues such as the brain (Chen et al., 1998). 
 
Maintenance methyltransferase- UHRF1 
DNA methylation is a fundamental epigenetic mark essential for the propagation of 
methylation marks through each round of cell division from parent to daughter strand, in doing 
so it is important in the epigenetic regulation of gene expression. The ubiquitin ligase 
multidomain protein UHFR1 (ubiquitin-like, containing PHD and RING finger domains) is an 
essential accessory protein for this process (Hashimoto et al., 2008).  
In mammals, UHRF1 has been shown to be essential for maintaining DNA methylation as 
homozygous deletions phenocopied DNMT1 mutations (Sharif et al., 2007; Bostick et al., 
2007). UHRF1 recruits DNMT1 to hemimethylated replication forks (Bostick et al., 2007) 
through its ability to recognise and cooperatively bind hemi methylated CpGs (and 
H3K9me2/3) on newly synthesised DNA daughter strands via its SET and RING (SRA) 
associated domain- a methyl binding domain (Avvakumov et al., 2008; Hashimoto et al., 2008; 
Lallous et al., 2011). In doing so, UHRF1 can increase DNMT1's activity by ~5 fold 
(Bashtrykov et al., 2014). 
UHRF1 has additional domains which offer additional functionality, the tandem tudor domain 
(TTD) recognises H3K9me3, and unmethylated H3K4 (Nady et al., 2011; Avvakumov et al., 
2008). UHRF1 co-localises with DNMT1 during the synthesis phase of the cell cycle (Liu et 
al., 2013) and is involved in the formation of closed conformation heterochromatin, facilitated 
by binding to H3K9me3. This interaction is also important for DNA methylation, Rothbart et 
al. (2012) showed that a H3K9me3 defective UHRF1 mutant was incapable of restoring 
methylation levels in UHRF1 knock down (KD) cells. A further domain- the plant 
homeodomain (PHD) of UHRF1 binds H3 tails that are unmodified at residue arginine 2 
(H3R2). The PHD domain has been shown to assist in the reorganisation of pericentromeric 
heterochromatin in DNA replication (Papait et al., 2008).   
UHRF1 is capable of binding both the H3R2 and H3K9me3 of one H3 tail simultaneously 
through its PHD domain via the PHD TTD respectively (Xie et al., 2012; Arita et al., 2012). 
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This coordinated recognition of H3R3 and H3K9me3 is required for DNA methylation 
maintenance (Rothbart et al., 2012). 
A further domain belonging to UHRF1 is the RING (really interesting new gene) domain, 
responsible for the E3 ubiquitin ligase activity that ubiquitinates both histones and DNMT1; 
therefore, helping to regulate the chromatin structure and stability of DNMT1 (Citterio et al., 
2004). 
UHRF1 can also be localised to euchromatin, where it is responsible for the regulation of gene 
expression, notably TSGs (tumour suppressor genes) such as BRCA1. The effects on 
methylation of UHRF1 deficient cells is similar to that of DNMT1 knockout in mice and mESC 
cells (Li et al., 1992) whereby global hypomethylation is observed. In Uhrf1-/-  ESCs major and 
minor satellite repeats in addition to Intracisternal Alpha Particles (IAP) elements were most 
demethylated in comparison to other genomic elements (Bostick et al., 2007). Sharif et al 
(2007) also showed how the effects of hypomethylation in Uhrf1-/- ESCs affected ICRs 
including Igf2-H19m and Dlk1-Gtl2. 
 
The association of USP7 with UHRF1 and DNMT1  
USP7 (ubiquitin specific peptidase 7) is a de-ubiquitinating enzyme (Qin et al., 2011) that acts 
as a regulator for the DNMT1 dependent methylation at hemimethylated DNA sites by actively 
stimulating the enzymatic activity of the DNMT1 and USP7 complex (Felle et al., 2011). The 
UHRF1 protein directs the dimeric complex to sites of methylation, and in doing so forms a 
trimeric complex in conjunction with chromatin. USP7 is therefore acknowledged as playing 
the role of the middle man between UHRF1 and DNMT1, regulating their interaction and 
maintaining the stability of DNMT1 by its deubiquitination (Qin et al., 2011). This regulation 
is possible due to two domains on USP7; the C-terminal and the DRAF domain which interact 
with their corresponding domains of UHRF1, capable of stimulating both the de novo and 
maintenance methylation properties of DNMT1 both in vivo and in vitro (Felle et al., 2011). 
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De novo methyltransferases – DNMT3A and DNMT3B  
In the early 2000s, Dnmt1 had still not been proven to initiate de novo methylation in vivo 
despite showing activity in vitro (Chen et al., 2003). Yet in contrast, Dnmt3a and Dnmt3b had 
been shown to be essential for the de novo methylation where they are strongly expressed in 
ESCs, early/post implantation embryos, developing germ cells (and imprints of) (Okano et al., 
1999) but conversely Dnmt3a and -3b are both expressed at low levels in differentiated somatic 
cells (Chen et al., 2003). Studies of Dnmt3a and -3b inactivation in ESCs provided also 
evidence that these genes encode the proteins needed to de novo methylate proviral genomes 
and repetitive elements (Okano et al., 1999). 
Dnmt3a loss of function (LOF) phenotypes usually present with postnatal lethality between 4-
6 weeks and a failure to establish the methylation pattern of imprints in male and female germ 
cells (Li et al., 2004). A Dnmt3b LOF phenotype however causes embryonic lethality at e14.5 
due to vascular and liver complications, in addition there is demethylation of minor satellite 
DNA. For those null embryos that lack both Dnmt3a and -3b, de novo methylation is not 
initiated after implantation and consequently the deficient embryos die at e9.5 (Li et al., 2004). 
Dnmt3a and 3-b have also been shown to play a role in the maintenance of DNA methylation 
patterns (Chen et al., 2003). 
DNMT3L 
The zinc finger containing gene DNMT3L (DNA cytosine-5-methyltransferase-like) was 
originally isolated in the human system by Aapola et al., (2000) where it was observed to retain 
a high degree of homology with human and mouse de novo DNMT3A and -3B (Xie et al., 
1999; Okano et al., 1998).   
DNMT3L has since been identified to be important in the establishment of methylation at 
gametic differentially methylated regions (gDMRs) in mouse oocytes (Kelsey and Feil, 2013), 
maturing sperm (Kaneda et al., 2004) and it is highly expressed in both the ovary and testis. 
De novo methylation by DNMT3A is stimulated by DNMT3L, which acts as an essential 
cofactor in the germline (Chedin et al., 2002). Kaneda et al. (2004) reported on observations 
that offspring derived from Dnmt3a conditional mutant female mice are not viable in utero. 
These offspring were identified to have altered methylation levels in addition to allele-specific 
expression at all of the maternally imprinted loci examined (Kaneda et al., 2004). On the other 
hand, Dnmt3a conditional mutant males were observed to show impairment in the process of 
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spermatogenesis whilst lacking methylation at two of three paternally imprinted loci examined 
in spermatogonia. Interestingly the Dnmt3b conditional mutants showed no germline 
phenotype, though they died shortly after birth (Kaneda et al., 2004).  
Binding of both DNMT3A in oocytes (Kaneda et al., 2004) and its cofactor DNMT3L is 
sensitive to the modification state (Liu et al., 2013) of the N-terminal tail of H3. Histone tail 
binding by DNMT3L and -3A is hindered by methylation at lysine 4 (Ooi et al., 2007) while 
the PWWP domain of DNMT3A specifically binds H3K3me3 (Zhang et al., 2010; Ooi et al., 
2007). 
Silencing of retrotransposons and other repetitive DNA elements  
Repetitive DNA elements make up ~55% of the human genome as revealed when the human 
genome was originally sequenced in 2001 (Lander et al., 2001). These repetitive DNA elements 
are transposable and as such are able to relocate within the genome by jumping from one 
chromosome to another. These elements and their abundance in the human genome can be 
further classified as simple sequence repeats, tandem repeats, satellite DNA and segmental 
duplications and processed pseudogenes (~10%) with the remaining ~45% made up of DNA 
transposons and retrotransposable elements (RTEs) (Criscione et al., 2014). 
Retrotransposition can be described as the transcription of an mRNA intermediate followed by 
its reverse transcription into cDNA. This process causes insertional mutagenesis and as such 
disrupts genes in the human genome. Retrotransposition has been shown to happen in the germ-
line in a de novo fashion, resulting in single gene mutations such as that of e.g. haemophilia A 
(Hancks and Kazazian, 2012). As such despite playing a role in regulation gene expression 
transposable elements are frequently silenced to prevent the elements relocating and inserting 
to the coding region of a gene.  
RTEs have the most prevalent transposable element in the human genome and they can be 
further subdivided into long terminal repeat (LTR) elements, and non-LTR elements. LTRs are 
similar to retroviruses with respect to their structure and mechanism of retrotransposition, 
whilst the non-LTRs are akin to integrated mRNAs capable of inserting into the genome in a 
cut and paste style mechanism that involves the reverse transcription of an RNA intermediate 
and insertion of its cDNA copy at a new chromosomal location (Goodier, 2016). The non-LTR 
elements can be further divided into LINES (Long Interspersed Nuclear Elements) or SINES 
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(Short Interspersed Nuclear Elements) (Levin and Moran, 2011) as represented in Fig. 2 (Wolff 
et al., 2017) and are as old as the oldest multi-cellular organism that has existed on earth.  
The LTR containing elements are predominantly represented by the Line-1 (L1) families and 
ERVs (endogenous retrovirus transposons), and the non-LTR elements by the Alu families 
(Criscione et al., 2014). The most prominent group of LTR containing elements however are 
the ERVs making up 8% of the human genome (McCarthy and McDonald, 2004). Along with 
the non-LTR LINES, both of these elements employ an autonomous method of transposition 
(Figure 2) whereby they are capable of active transposition. Non-LTR SINE elements however 
use non-autonomous retrotransposition and retrotranspose in-trans with use of the protein 
machinery belonging to L1.  
A class of LTR-containing ERVs are the IAPs which have flanking LTR sequences which are 
generally heavily methylated (Rebollo et al., 2012), and a pol gene which encodes the reverse 
transcriptase. When these IAPs become unmethylated in for e.g. Dnmt1-deficent mouse 
embryos a significant number of transcripts are observed to accumulate when DNA 
maintenance methylation activity is reduced showing that Dnmt1 is essential for the silencing 
of IAPs in mouse. This is true too for the silencing of L1 elements (Walsh et al., 1998; Bourc'his 
and Bestor, 2004). Generally, CGI are widely acknowledged to have low methylation despite 
their high density of CG dinucleotides. CpG sites however outside the typical CG dense regions 
such as promoters have been found to be highly methylated. Highly methylated CGI include 
those of selfish DNA elements which act to suppress retrotransposons that could potentially 
have deleterious effects on the genome (Walsh et al., 1998). Other epigenetic players can be 
utilised to induce the silencing of potentially deleterious transposable elements such as 
H3K4me3 in mESCs (Karimi et al., 2011) and CTCF that act to maintain ERVs in an 
unmethylated state (Rebollo et al., 2012). 
Many of retroviral insertions into the human genome are as a result of evolutionary insertions 
that have been later mutated or disintegrated and as such have become 'junk DNA' (Wolff et 
al., 2017). There are exceptions to this and some ERVs are capable of being re-transcribed and 
incorporated into the genome (Kassiotis and Stoye, 2016) where they play a fundamental role 
in gene expression through cis-acting transcriptional influences (Rowe et al., 2013) and gene 
regulation (Oliver and Greene, 2011). 
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Figure 2- Summary schematic of retrotransposon taxonomy. Class 1 retrotransposons can be 
delineated into LTR containing, and Non-LTR containing elements. The most highly documented LTR 
containing retrotransposons are the ERVs. The ERVs along with the non-LTR LINE elements deploy 
a method of autonomous retrotransposition. This is in direct contrast to the SINE elements such as Alu 
that are unable to perform autonomous retrotransposition despite their potential to move with the help 
of the LINE elements. Figure was adapted from Wolff et al. (2017) under the terms of Creative 
Commons Attribution 4.0 International License. 
 
Mutations in the DNA methyltransferases and their linked syndromes 
Mutations in each of the methyltransferases DNMT1, -3A and -3B have been found in human 
diseases (Edwards et al., 2017). Some of these diseases and associated pathogenic mutations 
are discussed further below; 
ICF syndrome and DNMT3B mutations 
The first documented mutation in the human DNA methyltransferase DNMT3B (Hansen et al., 
1999) was identified in patients with ICF syndrome (discriminated usually by a variable 
immunodeficiency, centromeric instability and mild facial anomalies) as one of the two main 
causes of the syndrome. ICF syndrome (OMIM 602900) is a rare autosomal recessive disorder 
originally described in the 1970's in patients across Europe (Tiepolo et al., 1979) with an 
incidence rate of (<1 /1,000,000). The condition typically features centromeric instability 
(decondensation) of Chr1, Chr16 and infrequently Chr9 (Ehrlich et al., 2006) in addition to 
aberrant hypomethylation of CpG sites in the cognate pericentromeric satellite repeats (Hansen 
et al., 1999). The condition is characterised by a range of clinical features that include facial 
dimorphisms such as a flat nasal bridge, and macroglossia in addition to mental retardation and 
skin and digestive system infections. ICF can be further subdivided into five clinical groups 
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dependent on the underlying causative genetic defect- ICF1, ICF2, ICF3, ICF4 and ICFX 
(Thijssen et al., 2015).  
The enzymatic activity of DNMT3B is frequently perturbed in ICF patients due to a single 
amino acid substitution (A766P and R840Q) in its conserved catalytic domain (Xie et al., 
2006).  In addition to this conserved catalytic domain found in DNMT3B (and 3A) the de novo 
methyltransferases also contain an N- terminal regulatory region that houses several conserved 
domains. These domains include the PWWP domain that is 100-150 amino acids (aa) in length 
and it is frequently associated with chromatin associated proteins, and in particular pericentric 
heterochromatin (Chen et al., 2004). A missense mutation in the PWWP domain of DNMT3B 
can cause ICF (particularly ICF1) (Weemaes et al., 2013) and a loss of chromatin targeting 
capabilities (Ge et al., 2004) in around half of the ICF patients diagnosed. 
DNMT3B is responsible for establishing DNA methylation de novo early in mammalian 
embryonic development, and experiments performing site-directed DNMT3B mutations 
associated with ICF syndrome show that DNMT3B requires a genetic co-factor to bind to in a 
stable manner (Moarefi & Chedin, 2011).  Indeed the mutations in DNMT3B linked with ICF 
are associated not just with the catalytic domain, but to regions affecting homo-oligerisation, 
SAM binding and utilisation, and DNA binding (Moarefi & Chedin, 2011). It is important to 
emphasise that Dnmt3b knockout (KO) in mice is lethal (Okano et al., 1999) proving the 
essentiality of this catalytically active enzyme for downstream functions (Ehrlich et al., 2006). 
Aside from the causative mutations in DNMT3B, Weemaes (Weemaes et al., 2013) reported 
that 30% of a cohort of 44 patients clinically diagnosed with ICF had mutations in ZBTB24 
(zinc-finger-and BTB domain containing 24 gene) (Nitta et al., 2013) and this is referred to as 
ICF2. Interestingly loss of functional Zbtb24 has been shown to cause embryonic lethality in 
mouse (Wu et al., 2016). The subtypes ICF3 and -4 have been recently linked to mutations in 
cell cycle CDAC7 and HELLS respectively. For those clinical diagnoses not stratified into the 
subtypes 1-4, these are referred to as ICFX (Thijssen et al., 2015). 
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Leukaemia and DNMT3A mutations 
Interest in the de novo methyltransferase DNMT3A with respect to leukemic conditions has 
gained momentum due to the incidence of mutations of this enzyme in an array of hematologic 
neoplasms (Roller et al., 2013; Yang et al., 2015). Currently all the contributory mutations to 
Acute Myeloid Leukaemia (AML) in DNMT3A may not be defined (Cancer Genome Atlas 
Research Network et al., 2013), but overexpression of DNMT3A has been frequently reported 
in many cancers (Mizuno et al., 2001; Rahman et al., 2010). In fact, heterozygous somatic 
mutations found in the de novo methyltransferase DNMT3A are present in nearly 15% of 
confirmed patients (Ley et al., 2010) with AML (OMIM 601626) and in some myelodysplastic 
syndromes (Edwards et al., 2017). The successful use of pharmacological hypomethylating 
treatments such as 5-aza-2’-deoxycytosine in malignancies further supports the oncogenic 
overexpression of DNA methyltransferases in tumour cells as one of the most frequent 
observations (Santini et al., 2001). 
Some advances have been made in attempting to identify these mutations by Ley et al (2010) 
who identified 18 somatic missense mutations of DNMT3A in AML patients using massively 
parallel DNA sequencing. The median overall survival among patients with such mutations is 
significantly lower (12.3 months, p <0.001) than among AML sufferers without such mutations 
(41.4 months) (Ley et al., 2010). In most instances, the mutations affect the R282 codon 
causing a C → T mutation at a methylated CpG site ultimately converting the codon to one of 
cysteine if the top strand is mutated, and conversely a histidine codon if the bottom strand is 
affected (Edwards et al., 2017). This has lately been supported by Brunetti et al. (2017) who 
state that the mutations in DNMT3A which occur early in leukemogenesis correlate (Yang et 
al., 2015; Shlush et al., 2014) with a poor prognosis for AML patients. As such mutations in 
DNMT3a offer potential targets for the development of new therapeutic targets (Brunetti et al., 
2017) 
Tatton–Brown–Rahman syndrome (TBR) 
TBR is an overgrowth syndrome (OMIM 615879) caused by a heterozygous germline mutation 
in DNMT3A on Chr2p23. In a study of 55 individuals diagnosed with the overgrowth 
syndrome (Tatton-Brown et al., 2014) over 80% of individuals presented with both an 
overgrowth and intellectual disability, in addition to a lower incidence of joint hypermobility, 
obesity, hypotonia and prominent facial features that include low set heavy eyebrows and 
prominent upper central incisors (Tatton-Brown et al., 2018). 
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TET proteins  
The TET family of enzymes are responsible for the oxidation of 5mC and its subsequent 
demethylation at select genomic loci. The first of the TETs to be discovered was TET1 
(Tahiliani et al., 2009) and it is frequently grouped together with TET2 and -3. This family of 
proteins are multidomain enzymes around 180-230kDA in size and contain a conserved double 
stranded β helix, binding sites for cofactors 2-oxoglutarate and Fe (II) that form part of the 
core-catalytic region in the C-terminus, and a cysteine rich region (An et al., 2017). The core 
catalytic regions preferentially bind cytosine rich CpG, whilst TET1 and -3 have an additional 
N-terminal Zinc finger domain (CXXC) that can bind DNA (Frauer et al., 2011) (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Domain structure of TET proteins. The carboxyl-terminal core catalytic domain is 
conserved within the TET family. The core catalytic domain is made up of a DSBH and a cysteine rich 
domain. The cysteine rich domain has two subdomains and is responsible for the modulation of the 
chromatin targeting functionality of TET proteins. Whilst the DSBH domain has a set of catalytic motifs 
e.g HxD motif that is capable of interacting with Fe (II) and 2OG. The large low complexity insert 
highlighted in grey is found in the DSBH domain but no function has yet been assigned to it. Image 
permitted for reuse under Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) from An et 
al. (2017). 
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5hmC levels in somatic tissue are relatively low, with the exception of brain tissue where high 
levels have been reported (Tahiliani et al., 2009). The high levels in ESCs decline steadily as 
cell lineages progress through differentiation (Ko et al., 2011). This family of enzymes catalyse 
the oxidation of 5mC to 5hmC in addition to both 5-formylcytosine (5fC), and 5-
carboxylcytosine (5aC) (Ito et al., 2011). Functionally however the TET enzymes play a role 
in the regulation of DNA methylation patterns through ‘Active’ and ‘Passive’ DNA 
demethylation mechanisms. Passive DNA demethylation refers to the lack of maintenance of 
DNA methylation patterns through cell divisions. This is thought to cause a replication-
dependent dilution of 5mC (Rasmussen and Helin, 2016), whereas active DNA demethylation 
is an enzymatic process whereby the 5mC bases along with their oxidised intermediates such 
as 5fC are replaced with unmodified cytosines in a replication-independent manner i.e. as 
catalysed by TETs. 
The TET family of enzymes are implicated in Cancer by acting as tumour suppressors- TET2 
commonly appears as a mutated gene in hematopoietic malignancies. TET1, -2 and -3 all 
appear to be mutated in various cancer types showing reduced levels of expression (Rasmussen 
and Helin, 2016). Through their primary function, TETs play a role in the regulation of DNA 
methylation patterns and in the progression of normal development, through ensuring 
protection against anomalous cellular transformation (Rasmussen and Helin, 2016). 
Additionally, the deposition of 5hmC may induce passive DNA demethylation. Studies have 
demonstrated that in vitro DNMT1 activity can be reduced up to 60-fold on a DNA substrate 
containing 5hmC (Valinluck and Sowers, 2007). Therefore, such TET-mediated 5hmC 
deposition could prompt passive DNA demethylation on the opposite DNA strand, which could 
be important to hinder the accumulation of aberrant DNA methylation patterns over cellular 
generations. 
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Figure 4: Genome wide DNA demethylation during mouse developmental stages mouse with the 
relevant Tet protein expression.  Epigenetic reprogramming occurs in the early zygote and in the 
PGCs of a developing embryo. At E.05 the paternal genome of the zygote is decondensed and quickly 
demethylated. Until the E3.5 blastocyst stage the maternal and paternal experience a loss of 
methylation, prior to implantation. DNA methylation levels are re-established by the de novo 
methyltransferases following implantation in the epiblast. The second demethylation event in the PGCs 
occurs is a marker of germline development.  This round of demethylation is when the methylation of 
genomic imprints and repetitive elements is reduce thanks to the Tets. This hypomethylated phase lasts 
from E8.5 through to post-natal development of the female germ cells during oocyte growth whilst the 
male germ cells regain their DNA methylation levels quickly following the global demethylation event. 
Figure sourced from Hill et al. (2014). Reuse was obtained through Copyright Clearance Centre under 
licence #4270180488769. 
 
In recent years it has been shown that DNMT1 and its recruiting enzyme UHRF1 (and UHFR2) 
are capable of binding 5hmC DNA (Frauer et al., 2011; Spruijt et al., 2013; Iurlaro et al., 2013) 
and both UHRF1 and UHRF2 have a role in the maintenance of DNA methylation through 
recruiting DNMT1 to regions of hemi-methylated DNA. In addition, the two isoforms of the 
de novo methyltransferases DNMT3A2 and DNMT3B2 have also been implicated in the 
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maintenance of DNA methylation (Chen et al., 2003) in addition to the establishment of DNA 
methylation on previously unmethylated CG dinucleotides.  
 
 
Figure 5: Common cytosine modifications in mammalian DNA. Genomic methylation events are 
frequently catalysed by both the maintenance and de novo methyltransferases, and the Tet family of 
enzymes. The Tet family discovered in 2009 are associated with active and passive mechanisms of 
DNA demethylation. Figure sourced from Hill et al. (2014). Re-use obtained through Copyright 
Clearance Centre under licence number 4270180488769 
 
The developmental cycle of DNA methylation  
Methylation marks are globally erased following fertilisation on both the maternal and paternal 
genomes as represented in Fig.4. Following implantation however the methylation marks are 
reset by the de novo methyltransferases DNMT3A and -3B (Okano et al., 1999b). This 
sequence of methylation changes is fundamental to ensure the appropriate differentiation of the 
organism. DNA methylation patterns are further erased in the diploid primordial germ cells 
(PGCs) to allow the sex dependent methylation marks to be reset, maintenance of which is 
carried out by DNMT1. 
Germ-cell development 
At an early stage of development, there are a number of cells allocated to form oocytes and 
spermatozoa and these are referred to as PGCs. The PGCs will migrate to the posterior 
endoderm and onto the genital ridge, which forms the location of the respective developing 
gonad, and then the surrounding tissue will form the somatic cells of the gonad around them.  
These germ cells are precursors to the gametes that are responsible for establishing the next 
generation in the form of a zygote thanks to their totipotent potential with the inheritance of 
both genetic and epigenetic information from each parent (Nikolic et al., 2016; Hill et al., 
2018). PGCs undergo a wave of demethylation during migration to allow parental specific 
methylation marks to be reset (Hajkova et al., 2002; Lees-Murdock et al., 2003; Li et al., 2004). 
29 
 
 
 
 
In the mouse genome, germline specification begins its initial stage at gastrulation around 
E6.25 in the proximal epiblast (Nikolic et al., 2016). As the PGCs migrate into the respective 
developing gonad they undergo a wave of epigenetic reprogramming E10-E11.5 (Guibert et 
al., 2012) through a genome-wide loss of 5mC (Hackett et al., 2012). The events leading to 
global demethylation (in an attempt to restore the epigenome for totipotency) are yet to be fully 
defined but are considered to be as a result of a combination of both active and passive 
demethylation (Hackett et al., 2013), and other mechanisms working in parallel such as that of 
the interplay with chromatin, and Tet dioxygenases (Hackett et al., 2012). It should be noted 
however that some IAPs, LTR-ERV1 retroelements and single-copy sequences are capable of 
resisting global demethylation events in PGCs (Hajkova et al., 2002; Lees-Murdock et al., 
2003; Li et al., 2004). 
X chromosome inactivation  
X-chromosome inactivation (XCI) is a method of dosage compensation in mammal genomes 
whereby one X chromosome is transcriptionally silenced in the female (Lyon, 1961). This 
heterochromatinisation of the one X chromosome is important (Slotkin and Martienssen, 2007) 
to make sure that both females (XX) and males (XY) have equivalent X-linked gene dosage 
(Lyon, 1961; Wutz, 2003). X-inactivation occurs at the X-chromosome inactivation centre 
(XIC) in the embryo early in development– a cis acting sequence, initially before the effects 
are distributed across the chromosome into adjacent chromatin where some regions are more 
efficiently inactivated than others on the X chromosome (Panning and Jaenisch, 1996).  
Xist is the lncRNA (long non-coding RNA) necessary for selective silencing of one X 
chromosome per cell (Zlotorynski, 2015), it is expressed from the inactive X chromosome in 
female somatic cells (Borsani et al., 1991) and continues to be expressed throughout subsequent 
cell divisions where it is thought to recruit additional silencing factors necessary for inducing 
a stable heterochromatic conformation (Ng et al., 2007). Beard et al. (1995) reported 
observations that when Dnmt1 expression is disrupted, Xist becomes hypomethylated resulting 
in an increased levels of Xist RNA in the male Dnmt1 mutant ESCs and embryos; and 
therefore, showing a functional role of DNA methylation in regulating Xist expression 
appropriately in the differentiation of murine somatic cells (Beard et al., 1995). As such 
DNMT3A is essential for methylation of the Xist promoter of the X chromosome and is 
therefore important for X-inactivation (Chen et al., 2003). This is echoed in a review by Barbara 
Panning (Panning, 2008) who discusses the role of DNA methylation in X-inactivation.  
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Xist promoter methylation has been shown to correlate with Xist expression in ESCs (Nesterova 
et al., 2008). There are two regions that flank the Xist transcription start site (TSS) which 
exhibit high levels of DNA methylation. In fact, Nesterova et al. (2008) showed in two XY 
ESC lines that had mutations in the Xist promoter mutations that Xist expression increased in 
accordance with DNA hypomethylation at these locations. The methylation of the Xist 
promoter occurs before the onset of X-chromosome inactivation and is affected by the levels 
of sense and antisense transcription, independent of the RNAi pathway (Nesterova et al., 2008) 
(as shown in Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: RNAi mechanism of transposable element silencing. Post transcriptionally double stranded 
RNA (dsRNA) is cleaved by the dicer proteins into small interfering RNAs (siRNA). These siRNAS 
become incorporated into the RISC complex. Which then cleaves complementary transcripts to the 
loaded siRNA. Image was redrawn from Slotkin & Martienssen (2007). Reuse was obtained through 
the Copyright clearance centre under licence number 4271071318628. 
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DNA methylation of germline specific genes  
DNA methylation acts as an epigenetic barrier to the expression of many gene classes, namely 
the germline genes expressed in the mammalian germ cells (Borgel et al., 2010). The 
expression of these germline specific genes are predominately controlled by DNA methylation 
in a tissue specific manner.  
In early mammalian development, the genome undergoes extensive reprogramming, for which 
DNA methylation plays a fundamental role.  Typically, the CGI that are located at promoters 
of germline specific genes become de novo methylated in mammalian germ cells in an attempt 
to maintain their suppression. This however is not true of all promoters; some repressed genes 
do have such methylated CGI at their promoter to encourage repression where long-term 
stabilisation of their repressed state is preferred. Such classes of genes include the imprinted 
genes, those found on the X chromosome in addition to those only expressed from the germ 
cells. The repression of the germline specific genes is important in somatic tissue where their 
expression is unsuitable (Jones, 2012).  This phenomenon is important in the epigenetic 
reprogramming of PGCs, particularly in the instance where if the germline specific genes were 
to be inappropriately expressed ectopically there could be deleterious downstream effects 
(Maatouk et al., 2006; Borgel et al., 2010). For example, Dnmt3l KO mice are viable but due 
to the diminished ability to assist in the de novo methylation of germline genes, as well as 
inappropriate expression of RTEs, the knockout can cause male sterility and embryonic 
lethality of the maternal null derived embryos (Bourc'his et al., 2001; Bourc'his and Bestor, 
2004). Dnmt3l is an important cofactor of the de novo methyltransferases Dnmt3a/b and plays 
an important role in methylation despite its poor catalytic activity (Chedin et al., 2002). 
 
DNA methylation andtTranscription  
The epigenetic mechanism of DNA methylation involves the addition of a methyl group to the 
C5 position of cytosine to form 5mC. This mechanism is important to regulate gene expression 
through the recruitment of proteins that are involved in expression or alternatively through the 
inhibition of a variety of transcription factors. During mammalian development, DNA 
methylation undergoes a wave of changes due to the interaction of de novo and maintenance 
methyltransferases and is important in downstream processes such as X-inactivation, silencing 
of transposable elements and genomic imprinting (Smith and Meissner, 2013). To promote 
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active transcription, DNA methylation in the gene body can enhance gene expression. This is 
converse to methylation at the gene promoter where DNA methylation is associated with gene 
repression in a tissue specific manner (Moore et al., 2013) e.g. germline genes in somatic 
tissues. The gene body frequently refers to the genomic region following the first genic exon 
(Moore et al., 2013). The exact mechanism by which DNA methylation of the gene body can 
contribute to gene regulation is yet to be fully elucidated.  
Cells treated with the cytosine analogue 5-aza-2′-deoxycytidine reactivate genes and decrease 
expression of genes such as those genes regulated by c-MYC e.g. genes involved in metabolic 
processes. DNA demethylation of the gene bodies causes down-regulation and the expression 
of genes is restored by the de novo methyltransferases. Given the effect of methylation at the 
gene body this may offer a therapeutic target for alternative DNA methylation inhibitors that 
can assist in the normalisation of gene overexpression that is a consequence of carcinogenesis 
(Yang et al., 2014). 
 
DNA methylation and cancer generally 
The initial observation of a link between DNA methylation and cancer was published in 1983 
showing how cancers have a tendency to exhibit global hypomethylation on comparison with 
normal human controls (Feinberg and Vogelstein, 1983; Gama-Sosa et al., 1983). Indeed, 
aberrant DNA methylation is a prominent event in carcinogenesis and the associated loss of 
methylation was soon shown to be an early event in tumorigenesis (Feinberg et al., 1988) 
resulting in tumour progenitor cells.  
With this knowledge in hand, cancer research at that time reverted to focusing on dense regions 
of hypermethylation (predominantly at promoters) with the idea that the epigenetic silencing 
of TSGs could act as a “second hit,” thereby essentially nullifying the need to inactivate the 
genetic pathway as reviewed in Baylin et al. (1997). 
In normal cells, CGIs are surprisingly rarely methylated with some exceptions such as those 
on the inactivated X chromosome and at imprinted genes. Aberrant methylation of CGI is not 
limited to cultured cells but can occur during aging and tumorigenesis (Baylin and Jones, 
2011). Observations indicate that unmethylated CGI are associated with a variety of genes that 
have either become partially or fully methylated in tumours cells and are able to undergo 
reactivation by 5-aza-2’-deoxycytidine. Some of the methylation at CGI has little to no effect 
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on downstream gene activity simply because these are CGI not associated with the regulatory 
regions of genes (Jones et al., 1998). 
In 2001, a study by Esteller et al. (2001) showed that in over 600 primary tumour samples 
tested the promoters associated with CGI in at least three or more genes (from a panel of 12 
known TSGs) were hypermethylated in 5–10% of the samples tested. Of these hypermethylated 
TSG at least one CGI was methylated in 80% of samples for each tumour type tested (Esteller 
et al., 2001).  Using methods that allow genome wide screening of CpG islands, it was observed 
that around 1% of CGI in DNA from tumour tissues are abnormally methylated whilst 
demonstrating tumour specific patterns of methylation (Costello et al., 2000). 
 
Imprinting 
Imprinting refers to the process of allelic restriction of the expression of genes depending upon 
the parent of origin (Docherty et al., 2014). Imprinting is maintained through various epigenetic 
mechanisms such as DNA methylation. DNA methylation involves the transfer of a methyl 
group from 5-adenosylmethionine to 5’carbon of a cytosine residue, converting it to 5-
methylcystosine (Gibney and Nolan, 2010) and it is essential for differentiation and normal 
development, due to its effects on long term stable gene repression (Cedar and Bergman, 2009). 
In addition to DNA methylation, the effects of the presence of particular repressive or active 
histone marks at a site of differential methylation may affect the levels of DNA methylation in 
an individual. As a more complete review of imprinting during development was conducted as 
part of the Review article (Paper-IV) I will here concentrate on aspects not covered there, 
namely correlations between imprinting and cancer.  
 
Cancer and Imprinting Syndromes 
A loss of imprinting (LOI) is frequently observed in human cancers and it is often caused by 
misregulation of epigenetically controlled genes (Ogawa et al., 2003; Cui et al., 2003; Holm et 
al., 2005). Monk (2010) suggests that there is in fact a higher frequency of epigenetic changes 
than DNA mutations in cancer. For example, LOI can include the reactivation of the typically 
silenced copy of the imprinted growth promoting IGF2 or silencing of the active parental copy 
of p57KIP2 (a growth inhibitory gene) (Diaz-Meyer et al., 2003). LOI is so prevalent that is 
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has been reported in 100% of all documented cases of chronic myeloid leukaemia (Randhawa 
et al., 1998), in addition to 70% of Wilm’s tumours (Mummert et al., 2005) and even 80% of 
ovarian tumours (Kamikihara et al., 2005). 
 
The imprinted control region of the growth-related locus IGF2/H19 ICR in Wilm’s tumour is 
a well-documented and common cancer that is found in patients (mostly children) who have 
the overgrowth imprinted disorder Beckwith-Wiedemann (BWS). The degree of risk of a child 
with BWS developing a Wilm’s tumour is dependent on the causative molecular mechanism, 
with some mechanisms thought to be lower risk than others e.g. loss of methylation at the 
centromeric imprinting centre (IC2) (Brzezinski et al., 2017). Despite the efforts made to 
stratify Wilm’s tumours the Weksberg lab still recommends that all children diagnosed with 
BWS continue to be screened for Wilm’s tumours until the age of eight (Brzezinski et al., 
2017).  As a consequence of having this disorder, there is biallelic expression of the growth 
promoting gene IGF2, which has the effect of promoting the growth of cancer cells (Ogawa et 
al., 1993).  
Cancerous cells in humans generally undergo global DNA hypomethylation with locus specific 
hypermethylation. These events have the consequence of initially causing a decondensation of 
chromatin, activation of certain retroviral elements and can cause chromosomal 
rearrangements due to the inherent instability caused (Monk, 2010). Hypomethylation of genes 
is usually paired with the derepression of e.g. oncogenes (e.g. c-Myc and c-Ha-Ras) (Cheah et 
al., 1984) and MAGE-A1 or-A3 germline genes (De Smet et al., 2004). Conversely, 
hypermethylation of DNA promoters can cause gene-specific silencing, and in some cases 
these genes can be tumour suppressors for e.g. non-small cell lung cancer (Liu et al., 2016). 
Genic misregulation can also be caused by aberrant methylation through atypical DNMT 
expression. If there is an overexpression of the maintenance methyltransferase DNMT1 
hypermethylation might result (Etoh et al., 2004), whereas global hypomethylation appears to 
correlate with the expression of an abnormal isoform of DNMT3B (DNMT3B4) which does 
not have the normally conserved methylation motifs and so cannot participate in sufficient 
maintenance or de novo methylation activity (Saito et al., 2002).  
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Pharmacological inhibition of DNMT1- Mechanism of Action 
The pharmacological DNMT1 inhibitors 5-azacytidine (5-aza) and 5-aza-2′-deoxycytidine (5-
aza-dC) were originally synthesised in 1964 (Sorm et al., 1964). 5-aza in particular was 
developed as a nucleoside antimetabolite for AML, where it could be activated to the 
nucleoside triphosphate. As a result, it was capable of being incorporated into the replicating 
DNA and preferentially into the RNA (Herman et al., 1998). 
The hypomethylating effect of 5-aza-dC (or Decitabine as it is clinically known) however is 
thanks to the DNMT1 inhibitors innate ability to act as cytosine analogue (Patel et al., 2010). 
5-aza-dC was initially developed as a cytostatic agent (Sorm et al., 1964), but treatment of 
human cell lines with the agent showed it was capable of inhibiting DNA methylation activity 
and thus the DNMT1 inhibitor stimulated the development of such azanucleosides as potential 
epigenetic drugs (Stresemann and Lyko, 2008). The DNMT1 inhibitor and cytosine analogue 
5-aza-dC is preferentially incorporated into DNA. This is despite 5-aza-dC having ten times 
more cytotoxicity than 5-aza (Flatau et al., 1984; Momparler et al., 1984). 
When 5-aza-dC is incorporated into DNA, an irreversible covalent bond is formed between 5-
aza-dC and a cysteine residue located within the active site of DNMT1 (Seelan et al., 2017). 
This binding renders the DNMT1 ineffective and unable to operate its full methylation 
maintenance activities at CG dinucleotides of freshly synthesised DNA.  
The treatment dose levels of 5-aza and 5-aza-dC are low enough to avoid causing cell death, 
as they incorporate into the replicating DNA of cells in culture, ultimately leading to a rapid 
loss of DNA methyltransferase activity as the enzyme becomes irreversibly bound to the 
cytosine residues in the DNA (Fig.7). Consequently, the amount of hemi-methylated DNA 
available falls according the amount of cytosine that is methylated. In Fig. 7B treatment also 
causes the 5-aza-dC incorporated DNMT1 to be targeted for proteosomal degradation 
(Fig.7B.2) (Ghoshal et al., 2005). Such degradation of unbound DNMT1 reduces the DNMT1 
available to bind to the hemi methylated DNA and prevents it from being remethylated 
(Fig.7B.3), as such this contributes to local hypomethylation at this location. 
The extent of the hypomethylation caused by 5-aza-dC is more noticeable at low concentrations 
where the formation of 5-aza-dC-DNMT adducts is restricted as to not hinder normal DNA 
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synthesis. At higher concentrations of the inhibitor however, a larger number of adducts are 
formed which has the effect of restricting DNA polymerase from carrying out its normal 
function. This ultimately causes a change in gene expression, decondensation of chromatin 
(Jones, 1985) growth arrest and in many instances cell death (Kuo et al., 2007). Although it is 
worth noting that the inhibition of DNA synthesis does not take effect until at least two cycles 
due to the lack of repair or the DNMT1- 5’aza-dC adducts (Davidson et al., 1992). 
Interestingly there is evidence indicating that administering 5-aza-dC treatment may also act 
by enabling the reactivation of ERVs that are typically found to be silenced through epigenetic 
mechanisms (reviewed in Wolff et al., 2017). Pharmacological agents such as the DNMT 
inhibitor 5-aza-dC has been reported to upregulate immune signalling in cancerous cells 
through the viral defence pathway (Chiappinelli et al., 2015). Indeed, viral defence genes that 
include IFI27, ILI44 and IFNB1 have been found to be upregulated in primary ovarian tumour 
samples sourced from 19 patients and this significantly correlated with the high expression of 
the levels of ERV transcript (p = 0.000141). 
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Figure 7- Impact of treatment with 5-aza-dC on DNA methylation and subsequent breakdown of 
DNMT1. DNMT1 selectively binds to the hemi-methylated DNA created as part of the usual DNA 
synthesis process under the action of DNA polymerase in actively dividing healthy somatic human 
cells. At this stage, there is a free interchange of the maintenance methyltransferase and the chromatin 
as shown in A) by the arrow. In such cells, there is a minimal amount of hemi-methylated DNA 
available due to efficient maintenance methylation being carried out by DNMT1 (mostly). Upon 
addition and incorporation of 5-aza-dC, in B) DNMT1 tries to methylate the analogue by flipping out 
the base but is unable to complete the reaction and so becomes trapped in a dosage dependent manner 
(as shown by the red dashes) (1). Figure was sourced from Patel et al. (2010): Copyright Clearance 
Centre #4270170712545. 
 
Main clinical uses- Effectiveness of DAC 
A range of nucleoside inhibitors such as 5-aza-dC, Decitabine (FDA) (Kaminskas et al., 2005) 
or Dacogen (NICE) -have been approved for the treatment Myelodysplastic syndromes (MDS) 
and for AML under the condition that the marrow blast counts are between 20-30% in addition 
to fulfilling the criteria for AML as per the World Health Organisation (WHO) classification 
of the condition (Nieto et al., 2016). 
The main uses of nucleoside analogues 5-Azacytidine and 5-aza-2′-deoxycytidine primarily 
reside in their role as therapeutic agents for the treatment of certain cancers through epigenetic 
silencing of important regulatory genes. The inhibitors can do this through hypomethylation of 
aberrantly methylated CpG promoters that leads to re-expression of e.g. TSGs (Wolff et al., 
2017). This is frequently referred to as ‘Epigenetic Therapy’ (Li et al., 2016). When 5-aza-2′-
A B 
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dC was administered to AML patients aged over 60 in a study by Yan et al., (2012) global 
methylation was significantly reduced when compared with pre-treatment baseline in cells of 
AML patients. 
Yang (2014) reports that 5-aza dC treatment successfully down regulates genes due to DNA 
hypermethylation of the gene bodies and transient exposure to this agent can cause also 
demethylation of CGI promoters (Tsai et al., 2012). Both effects exhibit anti-tumour 
capabilities.  Aza's widespread demethylating effects have been shown in a range of cell lines 
by the Walsh lab (Irwin et al., 2014; Rutledge et al., 2014) and previously by others (Jones and 
Taylor, 1980).  
Such pharmacological loss of DNMT1 is problematic for normal non-cancerous cells. DNMT1 
is essential for cell viability, Dnmt1-/- mouse embryos are embryonically lethal and fail to 
develop throughout the gestation period (Li et al., 1992). On the other hand ESCs can continue 
to proliferate without DNA methylation (Tsumura et al., 2006) but Dnmt1 KO ESCs die when 
promoted to differentiate (Li et al., 1992). The appropriate maintenance of DNMT1 is of crucial 
importance for development as it is used to silence genes at developmentally important 
milestones in embryo development. Post development, DNMT1 has been associated with cell 
viability with evidence in a range of adult differentiated cells which have diminished viability 
when DNMT1 expression has been reduced (Jackson-Grusby et al., 2001; Chen et al., 2007).  
Loss of DNMT1 has also been implicated in the activation of the DNA damage response (DDR) 
pathway. The DDR is employed to protect the integrity of the human genome and its 
mechanisms predominately include cell-cycle checkpoints, the detection of DNA lesions and 
DNA repair as nicely reviewed in Giglia-Mari et al., (2011). DNMT1 deficient hypomorphic 
systems such as those sequenced in O'Neill et al., (Paper II) offer an opportunity to look at 
which enriched genes/proteins of the DDR become up/down regulated when the DDR is 
activated and so identify those that affect cell viability. Many studies into the effects of acute 
depletion of DNMT1 have been performed in hypermethylated cancer cell lines where the 
effects make it more difficult to identify the triggers for DDR and cell death (Loughery et al., 
2011). DNA repair pathways and 5-aza dC-mediated DNMT1 depletion correlates with the 
active recruitment of DNMT1 to sites of potential DNA repair in cells that have undergone cell 
cycle arrest where it can restore methylation marks (Easwaran et al., 2004). The major 
checkpoint mediator p53 has been identified to be activated in cell death following the 
pharmacological depletion on DNMT1 with the creation of 5-aza dC adducts in DNA (Karpf 
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et al., 2001); for example, the mediator p53 is required to safeguard G2/M arrest seen under 5-
aza-dC treatment of the colon-cancer HCT116 cell line (Schneider-Stock et al., 2005). A 
PARP-mediated cell killing mechanism involving PARylation of the DNA and apoptosis-
inducing factor 1 (AIF1) translocation, and which is at least partially independent of p53 but 
sensitive to PARP inhibitors, is also involved in DDR in DNMT1-depleted hTERT-1604 and 
HT29 cancer cells (Loughery et al, 2011).  
DNA packaging into chromatin  
Chromatin allows for the packaging of DNA into a dynamic structure within the nucleus of a 
cell in such a way that the DNA can be propagated and transmitted within cell division. 
However, DNA must be packaged appropriately for it to remain accessible to the protein 
machinery required for transcription, DNA repair and even recombination (Rothbart and Strahl, 
2014). Chromatin is a complex of DNA and histone proteins, the basic unit of which is a 
nucleosome. A nucleosome contains 145-147bp of DNA wrapped around a histone octamer 
(Lawrence et al., 2016). The histone octamers are made up of two copies of H2A, H2B, H3 
and H4 each, resulting in a nucleosome core particle (Kornberg and Lorch, 1999) forming the 
basis of chromatin. Chromatin can take the form of euchromatin and heterochromatin; 
euchromatin has a looser packing structure and its more open conformation is more accessible 
to transcription machinery. Heterochromatin on the other hand is associated with a closed 
chromatin conformation due to its condensed packing and it is considered to be repressive to 
active transcription (Li and Reinberg, 2011).   
The organisation and packing of chromatin is dependent on factors which include; the action 
of linker histone H1, chromatin remodellors and histone chaperones among others.  The histone 
H1 in particular regulates the creation of higher order chromatin states (Harshman et al., 2013) 
through its 50bp linker region and the associated ability to tether to DNA on the outside of the 
nucleosome allowing nucleosomes to interact together. Ultimately this allows for the formation 
of a spiral of 6-8 nucleosomes/turn creating a 30nm fibre- a solenoid. Heterochromatin results 
when the solenoids are folded to form the dense transcriptionally repressive chromatin (Li and 
Reinberg, 2011) and a resultant metaphase chromosome (Annunziato, 2013). 
The ordered structural organisation of chromatin is key for the appropriate regulation of 
transcription, DNA repair and the process of replication and so too are the building blocks of 
chromatin- nucleosomes. Nucleosomes are known to vary in their composition of the histone 
protein element due to the incorporation of a range of histones and the post-translational 
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modifications of their amino acid side chains (Luger et al., 2012). These chains can be targeted 
by the chromatin remodelling complexes, and through the hydrolysis of ATP the nucleosomes 
can be mobilised using DNA translocase. This allows the DNA to unwind as nucleosomes are 
evicted to improve accessibility to the transcriptional machinery through such alternation of 
the chromatin structure (Venkatesh and Workman, 2015). 
Histone modifications 
As discussed previously the nucleosome units have amino acid side chains which extend from 
the nucleosome. These side chains can be modified post-translationally mostly at the N-
terminal of the tails, but also some at the C-terminal. Some modifications however can take 
place in the histone folds (globular domains) responsible for regulating interactions between 
histone-histone and histone-DNA (Cosgrove et al., 2004). The lateral surfaces of these globular 
domains is the outer region of the histone octamer and so they have direct contact with the 
DNA. Recently mass-spectrometry has revealed novel modifications in this area as described 
in Lawrence (Lawrence et al., 2016) and Tropberger (Tropberger and Schneider, 2013). 
The post translational modification of histones is important for the regulation of processes such 
as replication, transcription and DNA repair and for nucleosomal architecture (Tessarz and 
Kouzarides, 2014). Covalent modifications of the histones can alter not only the organisation 
of chromatin, but also chromatin function. The covalent modifications are laid down by 
chromatin modifying enzymes where they act as docking sites for specific chromatin readers. 
This has the effect of recruiting chromatin modifiers and other such remodelling factors 
(Tessarz and Kouzarides, 2014). Examples of post-translational modifications include 
methylation, acetylation, phosphorylation, ubiquitinylation and sumoylation (Lawrence et al., 
2016). Many of these modifications are carried out by specialised enzymes such as the histone 
methyltransferases, acetyltransferases and deacetylases. Recently there have been additional 
modifications that have been described - propionylation and butyrylation (Kebede et al., 2015). 
Some of the modifications found on the N-terminal of the side chains are able to directly affect 
the nucleosome-nucleosome interactions. This is evident in H4K16ac which has the effect of 
causing a reduction in the level of chromatin compaction and increasing transcription both in 
vitro and in vivo (Shogren-Knaak et al., 2006). Conversely the tail modifications can cause 
increasing chromatin condensation in vitro e.g.  H4K20me2/me3 (Lu et al., 2008). 
Furthermore, post-translational histone modifications can recruit effector proteins which 
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activate downstream signalling (Wysocka et al., 2006), in addition to blocking the access of 
chromatin remodelling complexes. Additionally, such modifications can also affect the 
recruitment of both transcription factors and chromatin modifiers. It is important to note 
however despite the effect of such modifications on nucleosomal activity, the tails and their 
modifications can be removed whilst having minimal effect on nucleosomal stability and 
integrity (Ausio et al., 1989). 
The majority of post-translational histone modifications are reversible to provide a level of 
regulation over how long a mark can reside at a particular genomic location endeavouring to 
maintain genomic instability in addition to offering a mechanism to remove any aberrantly 
placed marks; for e.g. acetylation of H2A.Z (a variant of H2A) by the promoter bound 
acetyltransferase acts to prevent its removal from the promoter by the INO80 remodeller 
complex (Lawrence et al., 2016). 
Histone methylation is one of the most well described post translational modifications in the 
literature and some of the most extensively studied histone methylation sites include H3K4, 
H3K9, H3K27, H3K36, H3K79 and H4K20 (Greer and Shi, 2012). The addition of a methyl 
group is catalysed by the enzyme histone methyltransferase which uses SAM as a methyl group 
donor. Histone methylation can occur at residues including arginine, lysine and histidine, whilst 
the removal of methyl groups can be facilitated by the histone demethylases. The lysine residue 
can be monomethylated, di- or trimethylated on their ɛ-amine group, whilst arginine can be 
monomethylated, symmetrically dimethylated or asymmetrically dimethylated on their 
guanidinyl group. Histidines on the other hand have been reported to be monomethylated but 
this methylation is rare with little investigation to further characterise it, as reviewed in Greer 
& Shi (2012). 
Chromatin remodelling complexes 
As discussed previously, the amino acid side chains of the nucleosomes can be targeted by 
chromatin remodelling complexes. For the most part, these large macromolecular complexes 
are ATP-dependent, using energy from ATP hydrolysis to structurally alter the nucleosomes 
by sliding, disassembling or other means (Luger et al., 2012). The remodelling complexes are 
found at a ratio of 1:10 to the nucleosomes (Langst and Manelyte, 2015). Such ATP-dependent 
chromatin remodelling complexes have been identified as novel targets for cancer therapy (as 
described in (Mayes et al., 2014). These complexes possess 2 to 20 non-catalytic subunits 
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essential for the targeting and regulation of nucleosome positioning activities of the 
remodelling complexes. Thus, they are very important for the determining gene expression and 
the cell fate. 
The ATP-dependent complexes contain an ATPase subunit, part of the SNF2 superfamily. The 
SNF3 superfamily can be subdivided into three groups; SWI1/SNF2, the imitation group SWI 
(ISWI), and the ATP-dependent complexed which contain a Snf2-like ATPase. This third class 
has also been shown to exhibit deacetylase activity (Vignali et al., 2000). The SWI/SNF family 
has an N-terminal located HSA (helicase-SANT) domain which recruits actin and other such 
related proteins, and at the C-terminal there is a bromo domain used for binding the acetylated 
lysines of histones (Filippakopoulos and Knapp, 2012). The ATPases of the ISWI family on 
the other hand have a C-terminal SANT domain beside their SLIDE domain (SANT-like 
ISWI). These components form a nucleosome recognition unit that is able to bind to DNA and 
unmodified H4 (Clapier and Cairns, 2009). 
There is another class of remodelling complexes- the ATP independent complexes. The 
rearrangement of the nucleosomes has a direct impact on the transcription levels as accessibility 
of the DNA is affected by the chromatin packing and organisation (Gibney and Nolan, 2010). 
Most of the known mutations in chromatin remodelling complexes identified in a variety of 
cancers can be found in the SWI1/SNF2 complex. The mutations within this particular 
remodelling complex can be found in ~20% of cancers, most of which have been identified to 
be inactivating mutations and as such suggest a tumour suppressive function (Kadoch et al., 
2013).  
 
Polycomb Interaction 
Histone modifications can also be influenced by the polycomb group of proteins, originally 
identified in 1985 in the species Drosophila melanogaster (Jurgens, 1985).  The polycomb 
proteins are a set of transcription regulatory factors and can be stratified into functionally 
distinct groups- PRC1, and PRC2. PRC1 has E3 ligase activity, and its substrate is the 
monoubiquitinated form of H2A at lysine 119. PRC2 on the other hand has methyltransferase 
activity and generates H3K27me2/me3 (Di Croce and Helin, 2013). One of the main PRC2 
enzymes is EZH2 (enhancer of zeste 2) which contains a SET domain responsible for the 
methyltransferase activity of the complex (Aranda et al., 2015). Both PRC1 and -2 further 
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interact with additional factors to regulate enzymatic activity and in which fashion the 
chromatin is recruited to the complex (Aranda et al., 2015). Moreover, PRC2-Ezh1 and –Ezh2 
exhibit distinct chromatin binding properties, as illustrated by the specific chromatin 
compaction property of PRC2-Ezh1 (Margueron et al., 2008). 
The activity of polycomb proteins during development is critical for successful gestation: 
deletions of some of the polycomb proteins such as Eed, Ezh2 or Suz12 results in embryonic 
lethality in mice (Schuettengruber and Cavalli, 2009). The abundance of polycomb proteins in 
development is also depicted by Mohn who reported that PRC2 targets represent ~10% of the 
genes in ESCs (Mohn et al., 2008). 
Epigenetic mechanisms such as histone modifications and chromatin remodelling are key for 
the appropriate regulation of gene expression. Post-translational modifications to the side 
chains extruding from the nucleosomes include histone acetylation and methylation. Such 
modifications impact on the packing and structure of chromatin controlling its accessibility to 
transcriptional machinery. The polycomb group of proteins are important part of silencing 
through its influence on histone modification in a cell and developmental stage specific manner 
(Gunster et al., 2001). These proteins are responsible for the repression of gene expression 
through histone methylation e.g. H3K27 and H3K9 (Lindroth et al., 2004), and also the 
ubiquitination of H2A (Wang et al., 2004). 
 
Relationship between post-translational histone modifications and DNA methylation 
DNA methylation and post-translational histone modifications are two fundamental 
mechanisms used to regulate transcription amongst other functions (Hu et al., 2009). There are 
a number of post-translational modifications involved in the recruitment and utilisation of the 
DNA methylation machinery. In particular, the histone modifications can play a fundamental 
role in shaping the DNA methylome (Stewart et al., 2015).  However, the mechanisms 
responsible for targeting the DNA methylation machinery at key developmental milestones are 
poorly understood.  
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H3K4 and DNMT3L 
DNMT3L is a regulatory co-factor for the de-novo methyltransferases DNMT3A and -3B 
(Chen et al., 2005). The co-factor DNMT3L binds to the tail of H3K4 in vitro. Ooi & Bestor 
discovered that it is the N terminus of H3 that is specifically required for de novo methylation, 
which occurs in dense regions of heterochromatin that lack H3K4 (Ooi et al., 2007). Dnmt3a’s 
methylation levels are dependent on the PHD domain of Dnmt3L’s ability to recognise the tail 
of H3 with its unmethylated lysine 4 which was shown through a functional analysis of 
DNM3L in mouse ESCs. 
Further evidence to support the role of de novo methylation is supported by observations 
through the targeted mutagenesis of Dnmt3L in mouse. Such observations have revealed that 
3L is required for the methylation of essentially all sequences, including imprinted loci in both 
the male and female germ cells (Hata et al., 2002; Kaneda et al., 2004), retrotransposons and 
other sequences, consistent with Dnmt3L’s ability to co-localize and co-immunoprecipitate 
with Dnmt3a and -3b (Hata et al., 2002). 
CpG islands experiencing active DNA methylation have been shown to have reduced levels of 
H3K4me2 and H3K4me3 in oocytes. In particular methylome profiling of oocytes that were 
deficient in H3K4 demethylase KDM1A or KDM1B showed that a lack of H3K4 methylation 
is fundamental for the correct methylation establishment at CpG islands (Stewart et al., 2015). 
Indeed, trimethylation and dimethylation of H3K4 (K4me3/K4me2) is uniformly associated 
with sites of transcription initiation (Deaton and Bird, 2011). It follows suit that the promoters 
of ESCs that are dense with CpG are associated with H3K4me3 which is supported by the 
observations that de novo DNA methylation is selectively inhibited by methylation of H3K4 
(Ooi et al., 2007; Otani et al., 2009; Williams et al., 2011). 
H3K27 and -3A 
H3K27 is associated with regions of the genome silenced by polycomb transcriptional 
repression, catalysed in particular by the Ezh1/2 components of PRC2 (Rose and Klose, 2014). 
Conversely to H3K4 and its association with a state of active transcription, the trimethylation 
of H3K27 is usually associated with transcriptional repression. However bivalent domains have 
been shown to exist in many developmental genes in ESCs. Bivalent domains are unique in 
that they contain both H3K4me3 and H3K27me3 and are thought to poise genes for future 
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activation or repression. Through stimuli, which promote differentiation the bivalent domains, 
are able to settle into either the active H3K4me3 or repressive H3K27me3 monovalent 
chromatin structures (Kong et al., 2016). The repressive H3K27me3 is not specifically 
localised to a particular element of the genome but instead is found widely distributed 
throughout. Interestingly the PRC2 complex, which methylates H3K27me3 is primarily 
localised to dense regions of unmethylated CpGs and afore mentioned bivalent domains reside 
here (Kong et al., 2016). The opposite is true however in somatic and cancerous cell lines where 
the repressive H3K27 is not strictly localised to CGI. 
 
Genome-wide techniques to study the epigenome 
History of technologies for assaying methylation and transcription 
Since the accelerated development of sequencing technologies following the first large-scale 
practical method coined by Sanger (Sanger et al., 1992) further development of the sequencing 
field was needed to promote automation, develop high throughput sequencing approaches and 
cut the cost of sequencing per base exponentially (as reviewed in Heather and Chain, 2016). In 
doing so massive parallelisation was achieved (Anderson and Schrijver, 2010). These early 
sequencing techniques are often referred to as first generation sequencing and were particularly 
important for the requirements of the large-scale collaborative Human Genome Project which 
was ultimately completed in 2003, with an initial draft published in 2001 (Lander et al., 2001).  
Throughout the 1980s and 1990s many research groups explored alternatives to electrophoretic 
sequencing which ultimately did not pay off until the human genome project. NGS 
technologies differ mostly from these techniques in their ability to multiplex, and cyclical 
biochemistry e.g. polymerase mediated incorporation of fluorescently labelled nucleotides and 
imaging- that is Sequencing by Synthesis (SBS). 
SBS methods are at the fore-front of these parallel DNA sequencing technologies. The 
principle of SBS is based upon the incorporation of four base-specific fluorescent dyes. The 
dyes are specific for each of the organic bases guanine, adenine, cytosine and thymine, and are 
used instead of the more traditional radioactive labels (Ju et al., 2006). The replacement of the 
laborious gel electrophoresis with automated capillary electrophoresis has also helped to 
promote parallelisation. Examples of these SBS techniques include pyrosequencing (Ronaghi 
et al., 1998), the sequencing of individual DNA molecules (Braslavsky et al., 2003) and 
polymerase colonies (Mitra et al., 2003). 
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Post-Sanger the development of DNA sequencing technologies enabled the explosion in 
capacity and the exponential drop in sequencing costs/base through massive parallelisation. A 
fragmented input sample of genomic DNA or cDNA (depending on the application of the array- 
can be whole genome or expression) is captured on an array in such a way that each well or 
feature is populated by a single target molecule (Trevino et al., 2007). 
Current methods for genome-wide assessment of DNA methylation  
Techniques currently available to assay methylation on a genome wide scale at single 
nucleotide resolution differ in respect to the amount of input DNA, resolution and probe 
coverage of the genome and the ease of downstream bioinformatic analysis of the respective 
platforms (Yong et al., 2016).  Such third-generation experimental approaches to study 
epigenetic profiling of the methylome can be categorised into the following experimental 
approaches (Figure 8);  
 
Figure 8- Diagram showing commonality of genome-wide techniques to analyse methylation. A) 
Fragmentation of DNA is often generated through sonication or digestion by restriction enzymes. From 
here the genomic segments of DNA can undergo MBD (Methyl Binding Domain) or antibody 
enrichment, bisulfite conversion (for the detection of 5mC or 5hmc as depicted by the circles) or TET 
oxidation. A microarray or NGS platform then analyses the enriched fragments. B) The methylation 
analysis of single cells permits the assessment of methylation heterogeneity in whichever populations 
of cells being tested. Contrarily, it is possible to assess methylation in pooled heterogeneous cell 
populations. The filled blue dots represent 5mC, whilst unfilled represent cytosine. Each track is one 
read. Figure sourced from Yong et al. (2016) with re-use allowed under the Creative Commons 
Attribution 4.0 International License. 
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i) Reduced-representation bisulfite sequencing (RRBS) 
Developed by Meissner et al (Meissner et al., 2008), this technique applied the reduced 
representation shotgun sequencing approaches used for SNP discovery to assay methylation. 
Here the genome is subjected to restriction enzyme digestion using one or more enzymes, 
fragments in a certain size category are selected then bisulfite conversion is followed by next-
generation sequencing for the downstream analysis of the patterns of specific fragments. While 
the digested fragments only represent typically 5-10% of the genome, they were found to 
capture 85% CGI when they were of 40-220bps in size. These CGIs mostly lay in promoter 
regions, which had the effect of limiting the genome coverage, as promoters are only found in 
1-3% of the genome; thus there is a lack of coverage at intergenic and some distal regulatory 
elements. This however is a more cost-effective approach than whole-genome shotgun 
sequencing (WGBS) yet retains high sensitivity and single base resolution. 
ii) TET-assisted bisulfite sequencing (TAB-seq) 
This expensive approach to sequencing allows the creation of 5hmC profiles at a single 
nucleotide resolution in both Human and mouse ESCs. In this instance the 5hmC is protected 
from TET-mediated oxidation through the addition of glucose to the 5hmC with the use of β-
glucosyltransferase (β-GT) to form β-glucosyl-5 hydroxymethylcytosine (Yong et al., 2016). 
Tet1 oxidises the 5mC to 5caC and this and the unmethylated C are susceptible to bisulfite 
conversion. Consequently, they are sequenced as T, and 5hmC is sequenced as C. There are 
complications with TAB-seq whereby the Tet enzyme is used at a low efficiency and as such 
may omit some methylated cytosines. This can be overcome by using more processive Tet 
enzymes with conversion rates of more than 96% (Yu et al., 2012). 
iii) Comprehensive High Throughput Arrays for Relative Methylation (CHARM) 
This approach uses a restriction enzyme McrBC to fractionate the input DNA, followed by 
hybridisation to an array (Irizarry et al., 2008). McrBC is responsible for cleaving half of the 
methylated DNA, and all the methylated CGIs (Sutherland et al., 1992), and after size selection 
hybridises the fragments to an array. The cost-effective method has a moderate resolution as 
the coverage is limited to sites that are close to the recognition sites of the restriction sites, 
however this does have the advantage that the CGs assayed are not selective to only CGI and 
promoter regions and so in this respect offers genome wide coverage. DMRs outside CGI 
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shores have been detected using this method, which is not possible with the 
immunoprecipitation-based methods like MeDIP. 
iv) Methylation DNA Immunoprecipitation (MeDIP) 
As a cost-effective method MeDIP uses an anti-methylcytosine antibody to immunoprecipitate 
DNA with CG sites that are methylated (Zhao et al., 2014). The enriched fractions can then be 
further analysed using either MeDIP-chip or MeDIP-seq. MeDIP-seq has a typical resolution 
of 100-300bp and is particularly sensitive in areas of low CG coverage. 1x coverage has been 
suggested by Taiwo et al (Taiwo et al., 2012) to cover up to 70% of all CpGs in human, and 
this can even be achieved with as little as 1ng of genomic DNA starting material. This proves 
useful for methylation analyses in small rare samples and micro-dissected tissue samples.  
v) Whole Genome Bisulfite Sequencing (WGBS) 
This approach uses purified and sheared genomic DNA fragments. The fragments are end 
repaired, a poly-A tail is added, followed by the ligation of methylated adapters (Urich et al., 
2015). Prior to bisulfite conversion and polymerase chain reaction (PCR), the fragments are 
size selected, and a library is sequenced. WGBS is an expensive method of sequencing, but it 
does offer nearly full resolution of all the CG sites (even at lower density CG regions and distal 
regulatory elements), despite not being able to discriminate between 5mC and 5hmC at these 
locations. WGBS has been employed by the large epigenome consortiums such as ENCODE 
(ENCODE Project Consortium, 2012) and BLUEPRINT (Adams et al., 2012). 
vi) Methylation sensitive Restriction Enzyme Sequencing (MRE-Seq) 
MRE based sequencing techniques rely on enzymes that include BstUI, HpaII, NotI and SmaI. 
MREs cleave at the unmethylated CpG, leaving the methylated DNA intact. Indeed, this is the 
underlying principle of MRE-seq, whereby upon enzyme mediated cutting of the unmethylated 
site, the fragmented DNA is selected upon size and sequenced (Li et al., 2015). Sequencing 
this way shows the MRE recognition sites within the unmethylated DNA fragment, and in this 
way DNA methylation can be estimated but at a low resolution due to the limiting factor of the 
recognition sites containing CpGs (Li et al., 2015). 
vii) Illumina Infinium Methylation Array- from Generation 27k to EPIC 
The Infinium family of methylation arrays from Illumina was adapted from its BeadArray 
technology that was originally designed for genotyping to quantify methylation at individual 
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CG dinucleotides at defined probes across the human genome (Bibikova et al., 2011). Prior to 
the launch of the HumanMethylation27 BeadChip (27k), the existing platforms required to 
assay methylation relied upon tiling microarrays, or large scale bisulfite-genome DNA 
sequencing for example. Both techniques relied upon a large amount of input material and were 
labour intensive with complex downstream bioinformatic analysis. These drawbacks rendered 
the use of such platforms useless where there were only small amounts of precious material in 
a large study.  
The 27k was released in 2008 (later phased out) and had the capacity to quantify DNA 
methylation at 27,578 CG dinucleotides over a region of over 14,000 genes in the human 
genome. Only 1µg of genomic DNA is required as input material with an availability of 12 
samples per chip to promote high throughput and comparable analyses. 
The 27k and later generations of the BeadChip use Infinium technology. Infinium technology 
is based upon the bisulfite conversion of genomic DNA, such that the unmethylated cytosines 
are deaminated to uracil whilst the methylation status of the methylated cytosines is 
maintained. Post conversion the individual samples are whole genome amplified and 
fragmented using enzymes. It is these bisulfite converted fragments that are purified before 
their addition to their respective BeadChips. 
There are two bead types- one type for the methylated cytosine, and the other for the 
unmethylated thymine at the CpG locus. Primers anneal in an allele specific fashion, before the 
single base extension facilitated by DNP- and Biotin-labelled dideoxynucleotides (ddNTP). 
Each bead type for the same CG dinucleotide can incorporate the same DNP/Biotin- labelled 
ddNTP, and this is incorporation is dependent on the base that is before the cytosine of interest 
at the CG dinucleotide for which methylation is to be measured. Both types can be measured 
in the same colour channel. 
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Figure 9: Schematic depicting the mechanism of each Infinium bead type in Illumina's 
Methylation BeadChip Arrays.  A- Infinium I assay) Each CpG locus has two correspondent beads, 
one for methylated cytosine, and one for unmethylated thymine at that dinucleotide. The same labelled 
nucleotide is associated with both bead types for that locus, and this is determined by the cytosine that 
precedes the cytosine at the CG dinucleotide being assayed for methylation; thus both values are 
recorded in the same channel. B- Infinium II assay) In this instance only one bead type correspondents 
to each CpG locus, not two as per the Infinium I assay. The probe contains 1-3 underlying CpG sites, 
in addition to a degenerate R base. This R base corresponds to cytosine at the CG dinucleotide. 
Methylation levels are assayed through single-base extension, and the locus is detected in two colours.  
Methylation state is detected by single-base extension. Infinium Image taken from Bibikova et al. 
(2011) according to the Copyright Clearance Centre under order number 4395961226402.  
 
After each subsequent extension the array is stained fluorescently and through scanning of this 
florescence the intensities of both the methylated and unmethylated beads is measured before 
downstream analysis via e.g. Illumina's BeadStudio software. DNA methylation is measured 
on a β scale from 0-1 that is from being an unmethylated CpG site to a fully methylated CpG 
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site (Barrera and Peinado, 2012). The beta score is derived from a ratio of the intensity of the 
methylated bead to the combined locus intensity. Initially the process preparing for and 
completing 27k was up to one week. 
The 27k was superseded in 2011 by the IlluminaHumanMethylation450 (‘450k’) array that had 
the ability to profile the methylation status of over 450,000 CG dinucleotides. The 450k probes 
cover 99% of RefSeq genes, spanning 17,755 unique CpG Islands with additional coverage in 
areas identified as CpG shores and miRNA promoters (Morris and Beck, 2015). The design of 
the 27k array uses Infinium I probe chemistry (two beads per probe- one bead in the red 
channel, and one in the green channel) unlike the 450k array that uses Infinium II. Infinium II 
was designed to allow more probes to be accommodated on the array, whilst retaining 30% of 
the Infinium probes (Morris and Beck, 2015). The genomic locations of probe types in the 450k 
array can be seen in Table 1. The presence of more than one Infinium probe type however can 
cause type II bias during analysis (Teschendorff et al., 2013), which needs to be corrected 
downstream through bioinformatic curation using normalisation strategies such as BMIQ (Beta 
Mixture Quantile dilation) (Teschendorff et al., 2013). 
 
 
 
 
 
Table 1- Number of 450k array loci stratified by probe design and genomic region. Different 
proportions of both probe types are aligned to delineated genomic regions ranging from the CG dense 
CGI to the sparse regions of the open sea. The proportions of probes reflect this density. The total 
number of probes on the 450k array were totalled at 485,512. Table adapted from Aryee et al. (2014). 
Reuse of this table was approved using Copyright Clearance Centres RightsLink® Service (Order 
Number 4317021403928). 
 
The 450k BeadChip however despite its improved coverage lacked probes over distal 
regulatory elements such as the enhancers, distal regulatory elements and DNase 
hypersensitivity sites. To address this, Illumina developed the MethylationEPIC (EPIC) 
BeadChip in late 2015. The EPIC BeadChip has an improved coverage compared to that of the 
450k, with probes for over 850,000 CG dinucleotides (with a concordant overlap of 90% with 
the 450k probes) with probes distributed across many genomic regions as shown in Table 2. It 
Region Type 
Probe Design 
Total 
I II 
CpG Island 77,764 72,850 150,524 
CpG Island Shore 22,371 89,696 112,067 
CpG Island Shelf 6,913 40,231 47,144 
Open Sea 28,518 147,529 176,047 
Total 135,476 350,036 485,512 
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is important to note however that all generations of the Infinium arrays contain probes 
specifically designated to determining the quality of the data generated, and some sample 
independent and –dependent controls (Illumina, 2011). Illumina responded to users of the 450k 
BeadChip for requests for improved coverage at regions such as enhancers (ENCODE) and 
DNase hypersensitivity which designers addressed. The EPIC array also covers the enhancers 
as identified by FANTOM5 across multiple human tissue types and miRNA promoter regions 
among others.  
  
 
 
 
 
Table 2: Distribution of EPIC array probes across multiple gene regions. The probes of EPIC area 
are distributed and spread across genomic features at a coverage level of 80-95% with 2-6 loci covered 
per feature (Illumina, 2015). 
 
BeadChip Array IDATs 
Intensity Data Files (IDAT) are used to store BeadChip array data generated by the Illumina 
suite of platforms that offer genome wide profiling e.g. the Illumina iScan system which can 
be used for epigenome wide 450k and 850k BeadChip methylation profiling (Smith et al., 
2013). IDATs are used by the respective scanner (e.g. iScan) to store intensity values for each 
of the array probes compactly. These IDATs can then be analysed using the Illumina licenced 
Genome Studio and/or a range of open source platforms and pipelines such as the R packages 
illuminaio or RnBeads- both of which can be used in RStudio. However, it is important to note 
that the Genome Studio software supported by Illumina fails to extract all of the available 
information that can be extracted from IDATs such as the control probe intensities and meta-
information that provides information about the physical scanning process and software 
versions. 
 
The type of array platform used dictates the type of IDAT that is formatted and used as the 
output. The IDATs generated in the process of methylation array profiling using the BeadChips 
Feature Type No Covered % Covered Avg No Loci/Feature
Island 26,000 >95 6
North Shore 25,000 >90 3.5
South Shore 25,000 >90 3.5
North Shelf 22,000 >80 2
South Shelf 22,000 >80 2
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are binary files – in that the red and green channels have distinguishable and individual IDATs. 
These binary files contain an identification of the bead type from whichever array has been 
used, their mean and standard deviation intensities and the number of each type of bead present. 
Metadata including details about the array are also included such as the type of BeadChip and 
specific software used in the generation of the respective output IDAT. On the other hand, gene 
expression BeadArray data is usually presented in encrypted XML (eXtensible Markup 
Language) format with ten fields of data, compared to four fields for BeadArray Methylation 
data.  
 
Illuminaio was one of the first free packages that offered a user-friendly approach to extracting 
data for downstream analysis from the IDATs from Illumina BeadChip sequencing platforms 
whilst opening the possibility of creating an open-source sharing of array data in open access 
databases. This in turn has facilitated the use of publicly available data between multiple 
research groups on an international scale. As of 2013 (Hansen) 1.5% of the Illumina BeadChip 
array data submitted to GEO have included these raw IDATs as supplemental material 
 
RnBeads 
As one of the freely available software tools used to analyse 450k (Assenov et al., 2014) and 
more recently 850k IDATs, it is arguably one of the most comprehensive packages that 
currently exists to manage high resolution Infinium DNA methylation array data. RnBeads 
offers a manageable approach to allow the user the opportunity to avail of a completely 
integrated pipeline capable of the running and tailoring of multiple analytical modules. Some 
of these workflow modules include normalisation, quality control (QC), exploratory analysis, 
differential methylation and others specific to the user’s defined analysis aim, all from one 
individual function rnb.run.analysis(). Some of the modules in the workflow such as 
normalisation can be run with various options depending on the nature of the study by using 
SWAN (Maksimovic et al., 2012), BMIQ (Teschendorff et al., 2013), watermelon (Pidsley et 
al., 2013), or the methylumi noob method (Davis et al., 2007).  RnBeads was designed based 
on a review of other software tools that previously existed to analyse DNA methylation 
microarray data; with this in mind the developers of RnBeads based their development on 
several key essential features (Table 3). 
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Table 3: Fundamental features of RnBeads are based on seven key principles, for which a rationale 
is offered for each. This table is amended from text in Assenov et al. (2014). 
 
R and Object Orientated Programming 
R is an extensible programming language (XML) capable of introducing different approaches 
to object orientated programming (OOP).  OOP itself refers to a type of programming language 
model that combines data and functionality into an object. These objects are arranged into 
classes and interact with each other. For those who were responsible for developing R the two 
approaches to OOP were S3 and S4 class objects.  
S3 class objects allow computations to be carried out via a generic function that decides what 
type of method to call. These generic methods are simply ordinary functions.  S3 is a casual 
class object, easily manipulated and informal by nature and as such is widely implemented. On 
the other hand, S4 is a more rigorous and formal class system with special helper functions for 
defining generics and methods. S4 is capable of multiple dispatch permitting genetic functions 
to pick methods based on the class of multiple arguments and is frequently employed by 
Bioconductor in the analysis of large microarray datasets. S4 class objects offer lower error 
rates due to the rigorous definition of the object, and as such when a function acts on this type 
of object the function is clear as to what information is contained within that object. S4 objects 
Key Feature  Rationale 
Support Single nucleotide resolution from genome wide methylation assays 
Functionality Offers data visualisation of DNA methylation data, QC, exploratory 
analysis, differential methylation analysis. 
Interaction RnBeads can generate reports that are both interactive and adjustable 
within defined parameters.  
Standardised standardised yet configurable workflow outputs 
 
Flexibility 
RnBeads does not require high-spec computers or cluster and can 
even run through an online cloud service. 
Performance RnBeads maintains the ability to analyse not only 450k and 850k 
data but that of WGBS and RRBS methylation data. 
Reproducibility  The pipeline generates replicable outputs when using comparable 
input parameters and analytical options. 
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allow ease of coordination for multiple contributions to large datasets and projects (Gentleman 
et al., 2004).  
Bioconductor 
The Bioconductor project is an open source collaborative suite of bioinformatic software tools 
for the analysis of high throughput genomic data that primarily runs on the R programming 
language. The goals of the Bioconductor project are three-fold in that the collaborative effort 
aims to 1) nurture the on-going development of innovative software, 2) diminish potential 
barriers to initiating interdisciplinary scientific research, and 3) to bolster the success of remote 
reproducibility of research results for the wider scientific community (Gentleman et al., 2004). 
To comfortably use Bioconductor the user requires some background knowledge in biology, 
computer science and in statistics however many users are not aligned to be comfortable with 
all three disciplines. In this instance Bioconductor produces support documentation accessible 
to all users. 
The Bioconductor project attempts to simplify the statistical inferences researchers are required 
to perform when analysing large genomic data sets by providing a set of statistical methods 
that are easy to interact with. This is implemented by placing emphasis on data management 
and transformation, machine learning, and the continued development of data modelling 
strategies that are complementary to computational biology and bioinformatics. In addressing 
these areas of emphasis, Bioconductor offers a software environment that promotes 
transparency, reproducibility and efficiency of development.  
The team behind the development of Bioconductor had an interest in the data management, 
downstream analysis and problems therein of data contained in DNA microarrays. To suitably 
address these concepts, a programming environment was required that offers complex 
numerical analyses, potential for data visualisation, opportunity to access databases and 
provides a comprehensive range of statistical and mathematical algorithms.  
Minfi 
Minfi is a package implemented in the Bioconductor suite designed for the analysis of DNA 
methylation array (Aryee et al., 2014), and the Infinium 450k BeadChip array in particular 
from Illumina (Bibikova et al., 2011). Modifications have been made to the Minfi package 
since the release the Illumina HumanMethylationEPIC array (Fortin et al., 2017). Minfi 
functions through modular representations of the 450k array data by using S4 classes. Minfi 
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begins with the raw IDAT files that hold both the red and green channel intensities. From there, 
the ‘RGChannelSet’ class sorts the intensities into an object that can be accessed by multiple 
methods. Once the data is converted to methylation measurements it can be stored as the 
following four classes that each can form part of the pre-processing data; 
 MethylSet 
 GenomicMethylSet  
 RatioSet and,  
 GenomicRatioSet.  
‘Genomic’ refers to the non-reversible association of the methylation loci with a genomic 
location. Whereas the two classes MethylSet and GenomicMethylSet represent the raw 
Methylated and Unmethylated measurements. These two classes accommodate pre-processing 
routines that are responsible for the final measurements in these channels. These final 
measurements include normalisation that is currently included with Illumina’s GenomeStudio 
Software.  The RatioSet and GenomicRatioSet classes represent the data as beta values or M-
values (log ratios of beta values). The ratioConvert function converts MethylSet to RatioSet 
and GenomicMethylSet to GenomicRatioSet. This design provides a flexible framework for 
method development and downstream analyses, the natural starting point for which tends to be 
the GenomicRatioSet class.  
Minfi as a package simplifies the import of raw data from the IDAT files or pre-processed data 
from GenomeStudio (Illumina’s default software), or indeed the public deposited and available 
array data in NCBI GEO- from there the data can also be conveniently stored in 
GenomicRatioSet objects. 
 
Tertiary Analysis 
The resultant genomic data generated from processing of methylation array data is subject to 
downstream tertiary analysis. This analysis uses a variety of databases and reference systems 
to translate the output data to gene lists to allow functional annotation e.g. GO and KEGG 
classifications. However, whilst there are a growing number of databases for the functional 
annotation of genome information (such as PFAM, REPBASE, and ENSEMBL), I will 
concentrate here on those which were used most in the work presented in this thesis. 
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Galaxy 
The Galaxy web-based platform was initially launched in 2005 to offer scientists with minimal 
levels of computational expertise an opportunity to perform free informatic analysis of large 
datasets. The focus of the Galaxy online platform, which can be found on a public server at 
http://usegalaxy.org, is to offer a range of tools to aid downstream data manipulation and 
visualisation. The Galaxy software framework is an open-source application, with which the 
user interacts by uploading their data and analysing through servers. The platform is free and 
offers substantial CPU and disk space. 
The Galaxy platform offers an efficient approach to attacking large datasets and integrating 
these resultant gene lists using analysis tools and offers functionality to visualise interactive 
user defined tracks on genome browsers such as UCSC genome browser (Kent et al., 2002) or 
IVG (Robinson et al., 2011). The three-fold goals of the Galaxy project are to; 
 Increase access to complex computational analysis for those with limited 
computational knowledge. 
 Create workflows that are automated, multi-step and available for multiple users to 
promote analysis automation. 
 Provide collaborative analyses through enabling Galaxy users to share and publish 
their analyses online 
 
PANTHER Classification System  
Protein Analysis through Evolutionary Relationships (PANTHER) is a free online software for 
denoting gene function based upon evolutionary relationships, and to classify proteins for high-
through put analysis (Mi et al., 2010). PANTHER is financially supported through research 
grants from the National Human Genome Research Institute and the National Science 
Foundation and it is maintained at the University of Southern California (the Thomas lab). The 
latest version (13.1) dated 03/02/2018 contains 15524 protein families, divided into 79562 
functionally distinct protein subfamilies (http://www.pantherdb.org/about.jsp). 
Throughout the continued development of PANTHER, the primary function remains to be the 
accurate inference of gene and/or protein function from sizeable online sequence databases, 
using e.g. phylogenetic trees to further extrapolate from the minimal experimental information 
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generated in a limited range of model organisms (Mi et al., 2013). PANTHER is made up of 
two components- the PANTHER library and the PANTHER index. The library holds a 
collection of protein families in the form of a multiple sequence alignment, and a Hidden 
Markov Model (HMM) in addition to a family tree. The PANTHER index covers ontology and 
subsequent molecular functions and biological processes associated with the families (or sub-
families) (Thomas et al., 2003). 
 
DAVID 
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) is an online 
bioinformatics resource with built in tools used to functionally analyse large genome datasets 
particularly those derived from microarray analyses such as methylation or transcriptional array 
data. The database is a freely available online interface maintained by the National Institute of 
Allergy and Infectious Disease (NIAD), part of the National Institute of Health (NIH) and can 
quickly and comprehensively analyse sizeable uploaded gene lists. Thus, DAVID offers 
assistance in the interpretation of genome wide array derived datasets that can help bridge the 
gap between arbitrary gene lists to some translational biological meaning where themes can be 
derived. The processed data is presented in the forms of exploratory visualisation through 
functional classification, biochemical pathway maps, and conserved protein domain 
architectures. DAVID is updated weekly through an automated VBA procedure from multiple 
sources that come from the annotation data shown in Table 4. 
 
 
 
 
 
 
 
 
59 
 
 
 
 
 
 
Table 4 Annotation resources used complied into David. DAVID is updated on a weekly basis using 
Visual Basic (VB) to call a set of Perl and Java applications that are capable of downloading public data 
through a process of file transfer protocols. These are unpacked with any relevant annotation data; from 
here tab-delimited files are created for database import onto a regional database management system. 
Table 4 represents a list of the key resources from which data is imported (Dennis et al., 2003). 
 
DAVID is composed of four main modules 
1. Annotation Tool,  
2. Go Charts,  
3. Kegg Charts, and  
4. Domain Charts.  
The Annotation Tool is an automated method for the functional annotation of gene lists. Any 
combination of annotation data can be chosen from options including GenBank, Unigene, 
LousLink, Refseq and others. The annotations are added to the user defined submitted gene list 
to return a HTML table containing the user's original list of identifiers and the chosen functional 
annotations.  The next module GoCharts is responsible for a graphical display of the 
distribution of differentially expressed and/or methylated genes among functional categories 
using the controlled vocabulary of the Gene Ontology Consortium (GO) 
The third module Kegg Charts display the spread of differentially expressed and/or methylated 
genes among KEGG biochemical pathways in the form of graphs. Each pathway is linked to a 
KEGG pathway map, wherein differentially expressed/methylated genes from the original list 
are highlighted in red to allow individual gene delineation. Finally, the DomainCharts module 
displays the distribution of differentially expressed genes among PFAM protein domains 
Resource URL 
GenBank http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html  
UniGene http://www.ncbi.nlm.nih.gov/UniGene/ 
RefSeq http://www.ncbi.nlm.nih.gov/RefSeq/ 
LocusLink http://www.ncbi.nlm.nih.gov/LocusLink/ 
KEGG http://www.genome.ad.jp/kegg/ 
OMIM http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM  
Gene 
Ontology 
http://www.geneontology.org/ 
University of 
Michigan 
http://dot.ped.med.umich.edu:2000/ourimage/pub/shared/JMR_pub_affyannot.ht
ml  
NetAffx http://www.affymetrix.com/analysis/index.affx  
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(Dennis et al., 2003). Each domain designation is linked to the Conserved Domain Database 
(CDD) of the National Centre for Biotechnology Information (NCBI). 
 
Concluding Remarks 
DNA methyltransferases play a critical role in the regulation of gene expression at key 
development stages and continuously during mammalian life. DNA methylation interacts with 
additional epigenetic modifiers such as the polycomb and the histone proteins to do this. A 
number of gene classes are regulated by DNA methylation and are especially sensitive to global 
methylation changes, namely the imprints and those on the X chromosome.  In this thesis I 
describe global demethylation changes caused by transient and stable reductions of DNA 
methyltransferases in human and mouse model systems and how we identified gene classes 
that are particularly sensitive to such methylation events. 
 
Aims of the Study 
Through the use of both bioinformatic and wet-lab experimental approaches in human and/or 
mouse model systems, I aim to; 
1) Identify whether a range of known and putative imprinted regions in mESCs are capabale 
of recovery of methylation once lost, 
2) Determine whether the de novo methyltransferases Dnmt3a/3b have a role in the 
maintenance of methylation in the mESCs, 
3) Identify if there are any enriched loci in the human genome that are particulary sensitive to 
a stable loss of maintenance methylation and whether this correlates with any other mark, 
4) Determine if there is any difference in the response of non-transformed hTERTs cells to a 
transient loss of methylation through DNMT1 targeting siRNA or treated with 5-aza-2'dC.  
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The main aims of this paper were to: 
1. Compare the roles of DNMT1 and the DNMT3A/B enzymes in maintaining 
methylation levels at imprinted genes in mouse ESC. 
2. Obtain more quantitative and systematic data on all gametic differentially methylated 
regions (gDMR) which control imprinted loci, including new putative gDMR recently 
identified. 
3. To re-examine the dependence of imprinted regions on germline passage to restore 
methylation, once lost.  
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contributed to the writing of the manuscript and edits. 
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Summary of the major findings; 
1. A loss of DNMT1 and DNMT3A/B created similar reductions in methylation levels at 
imprinted gDMRs. 
2. Recovery of methylation at imprints is possible when 3abKO cells are rescued with 
DNMT3a2. Methylation cannot be recovered however at imprints in the rescued 1KO+1 ES 
cells. 
3. It was observed at three gDMRS once methylation was lost; it was unable to be recovered.
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Widespread recovery of methylation 
at gametic imprints in hypomethylated mouse 
stem cells following rescue with DNMT3A2
Avinash Thakur1,2, Sarah‑Jayne Mackin1, Rachelle E. Irwin1, Karla M. O’Neill1,3, Gareth Pollin1 
and Colum Walsh1* 
Abstract 
Background: Imprinted loci are paradigms of epigenetic regulation and are associated with a number of genetic dis‑
orders in human. A key characteristic of imprints is the presence of a gametic differentially methylated region (gDMR). 
Previous studies have indicated that DNA methylation lost from gDMRs could not be restored by DNMT1, or the de 
novo enzymes DNMT3A or 3B in stem cells, indicating that imprinted regions must instead undergo passage through 
the germline for reprogramming. However, previous studies were non‑quantitative, were unclear on the requirement 
for DNMT3A/B and showed some inconsistencies. In addition, new putative gDMR has recently been described, along 
with an improved delineation of the existing gDMR locations. We therefore aimed to re‑examine the dependence of 
methylation at gDMRs on the activities of the methyltransferases in mouse embryonic stem cells (ESCs).
Results: We examined the most complete current set of imprinted gDMRs that could be assessed using quantitative 
pyrosequencing assays in two types of ESCs: those lacking DNMT1 (1KO) and cells lacking a combination of DNMT3A 
and DNMT3B (3abKO). We further verified results using clonal analysis and combined bisulfite and restriction analysis. 
Our results showed that loss of methylation was approximately equivalent in both cell types. 1KO cells rescued with a 
cDNA‑expressing DNMT1 could not restore methylation at the imprinted gDMRs, confirming some previous observa‑
tions. However, nearly all gDMRs were remethylated in 3abKO cells rescued with a DNMT3A2 expression construct 
(3abKO + 3a2). Transcriptional activity at the H19/Igf2 locus also tracked with the methylation pattern, confirming 
functional reprogramming in the latter.
Conclusions: These results suggested (1) a vital role for DNMT3A/B in methylation maintenance at imprints, (2) that 
loss of DNMT1 and DNMT3A/B had equivalent effects, (3) that rescue with DNMT3A2 can restore imprints in these 
cells. This may provide a useful system in which to explore factors influencing imprint reprogramming.
Keywords: Imprinting, DNA methylation, Reprogramming, ESC
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In mouse, DNA methylation is found predominantly at 
cytosine when followed by guanine (CpG) and is associ-
ated with various biological functions including the reg-
ulation of gene expression, X chromosome inactivation, 
silencing of retrotransposons and imprinting [1]. Many 
CpGs are protected from methylation by being clustered 
into CpG islands (CGI), which are commonly found near 
the transcriptional start sites of genes and are normally 
unmethylated, except for CGI on the inactive X or on 
inactive imprinted alleles. DNMT1, a maintenance meth-
yltransferase [2], is crucial to ensure the regular propa-
gation of DNA methylation patterns to the daughter 
strand during replication [3]. This enzyme is predomi-
nantly found near replication foci [4] and preferentially 
targets hemi-methylated DNA [4–6] suggesting its main 
functions as a maintenance methyltransferase [7–9]. The 
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addition of methylation to an unmethylated template (de 
novo) is carried out by DNMT3A and DNMT3B, with 
the former responsible for most de novo activity in germ 
cells [10], while the latter predominates in somatic tis-
sues [11]. However, in addition to their de novo methyla-
tion activity, several reports on DNMT3A and DNMT3B 
indicate a role in methylation maintenance in embryonic 
stem cells (ESCs), although the extent of their require-
ment at imprinted loci remains unclear [12, 13].
Once established on a DNA duplex, methylation is 
stably maintained through most of life [14, 15], but dur-
ing certain developmental stages undergoes large-scale 
changes [11–13, 16]. Methylation patterns inherited from 
the sperm and oocyte are remodelled during pre-implan-
tation development, when the paternal and maternal 
genomes of the embryo undergo widespread active dem-
ethylation involving the TET enzymes as well as passive 
demethylation via replicative dilution [15, 17]. The blas-
tocyst stage sees methylation reach its nadir, but follow-
ing implantation, a wave of de novo methylation occurs 
causing overall global hypermethylation at most non-
island CpG in the adult tissues [18]. This de novo activ-
ity is present at high levels in ESCs [5], developing germ 
cells and early post-implantation embryos [19] but is pre-
sent at lower levels in somatic cells [20, 21]. The presence 
of de novo activity in ESCs makes these cells a suitable 
model to study the mechanism of de novo methylation in 
mammals.
One group of genes that largely escapes global meth-
ylation remodelling during somatic development is the 
imprinted genes [14, 15]. These are a group of genes 
which exhibit expression from one parental allele only 
[22, 23]. Regulation of imprinting has biological signifi-
cance as imprinted genes are important for embryonic 
development and their dysregulation leads to embry-
onic death in mouse and to various disease syndromes 
in human [22]. Initiation of allele-specific gene meth-
ylation patterns starts in the male and female germline 
during gametogenesis [24]. For imprinted genes, one of 
the parental alleles acquires DNA methylation at cer-
tain locations, and these are detected as differentially 
methylated regions (DMRs) in somatic cells [25]. Due 
to their origin in the germline, they are known as the 
gametic differentially methylated regions (gDMRs) [26], 
to distinguish them from other types of DMR such as 
tissue-specific DMR. Some of the gDMR are at cis-act-
ing regulatory regions and are known to control mono-
allelic expression of more than one linked gene: where 
this has been proven by experimentation the DMRs are 
called imprinting control regions (ICRs) [27–31]. Meth-
ylation at gDMRs is established in the germline largely by 
the de novo methyltransferase DNMT3A with the aid of 
the essential cofactor DNMT3L [32–35]. The gDMRs at 
imprinted regions exhibit the property of being able to 
resist the processes of active and passive DNA demeth-
ylation during the pre-implantation stages of mammalian 
development or iPS formation [14, 18, 36, 37].
Loss of imprinting is thought to be irreversible and 
requires germline passage for its recovery due to the 
presence of essential factors and de novo methyltrans-
ferases needed for imprint establishment there [38]. 
Previous work has shown that rescuing DNA methyl-
transferase activity in Dnmt1−/− (1KO) cells by adding 
back a cDNA expressing the enzyme failed to restore 
methylation at paternal and maternal ICRs [38]. Other 
laboratories confirmed this but reported, however, that 
the paternally imprinted H19 gDMR regained meth-
ylation in Dnmt3a−/−; Dnmt3b−/− double knock-out 
(3abKO) cells rescued with a DNMT3A2 expression plas-
mid [39], suggesting that some imprints could be somati-
cally reprogrammed. As well as these differing results, 
the early studies were carried out on a very limited num-
ber of gDMRs using qualitative approaches, which had 
limited resolution. Given the important implications 
somatic resetting could have for imprinted disease syn-
dromes as well as cellular reprogramming generally, we 
wished to re-examine whether methylation at gDMRs 
could be established outside of the germline. Recent work 
has delineated the gDMRs far more sharply since the 
original studies were carried out, and more quantitative 
techniques are now available. We aimed to investigate (1) 
whether deletion of Dnmt3ab gives comparable methyla-
tion loss at imprinted loci to Dnmt1 mutated cells; (2) 
whether imprints can be restored in 3abKO cells, unlike 
1KO ESCs; (3) does loss of methylation result in dysregu-
lated expression of imprinted genes; and (4) are there any 
exceptional imprinted gDMRs that do not regain meth-
ylation in rescued cells?
Methods
Statistical analysis
All laboratory experiments were carried out in tripli-
cate with at least one biological repeat, with one or two 
exceptions as noted. Pyrosequencing, bisulfite sequenc-
ing and RT-qPCR data are represented as graphs, 
where error bars represent standard error of the mean 
(s.e.m). Statistical analysis was carried out using EXCEL 
and GraphPad PRISM software; for pyrosequencing 
data were compared by t test and Kruskal–Wallis, and 
bisulfite clonal analysis comparison was made using the 
χ2 test.
Cells
All cell culture media components were purchased from 
Invitrogen (Paisley, UK). Dnmt1 KO and Dnmt3a/3b 
double KO cells with matching WT were kind gifts from 
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Dr. Masaki Okano (RIKEN Center for Developmental 
Biology, Kobe, Japan). ESCs were maintained on Nunc 
plates (Davidson & Hardy, Belfast, UK) treated with 
0.1% gelatin (Sigma-Aldrich, Dorset, UK) and cultured 
in Knockout DMEM plus 15% knockout serum replace-
ment, 1% ESC-qualified Foetal Bovine Serum, 1× NEAA, 
2 mM l-glutamine, 0.1 mM β-mercaptoethanol (Sigma-
Aldrich, Dorset, UK) and 1000U/ml LIF (Merck Milli-
pore, Hertfordshire, UK).
Animal work
Tissues of interest were derived from outbred TO mice 
(Harlan, Huntingdon, UK). Sperm collection was carried 
out as previously described [13].
RNA extraction, cDNA synthesis and RT‑qPCR
RNA was extracted using the RNeasy kit (Qiagen, Craw-
ley, UK), according to the manufacturer’s instructions. 
For cDNA synthesis, 300–500 ng RNA was used in com-
bination with 0.5 μg random primers (Roche, West Sus-
sex, UK), 40  U RNaseOUT 0.5  μM dNTPs (Invitrogen, 
Paisley, UK) 1× RT Buffer (Fermentas, Cambridge, UK) 
and RevertAid reverse transcriptase (Fermentas, Cam-
bridge, UK) made up to a final volume of 20  μl using 
RNase-free water (Qiagen, Crawley, UK). Reactions were 
carried out in a thermocycler with conditions—25  °C 
for 10 min, 42 °C for 60 min and 70 °C for 10 min. One 
microlitre cDNA per well on a 96-well plate (Roche) was 
used for RT-qPCR with SYBR Green reagent and remain-
ing cDNA stored at −80 °C. RT-qPCRs were performed 
using a LightCycler 480 Instrument II (Roche, West Sus-
sex, UK). Gene expression was normalised to Hprt and 
relative expression calculated by the ΔΔCT method [40]. 
Each RT-qPCR contained 1×  buffer, 0.4  mM dNTPs, 
50 μM primers (Additional file 1: Table S1), 0.01 U Taq 
DNA polymerase (Invitrogen, Paisley, UK) and nucle-
ase-free water (Qiagen, Crawley, UK). Four primer sets 
for Dnmt1, Dnmt3a, Dnmt3b [47] and Hprt [13] were 
used. The general thermocycler conditions are as fol-
lows—94 °C for 3 min, followed by 30 cycles of 94 °C for 
30 s, 63 °C for 1 min, 72 °C for 1 min with a final elonga-
tion step of 72 °C for 4 min.
Protein analysis
Protein was extracted from cells growing in log phase 
using protein extraction buffer (50  mM Tris–HCl, 
150 mM NaCl, 1% Triton-X, 10% glycerol, 5 mM EDTA; 
all Sigma-Aldrich) and 0.5  µl protease inhibitor mix 
(Sigma-Aldrich, Dorset, UK). For Western blotting, 
30 μg protein was denatured in the presence of 5 μl 4× 
LDS sample buffer (Invitrogen, Paisley, UK) and 2 μl 10× 
reducing agent (Invitrogen) in a total volume of 20  μl 
nuclease-free water (Qiagen, Crawley, UK) via incubation 
at 70  °C. Proteins were fractionated on a 4–12% SDS-
PAGE gel, then electroblotted onto a nitrocellulose mem-
brane (Invitrogen, Paisley, UK) and blocked in 5% non-fat 
milk for 1 h at room temperature (RT). Membranes were 
incubated with anti-DNMT1 (ab87654, Abcam), anti-
DNMT3A (clone 64B1446, Novus Biologicals, Abingdon, 
UK), anti-GAPDH (clone 14C10, Cell Signalling Technol-
ogies, Leiden, Netherlands) or anti-β-actin (clone AC-15, 
Sigma-Aldrich) overnight at 4 °C, followed by incubation 
with the relevant HRP-conjugated secondary antibody 
(Sigma-Aldrich, Dorset, UK) for 1 h at RT and then visu-
alised using ECL (ThermoFisher Scientific, Loughbor-
ough, UK).
DNA isolation and bisulfite conversion
DNA extraction from sperm and tissues was as previ-
ously described [41]. All ESCs were pelleted and incu-
bated overnight at 55  °C in lysis buffer (50 mM Tris pH 
8, 0.1 M EDTA, 0.5% SDS (all from Sigma-Aldrich, Dor-
set, UK), 0.2  mg/ml proteinase K (Roche, West Sussex, 
UK) with rotation. DNA was extracted next day using 
the phenol/chloroform/isoamylalcohol (25:24:1, pH 8.0; 
Sigma-Aldrich, Dorset, UK) extraction method. The 
integrity of the DNA was checked on a 1% agarose gel 
(Eurogentec, Southampton, UK) and quality and quan-
tity checked using a NanoDrop UV spectrophotometer 
(Labtech International, Ringmer, UK). For bisulfite con-
version, 500 ng of DNA was processed with the EpiTect 
Bisulfite Kit (Qiagen, Crawley, UK) or EZ DNA Methyla-
tion Kit (Zymo, Cambridge, UK) according to manufac-
turer’s instructions.
Methylation analysis
Bisulfite-converted DNA was PCR amplified in a reac-
tion containing 1  μM primers, 1× buffer and 0.4  mM 
dNTPs, with MgCl2 at a concentration specific to the 
primer set and 0.01U Taq DNA polymerase (all reagents 
from Invitrogen, Paisley, UK). Combined bisulfite restric-
tion analysis (COBRA) on genes was carried out as pre-
viously described [13] using TaqαI enzyme for H19 and 
KvDMR and BstUI for Snrpn (both New England Bio-
labs, Hitchin, UK). Clonal analysis of bisulfite-converted 
PCR-amplified products in pJET1.2 vector (Fermentas, 
Cambridge, UK) was carried out using a PRISM 3130 
Genetic Analyzer (Applied Biosystems, Paisley, UK). All 
pyrosequencing assays (Additional File 2: Table S2) were 
designed in-house using PyroMark (V2.0) assay design 
software (Qiagen, Crawley, UK). The PyroMark PCR Kit 
(Qiagen, Crawley, UK) was used to amplify genes using a 
thermocycler (Techne, Stone, UK) with conditions: 95 °C, 
15 min; followed by 45 cycles of 94 °C for 30 s, 56 °C for 
30 s and 72 °C for 30 s; with final elongation at 72 °C for 
10  min. Subsequent pyrosequencing was carried out 
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using Pyromark reagents as per manufacturer’s recom-
mendations (Qiagen, Crawley, UK); 2 M NaOH was from 
Sigma-Aldrich (Dorset, UK) and Sepharose beads from 
GE Healthcare (Chalfont St. Giles, UK).
The Luminometric Methylation Assay (LUMA) using 
300 ng/μl of genomic DNA from the respective cell lines 
was carried out exactly as described previously [13, 49]. 
HCT116 WT DNA (hypermethylated) and DKO DNA 
(hypomethylated) samples were used as a control (data 
not shown).
Optimising primer alignment with galaxy user‑defined 
tracks
Wang et  al. [15] provided chromosomal coordinates 
for numerous known and putative germline imprints 
as part of their supplemental material. The coordinates 
delineated for each imprint were used as a tool to define 
the minimal gDMR regions, from which the respec-
tive genomic sequence was extracted by visualising 
these regions on UCSC genome browser. The extracted 
genomic sequence was used to promote specificity in the 
design of pyrosequencing assays. BED files were gener-
ated using these chromosomal coordinates and uploaded 
through the Galaxy interface [42] as user-defined tracks 
visible on UCSC genome browser. The genomic sequence 
of interest generated from each respective imprint primer 
set created was matched using the BLAT tool at UCSC 
against the user-defined track to confirm the positions of 
the assays (Additional file 1: Table S1).
Results
Initial gDMR examined and regions assayed
We began our study by designing and validating pyrose-
quencing assays, as it is crucial that the designed primers 
cover the right regions at imprinted loci where methyla-
tion, once established, remains unchanged throughout 
development. To validate the approach, we initially chose 
five of the best-characterised imprinted loci for which 
extensive data on the gametic differentially methylated 
regions (gDMR) are available and which are representa-
tive of the different kinds of imprinted locus. The posi-
tioning of the gDMRs at these five imprinted loci is shown 
in Fig. 1. The paternally imprinted H19 gDMR controls a 
small cluster of genes including Igf2 [Fig. 1a(i)] and repre-
sents an insulator model of imprinting. On the maternal 
chromosome, CCCTC-binding protein (CTCF) binds to 
the gDMR, located intergenically, and forms an insulator 
to stop the interaction of the enhancer with the Igf2 pro-
moter. Such binding results in the silencing of Igf2 on the 
maternal allele but allows the enhancers to activate H19 
(bent arrow) on the same allele. On the paternal chromo-
some, the ICR is methylated which prevents CTCF from 
binding; therefore, the enhancers can interact with Igf2, 
resulting in its transcription. The two parts of the inter-
genic gDMR covered by our pyrosequencing  assay and 
by the clonal analysis/COBRA are also shown [Fig. 1a(i)]. 
Current indications are that many other imprinted genes 
seem likely to follow a non-coding RNA (ncRNA)-medi-
ated model for regulation of imprinting. Two examples of 
this class are the maternally imprinted loci controlled by 
the Igf2r [Fig. 1a(ii)] [22] and KvDMR gDMRs [Fig. 1a(iii)], 
both located intragenically in introns. Igf2r and its neigh-
bouring genes show maternal expression, and the Igf2r 
gDMR generates a paternally expressed non-coding tran-
script Air [Fig. 1a(ii)]. The full-length Air ncRNA and its 
transcription are required for the silencing of Igf2r and 
other neighbouring genes [29, 43]. KvDMR is the ori-
gin of a paternally expressed long ncRNA Kcnq1ot1/Lit1 
[Fig.  1a(iii)], which regulates imprinting at the Kcnq1 
locus. Truncation of Kcnq1ot1 results in a loss of imprint-
ing [44, 45]. Maternally imprinted Snrpn and Peg1 repre-
sent another type of imprinted loci, where the gDMR is 
located directly at the promoter region of a gene, rather 
than intra- or intergenically. At these loci, methylation 
directly controls transcription [Fig. 1a(iv–v)]. 
Methylation at imprinted gDMRs in WT ESCs is similar 
to that in normal tissues
Using pyrosequencing assays designed to match the 
known gDMR, we found that the H19 gDMR (pater-
nally imprinted) was hypermethylated (84.2%) in sperm 
samples, while all maternally imprinted gDMRs dis-
played very low methylation (Fig.  1b), as expected. All 
the gDMRs assayed also showed methylation around 50% 
(range normally observed 40–60% [46]) in somatic tissues 
and WT ESCs, although the level of Igf2r methylation 
was reproducibly higher in WT ESC. Further, we con-
firmed a normal level of methylation for H19 and Snrpn 
gDMRs in WT ESCs by clonal analysis (Fig. 1c), which at 
56.3 and 45.8%, respectively, was very comparable to that 
seen by pyrosequencing (58.5 and 42%) (Fig.  1b). These 
data: (1) indicated that the regions assayed by pyrose-
quencing showed the expected levels of methylation in 
somatic tissue, validating these assays, and (2) that the 
parental ESCs from which all the subsequent knockouts 
were derived had relatively normal levels of methylation 
at the gDMR.
Comparable demethylation at imprinted loci in cells 
lacking DNMT3A/B or DNMT1
Cells lacking DNMT1 (1KO) and as well as a recued 
cell line expressing a DNMT1 cDNA from an inte-
grated transgene (1KO  +  1) have been previously 
described [39]: the same authors describe cells lacking 
both DNMT3A and DNMT3B (3abKO) or rescued with 
DNMT3A2, and both protein levels and mRNA levels of 
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the various proteins have been verified [39, 47]. Neverthe-
less, to ensure the cells have remained stable we verified 
the correct patterns of loss and rescue in the various cell 
lines using both westerns and RT-PCR (Additional file 3: 
Fig. S1). While previous studies have indicated a role for 
DNMT3A/B proteins in maintenance methylation at some 
repeats, and possibly at some other sequences in ESC, a 
potential maintenance role at imprinted gDMRs has not 
previously been examined in detail. All five gDMRs were 
found to be severely hypomethylated in 1KO and 3abKO 
cells. For the paternally imprinted H19 gDMR (Fig.  2a), 
significant loss of methylation from 52.19% to less than 
10% was observed for both cell types compared to WT 
ESCs (p value <0.05 for WT ESCs vs. 1KO and 3abKO). 
All maternal gDMRs also showed significant decreases 
in methylation in both KO cell types with p value <0.001 
for WT ESCs versus either KO for all genes except Peg1, 
where p values were <0.01 and <0.05 for both 1KO  and 
3abKO respectively. At the Igf2r locus, methylation is 
almost completely lost in both types of knockout line com-
pared to WT. We observed nevertheless a larger decrease 
in methylation for Snrpn in 1KO cells than 3abKO (8.7 vs. 
26.1%) cells (Fig. 2b). To check this, we used clonal analysis 
and could confirm that the methylation level at Snrpn was 
lower in 1KO (1.4%) compared to 3abKO (24.16%) samples 
(Fig. 2c). The H19 gDMR was equally hypomethylated in 
1KO and 3abKO cells as shown by clonal analysis (p value 
<0.001 for WT versus 1KO or 3abKO) (Fig. 2c).
Methylation can be restored following loss of DNMT3A/B, 
but not DNMT1
As DNMT1 and DNMT3A/B appeared to have broadly 
similar roles in maintaining methylation marks at 
imprinted gDMRs in this system, we further aimed to 
investigate whether the loci responded in the same way 
to restoration of the respective enzymes. We first inves-
tigated the methylation levels of these gDMRs in 1KO 
ES cells and in those rescued with a cDNA expressing 
the full-length DNMT1 protein (1KO + 1) [48]. As pre-
viously reported by ourselves and others, imprinted 
gDMRs failed to restore methylation to normal WT lev-
els (Fig. 3a). We also compared these results with 3abKO 
rescued cells (3abKO  +  3a2) expressing the full-length 
DNMT3A2 protein [48]. Surprisingly, the maternally 
methylated Igf2r gDMR displayed complete recovery of 
methylation in 3abKO rescued cells, while for Peg1, gain 
of methylation in rescued cells (3abKO +  3a2) brought 
the levels to somewhat higher than WT level. There was 
in addition very substantial recovery of methylation at 
the paternally methylated H19 gDMR (38.14%) as well 
as the Snrpn gDMR (38.88%) although recovery was not 
fully restored to normal WT levels (WT was 52.19% for 
H19 and 42% Snrpn, respectively). The increase in meth-
ylation for all gDMRs in 3abKO + 3a2 cells was also very 
significant when compared to 1KO + 1 (Fig. 3a).
As methylation at gDMR was not completely restored 
to WT levels in the 3abKO  +  3a2, we compared 
whole-genome methylation levels using LUMA [49], a 
bisulfite-independent quantitative assay that uses meth-
ylation-sensitive and methylation-insensitive enzymes to 
estimate total genomic methylation levels. LUMA analysis 
of 1KO and 3abKO cells shows clear loss of methylation 
compared to WT (set to 100%). While both 1KO + 1 and 
3abKO  +  3a2 cells showed gain in methylation, neither 
fully recovered to WT levels (Fig. 3b). HCT116 WT and 
DKO were used to confirm the LUMA was working: as 
expected, HCT116WT was found to be hypermethylated 
and methylation drops significantly for DKO cells lack-
ing DNMT1 and DNMT3B (data not shown). To further 
confirm our results with respect to the imprinted gDMR, 
we carried out COBRA on Snrpn and H19 gDMRs, 
which indicated clear losses of methylation in both KO 
cell types, no recovery in 1KO + 1 and almost complete 
methylation restoration in 3abKO + 3a2 samples (Fig. 3c). 
We also used clonal analysis for these gDMRs, which gave 
similar results (Fig. 3d, e).
(See figure on previous page.)  
Fig. 1 Five canonical imprinted regions in mouse and validation of gDMR methylation assays in WT ESCs. a Schematic showing the main features 
of the imprinted domains examined, along with positioning of imprinted gDMRs (narrow rectangles): (i) H19/Igf2 region; (ii) Igf2r region; (iii) KvDMR/
Kcnq1 region; (iv) Snrpn; and (v) Peg1. Exons are represented by dark-filled boxes, and expression of the genes from maternal or paternal alleles is 
indicated by bent arrows above or below the line, respectively. Wavy lines and narrow bars below the line represent long non‑coding RNA and CpG 
islands (CGIs), respectively. The number of CpG sites (circles) covered by pyrosequencing or clonal analysis, and enzyme restriction site positions and 
fragment sizes for COBRA are all shown below the gDMRs. Filled circles represent methylated sites, while empty circles are unmethylated. CCCTC‑
binding factor (CTCF) binds to H19/Igf2 ICR on the maternal chromosome only (i) to block access of the downstream enhancers to Igf2. On the 
paternal chromosome, CTCF binding is blocked by methylation and the enhancers preferentially interact with Igf2 rather than H19. b Methylation 
level of imprinted gDMRs in various mouse tissues and WT ESCs was quantified by pyrosequencing. Sperm was used as a control: all maternally 
imprinted genes exhibited low levels (<25%) of methylation and the paternally imprinted gene H19 showed high levels (>75%) of methylation here, 
as expected. All maternally and paternally imprinted genes show ~50% methylation at gDMRs in lung, heart and brain as assessed by pyrosequenc‑
ing. In WT ESC, methylation levels were very comparable, with only Igf2r a little high. Error bars indicate s.e.m. c Clonal analysis of Snrpn and H19 
gDMRs in parental WT ESCs. Each circle represents a CpG site assessed by bisulfite clonal analysis. Percentage total methylation is indicated at the 
bottom of each panel
Page 7 of 15Thakur et al. Epigenetics & Chromatin  (2016) 9:53 
Transcriptional activity tracks with methylation at the H19 
locus
To test whether the loss of these methyltransferases and 
their recovery are associated with abnormal expression, 
we carried out RT-qPCR on a number of imprinted loci. 
While most imprinted genes tested were not transcribed 
at significant levels in these ESC, precluding assess-
ment of response, we did find that the expression level of 
H19 was significantly higher in 1KO and 3abKO cells as 
compared to WT, consistent with biallelic expression of 
H19 in those cell lines (Fig. 3f ). Rescuing 1KO cells with 
DNMT1 did not restore repression but rescuing 3abKO 
cells with DNMT3A significantly reduced (p < 0.05) lev-
els of H19 mRNA (Fig.  3f ). In keeping with the regula-
tory mechanism in place at this locus [Fig.  1a(i)], Igf2 
showed the opposite pattern, with repression in 1KO and 
3abKO cells and greatest recovery in 3abKO + 3a2 cells 
(Fig. 3f ), though this did not reach significance because 
of the lower transcription levels. In addition, the Peg1 
mRNA, which is mildly depressed in the 3abKO line, 
showed a significant repressive effect of adding back in 
the DNMT3A2 enzyme (Fig. 3f ).
Failure to restore methylation at KvDMR
The KvDMR gDMR showed a normal level of methyla-
tion in WT ESCs, loses methylation in 1KO (5.3%) and 
does not regain methylation in 1KO  +  1 cells (Fig.  4a) 
as for the other imprinted loci. While this gDMR also 
showed a very low level of methylation in 3abKO (9.5%), 
unlike the other four benchmark loci examined, res-
cue with DNMT3A2 in 3abKO cells failed to reinstate 
methylation at this maternally imprinted locus (Fig. 4a). 
Differences in methylation were significant for WT ver-
sus 1KO, 1KO  +  1, 3abKO and 3abKO  +  3a2 (p value 
Fig. 2 Mutation of Dnmt3a/b or Dnmt1 gives comparable methylation loss at imprinted loci. a Pyrosequencing displaying methylation loss at 
various imprinted loci in DNMT1‑deficient cells (1KO) and cells lacking both DNMT3A and 3B (3abKO). The methylation levels drop significantly for 
1KO and 3abKO for all gDMRs assayed. b Clonal methylation analysis of imprinted gDMRs (Snrpn and H19) in 1KO and 3abKO ESCs. c Summary of 
methylation levels from the clonal data in b. There was a significant decrease in methylation for H19 and Snrpn in all KO cell types compared to WT. 
Error bars indicate s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001
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<0.001) and non-significant for 1KO versus 1KO  +  1, 
1KO versus 3abKO and 1KO +  1 versus 3abKO +  3a2 
(Fig. 4a). A small but significant decrease in methylation 
was observed in 3abKO + 3a2 cells compared to 3abKO 
cells, with a p value <0.05. We further verified these 
results overall using COBRA; a clear loss of methylation 
Fig. 3 Despite similar levels of methylation, imprints can be restored only in 3abKO cells. a Methylation level assessed by pyrosequencing for paren‑
tal (WT), DNMT1 rescued (1KO + 1) and 3abKO rescued (3abKO + 3a2) cells. Compared to WT, the methylation level remains significantly lower 
for all gDMRs in 1KO + 1 cells. All gDMRs show significant increase in methylation in 3abKO + 3a2 cells as compared to 1KO + 1. b Global DNA 
methylation in WT cells, 1KO, 3abKO and 3abKO + 3a2 rescued cells estimated by LUMA. c COBRA for two representative imprinted gDMRs, H19 
and Snrpn. Smaller fragments represent methylated DNA (me) and can be clearly seen in the WT and 3abKO + 3a2 lanes, but not in the 1KO + 1 
lanes: un, unmethylated (D) clonal methylation analysis for Snrpn and H19 showing methylation restoration in 3abKO + 3a2 cells and no recovery 
for 1KO + 1 cells. e Graphical summary of clonal data in d. f RT‑qPCR for H19, Igf2 and Peg1 in the different ES lines. For H19, a significant increase 
in expression was observed in 1KO and 3abKO cells compared to WT (p value <0.05 for all). Rescue with Dnmt3A2 (3abKO + 3a2), but not Dnmt1 
(1KO + 1), caused a significant decrease in transcription again (p value <0.05 3abKO + 3a2 vs. 3abKO cells). Igf2 transcription is inversely linked to 
H19 [Fig. 1a(i)] and as expected decreases significantly (p value <0.001 WT vs. 1KO and 3abKO) on loss of methylation in 1KO and 3abKO lines. Of the 
two rescue lines, 3abKO + 3a2 shows a greater recovery of transcription, though it fails to reach statistical significance. At the Peg1 locus, there is an 
increase in transcription on loss of methylation (n.s.) and a significant decrease on reintroduction of DNMT3A2. Error bars indicate s.e.m in all panels: 
only significant changes are shown
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was observed in 1KO and 3abKO cells with no meth-
ylation restoration for either rescued cell type (Fig.  4b). 
KvDMR was also found via clonal analysis to be 56, 0 and 
7% methylated in WT, 1KO + 1 and 3abKO + 3a2 cells, 
respectively (Fig.  4c), with differences in methylation 
between WT and rescued cell lines remaining very sig-
nificant (p value <0.001) (Fig. 4c, d). These results suggest 
that a unique mechanism may be associated with this 
maternally imprinted locus.
Loss of methylation of remaining known and putative 
gDMR in Dnmt3ab KO cells
To determine whether recovery of methylation in 
3abKO +  3a2 rescue cells is a general phenomenon for 
imprinted loci, we wished to extend our study to include 
all known imprints as well as the putative imprinted 
loci recently identified by Wang et  al. [15]. To this end, 
we designed pyrosequencing assays for all the remain-
ing known and putative gDMR based on the coordinates 
indicated in the latter. Assays were excluded which (1) 
gave low scores in the design software and poor peaks on 
assaying; (2) displayed methylation values outside ±1.5 
times the SD from the 50% methylation expected in a 
range of mouse somatic tissues [46]; and (3) did not show 
>75% (paternal) or <25% (maternal) methylation in sperm 
samples. The results for the remaining five known loci we 
could assay in somatic tissues (Plagl1, Innp5f, Grb10, Ras-
grf1 and Dlk1-Gtl2 IG) are shown in Fig. 5a and displayed 
relatively tight clustering around the median, which was 
noticeably higher in heart tissue.
Assays designed to cover four novel putative gDMRs 
described in Wang et al. [15] (Neurog3 upstream, FR149454 
promoter, Pvt1 promoter and 6330408a02Rik 3′ end) also 
validated in a range of mouse somatic tissue (Fig. 5b), with 
average values for the assays falling within the threshold 
criteria as per Fig. 5a. Notably, there was greater variation 
in the methylation values for these loci than for the known 
gDMR. There was less deviation from the median methyla-
tion value in liver than heart tissue, which has consistently 
exhibited a wider spread of results (Fig. 5a, b). The results 
for the known and putative imprints in mouse sperm sam-
ples are shown in Fig. 5c, where they displayed low (22.8% 
or below) methylation for maternally methylated gDMRs, 
or conversely hypermethylation (78%) at the respective 
paternally methylated regions.
With our validated assays, we next examined these 
nine additional known or putative gDMRs in the mouse 
ESCs. All of these loci showed decreases in methylation 
in 3abKO cells when compared to WT (Fig. 5d), though 
differences at some (Innp5f, Dlk1-Gtl2 IG and Pvt1 pro-
moter) did not reach statistical significance.
Fig. 4 Rescued 3abKO cells are inefficient at re‑establishing imprints 
on the KvDMR gDMR suggesting a unique regulatory mechanism 
associated with this imprinted locus. a Methylation level of KvDMR in 
various ES cell lines by pyrosequencing. The gDMR exhibits significant 
loss of methylation in 1KO and 3abKO cells, and methylation remains 
unchanged in both rescued lines. b Validation of pyrosequencing 
results by COBRA; TaqaI was used to digest the PCR product: me, frag‑
ments resulting from cleavage of methylated product; un, fragments 
when unmethylated. There is no increase in methylated fragments 
from 3abKO to 3abKO + 3a2 samples. c Clonal analysis for KvDMR in 
WT, 1KO and 3abKO + 3a2 cells. d Graphical summary of clonal data 
from c. Error bars indicate s.e.m
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Methylation can be restored following loss of DNMT3A/B 
at the majority of imprinted gDMR in DNMT3A2‑rescued 
ES cells
Our initial work reported above established a clear abil-
ity for DNMT3A2 to restore methylation marks at key 
imprinted gDMRs such as Igf2r in 3abKO cells. We now 
extended this analysis to the other known and putative 
gDMRs indicated above. For convenience, all of the assays 
from our work are presented together in Fig. 6a. Eight of 
10 known gDMRs assayed gained methylation when com-
pared to 3abKO (Fig. 6a), with only Grb10, in addition to 
KvDMR, showing a failure to regain methylation. Of the 
four putative gDMR assayed, only one (6330408a02Rik) 
did not show any increase in methylation. The maternal 
Fig. 5 Examination by pyroassay of remaining known and putative imprinted gDMR. a Validation of pyrosequencing assays for remaining known 
imprinted gDMRs. Average methylation levels across all CpG in each assay were plotted. The median for all assays is indicated by a horizontal line, 
and these did not significantly differ from one another using Kruskal–Wallis (p value 0.1821). b Results for putative imprinted gDMR, plotted as in a. 
While differences between medians are not significant (Kruskal–Wallis p value 0.7291), a greater variance can be seen, particularly in heart. c Verifica‑
tion that pyrosequencing assays for both known and putative maternal gDMR showed low methylation in sperm, while the paternal assay returned 
high methylation levels. d Methylation is lost at all known and putative gDMR, though the decrease is very small at Dlk1‑Gtl2 IG. Error bars represent 
s.e.m.; **p < 0.01; ***p < 0.001; n.s. not significant
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gDMR Igf2r showed the largest recovery of methyla-
tion when compared to the 3abKO ES cells at 62.30%. 
Gain in methylation was seen at all the known paternally 
methylated gDMRs assayed-H19, Rasgrf1 and Dlk1-
Gtl2 IG (Fig.  6a). Absolute methylation values for the 
3abKO + 3a2 cells are shown in Fig. 6b for comparison. 
Notably, KvDMR, Grb10 and 6330408a02Rik 3′ end not 
only fail to regain methylation (Fig. 6a), but instead con-
tinue to lose it in the 3abKO + 3a2 cell. This suggests that 
in the absence of DNMT3A/B the loci do not remain 
stable but rather continue to lose methylation (Fig.  6a). 
Our findings for the individual loci are summarised in 
Fig. 6c and in Table 1. 
Discussion
Maintenance methylation is a vital process as it is respon-
sible for the stable inheritance of this epigenetic signa-
ture from mother to daughter cells during the process 
of mitosis. At one time, DNMT1 was thought to be the 
only enzyme associated with maintenance of methylation 
Fig. 6 Summary of methylation responses at known and putative imprinted gDMR. a Changes in methylation seen in 3abKO cells rescued with 
DNMT3A2 for all of the known and putative gDMRs. Eleven gDMRs of fourteen which could be assayed showed gains in methylation, with nine of 
these reaching significance. KvDMR, Grb10 and 6330408a02Rik failed to recover methylation levels, instead showing significant additional reductions 
in methylation when compared to the 3abKO ES cells. b Absolute methylation levels in the 3abKO + 3a2 cells at the various gDMR. c Schematic 
summarising the changes in methylation seen in the two types of knockout and rescue. WT ESC cells grown in petri dishes were derived originally 
from inner cell mass (ICM) of early embryo and retained 50% methylation at most imprinted gDMR (half-filled bars: paternal at left, maternal at right). 
While loss of DNMT1 (pathway 1, top) gave comparable hypomethylation to loss of DNMT3A/B (pathway 2, bottom), no recovery of methylation 
at either paternally or maternally methylated imprinted gDMRs was seen in DNMT1‑rescued cells, whereas rescue with DNMT3A2 in 3abKO cells 
restored methylation non‑discriminately at both paternally and maternally imprinted gDMRs (pathway 2)
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due to its preferential binding to hemi-methylated DNA 
and its presence at the replication foci [4, 5]. Chen et al. 
[39] showed, however, that DNMT3A and DNMT3B 
were also important for maintenance methylation at 
some repeats and, using a qualitative technique, at cer-
tain imprinted loci. In a previous study, we confirmed 
that DNMT3A and 3B were needed at a few selected 
imprinted loci using a more quantitative approach and 
extended this observation to transiently imprinted genes, 
which also require DNMT3A/B for maintenance in ESCs 
[13]. Here we looked in greater depth at all the known 
gametic DMR as well as some newly identified imprinted 
gDMR and confirm their reliance (with 1–2 exceptions 
such as Dlk1-Gtl2 IG) on the DNMT3A/B enzymes for 
maintenance of methylation. Interestingly, the decrease 
in methylation at these gDMRs was found to be approxi-
mately the same in 1KO and 3abKO cells, suggesting an 
equal contribution by DNMT3A/B and DNMT1 in main-
tenance of methylation at imprinted gDMRs in ESCs.
Overexpression of DNMT1 in 1KO cells resulted in a 
global increase in methylation as reported previously; 
similar global increases in methylation were observed 
here in DNMT3A/B rescued cells using LUMA, although 
this increase does not bring the methylation level to the 
normal WT level globally. This could be due to a num-
ber of reasons: (1) it may indicate the presence of some 
sequences which are refractory to remethylation in ESCs; 
(2) the expression of the cDNA in the rescued cells may 
Table 1 Summary of findings with regard to methylation at gametic differentially methylated regions at imprinted loci
Data are presented for each gDMR for which a validated pyrosequencing assay (pyro assay) could be established. Known gDMR are listed first and then putative, with 
paternal imprints preceding maternal (none of the putative gDMRs were paternal)
Chr chromosome, Origin parent of origin of methylation mark, meth methylation
a mm10 release
b Parental origin of methylation: p paternal chromosome, m maternal
c Whether gDMR is well characterised (known) or recently discovered (putative)
d Somatic methylation = average methylation value across three adult tissues
Locus Chr Chromosomal 
regiona  
delineated 
by pyro assay
Originb gDMR statusc Sperm  
meth %
Somatic 
meth %d
Location 
within gene
CpG 
island
Gain in 3abKO  
+ 3a2 ESCs
H19 7 142,580,262–
142,580,434
P Known 84.19 51.06 Intergenic No Yes
Rasgrf1 9 89,872,365–
89,872,512
P Known 89.00 52.67 Intergenic No Yes
Dlk1‑Gtl2 IG 12 109,528,521–
109,528,661
P Known 96.33 57.92 Intergenic Yes Yes
Snrpn 7 60,004,993–
60,005,163
M Known 4.41 43.42 Promoter/Exon 1 Yes Yes
Igf2r 17 12,960,690–
12,962,806
M Known 3.00 45.71 Intronic Yes Yes
Peg1 6 30,687,444–
30,688,524
M Known 15.50 51.75 Intronic Yes Yes
Plagl1 10 13,091,014–
13,091,154
M Known 10.80 42.83 Promoter/Exon 1 Yes Yes
Inpp5f 7 128,688,173–
128,688,290
M Known 13.10 57.19 Intronic Yes Yes
Grb10 11 12,025,894–
12,026,044
M Known 7.38 45.80 Intronic Yes No
KvDMR 7 143,295,771–
143,295,910
M Known 6.33 50.54 Intronic Yes No
6330408a02Rik 
3′
7 13,260,963–
13,261,135
M Putative 19.43 47.71 Exon 13 Yes No
Neurog3 
upstream
10 62,127,922–
62,128,093
M Putative 15.44 43.84 Intragenic No Yes
FR149454 pro‑
moter
11 119,258,958–
119,259,182
M Putative 15.33 58.67 Intronic No Yes
Pvt1 promoter 15 62,037,136–
62,037,311
M Putative 19.42 43.30 Intragenic No Yes
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not be as high as the endogenous levels of DNMT3A2; 
and/or (3) some sequences may require both DNMT3B 
and DNMT3A2 to fully recover methylation to WT levels 
[11].
We showed here that in the 1KO + 1 cells there was no 
gain in methylation seen at any of the gDMR examined, 
confirming earlier results from a number of groups. In 
contrast, 3abKO cells rescued with DNMT3A2 showed 
clear and reproducible gains in methylation at the major-
ity of imprinted gDMR. These results were confirmed 
using up to three techniques per locus-pyrosequencing, 
clonal analysis and COBRA. Additionally, the transcrip-
tional status of H19 and Igf2 responded appropriately 
to the loss and regain of methylation, confirming that 
functional imprinting was being affected, at least at these 
loci (other loci showed transcription levels which were 
too low to reliably quantitate in these cells). While some 
previous studies have found that none [38] or only one 
[39] imprinted locus showed any gains in methylation on 
rescue, these were based on more qualitative techniques 
and in many cases could not examine the locus except at 
a low level of resolution using techniques such as South-
ern blotting. Here we show gain in methylation of greater 
than 10% at 11/14 gDMR, with substantially greater gains 
at most. Average gain was 28%, which in the context of 
an incomplete overall rescue as indicated from the global 
methylation levels (above) represents a corrected gain of 
close to 50%.
There were a few loci (3/14-KvDMR, Grb10 and 
6330408a02Rik 3′ end), which showed no gain in meth-
ylation, and in fact displayed evidence for further hypo-
methylation relative to the 3abKO cells. This latter is 
not unexpected since we have shown that ESC rely on 
DNMT3A/B for maintenance methylation as well as de 
novo activity, so if these three loci are refractory to the 
action of DNMT3A2 in the rescued line, they would be 
expected to continue to lose methylation. Our examina-
tion of ENCODE data and of the current literature has 
found so far no common denominator for these three 
loci. Nevertheless, these results show that for the major-
ity of imprinted loci, methylation at the gDMR, and in 
some cases functional imprinting, can be restored in a 
somatic cell type without germline passage.
What mechanism is associated with imprint recovery 
in 3abKO + 3a2 and not 1KO + 1 cells? This is particu-
larly puzzling since the two rescued cell types both have 
all three enzymes present. Two possibilities are that (1) 
loss of DNMT3A/B proteins could alter histone marks on 
chromatin, which then act to attract de novo methylation 
by DNMT3A2 on rescue or (2) loss of DNMT1 protein 
causes a change in histone marks, which mean that even 
after rescue, the DNA cannot be remethylated. Notably, 
triple KO cell lines lacking all three enzymes also fail to 
show imprint restoration when rescued [39], suggesting 
that it is the loss of DNMT1 which leads to an irreversi-
ble change in epigenetic potential, precluding rescue with 
DNMT3A2. It has been reported that the loss of DNMT1 
results in loss of H3K9me3 in ESC [50]. One possibility is 
that loss of H3K9me3 occurs in 1KO cells, but not 3abKO 
cells, and that the presence of this mark facilitates rem-
ethylation by DNMT3A2 in the latter. It has also been 
reported that the PWWP domain of DNMT3A is linked 
with targeting of chromatin carrying H3K36me3 [51]. 
Loss and gain of methylation marks on imprinted gDMRs 
could be due to the presence and absence of such inter-
actions between methyltransferases and histone marks 
associated with chromatin, which require further experi-
mental exploration in this system.
We clearly identified three gDMR, including KvDMR, 
where methylation once lost cannot be recovered. This 
supports other evidence, suggesting that mechanism of 
imprinting and response to methylation loss and recov-
ery can vary among imprinted genes [52]. In future, it 
will be interesting to compare the histone marks associ-
ated with KvDMR and with those associated with gDMRs 
that recover methylation in rescued cells. The Dlk1-Gtl2 
IG was also interesting in that it showed overmethyla-
tion in our experiments, gaining almost 40% methylation 
in 3abKO +  3a2. The tendency of this locus to become 
hypermethylated in human ES and iPS cells has been 
noted before [53, 54] and may reflect some fundamental 
mechanistic feature of imprinting at this locus, which in 
practise could act as a barrier to somatic reprogramming 
efforts.
During the course of writing, a paper from the Wong 
group investigating the behaviour of UHRF1 rescue cells 
found that a number of imprinted genes showed gains in 
methylation in that system too [55]. Methylation gain was 
only seen at some of the imprinted loci, and there was no 
clear link to the location of the gDMR, the presence of 
antisense transcripts or the type of imprint. Furthermore, 
they investigated common histone marks and found no 
relationship between any specific mark and the abil-
ity of the locus to gain methylation in the rescues. They 
did not, however, investigate transcriptional changes at 
the loci in their cells. Their data, taken together with the 
findings we present here, show that gametically acquired 
methylation at imprinted loci can be reset somatically in 
certain circumstances.
Conclusions
We have shown that (1) both DNMT1 and DNMT3A/B 
loss generate similar methylation changes at imprinted 
gDMRs in ESCs; (2) recovery of imprints in 1KO  +  1 
cell lines is not possible but imprints can be recovered in 
DNMT3A2-rescued 3abKO cells; and (3) there are some 
Page 14 of 15Thakur et al. Epigenetics & Chromatin  (2016) 9:53 
exceptional gDMRs where imprints, once lost, cannot 
be re-established. Our findings highlight important dif-
ferences between the two cell systems and indicate that 
it may be possible to restore imprints somatically under 
certain circumstances, an observation of clear relevance 
for imprinting disorders. This may provide a useful model 
system in which to further explore reprogramming.
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The main aims of this paper were to: 
1. To develop the first non-cancerous human differentiated cells stably depleted in the
main maintenance methyltransferase DNMT1.
2. To look for classes of genes sensitive to the genome-wide changes in methylation
consequent to DNMT1 depletion.
3. To correlate transcriptional alterations and methylation changes in the cells.
4. To determine if possible, why specific regions become differentially methylated and
not others.
CONTRIBUTION 
I performed an initial bioinformatic analysis of the methylation levels of the DNMT1-depleted 
clonally derived cell lines to help generate lists of genes that were differentially methylated 
when compared to WT hTERT-1604 cells. This formed the basis of two previous versions of 
this manuscruipt and the submission to two different journals, with respective rounds of 
revision. I carried out gene ontology analyses  on the enriched genes that displayed significant 
differential methylation when compared to WThTERT-1604 cells such as that presented in Fig. 
1F. Upon the lists of enriched genes, I performed downstream statistical analyses on the gene 
classes that were identified to be enriched in both the methylation and transcriptional array data 
and modelled this data using the Galaxy Interface to create user defined tracks on UCSC 
Genome Browser. I helped to design a panel of pyrosequencing assays for the olfactory 
receptors, grew all the cell lines in culture, extracted and bisulfite converted the DNA for 
103 
quantitative methylation analyses. To comply with submission guidelines, I created and 
deposited all the IDAT file data for both the 450k methylation and HT12 transcription array 
data for the manuscript onto the NCBI GEO archive along with supplemental information to 
promote reproducibility and data sharing under the terms of Open Access. I did not have any 
input on the polycomb data presented in the paper. 
Summary of the major findings
1. The KD of DNMT1 in the cell lines examined highlighted enriched groups of genes sensitive
to this loss of methylation- the protocaderin genes (PCDH), fat homeostasis/body mass genes, 
olfactory receptors (OR), cancer testis antigen (CTA) genes and those of the UGT1A complex. 
2. The methylation levels of both the fat/body mass genes and the UGT1A genes were affected
by both DNA methylation and the presence of polycomb marks. 
3. Widespread changes in methylation in each of the KD cell lines was not accompanied by
large-scale transcriptional derepression, with only a few hundred genes showing dysregulation, 
and the fold change in transcription being small. 
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Depletion of DNMT1 in differentiated 
human cells highlights key classes of sensitive 
genes and an interplay with polycomb 
repression
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Abstract 
Background: DNA methylation plays a vital role in the cell, but loss‑of‑function mutations of the maintenance meth‑
yltransferase DNMT1 in normal human cells are lethal, precluding target identification, and existing hypomorphic lines 
are tumour cells. We generated instead a hypomorphic series in normal hTERT‑immortalised fibroblasts using stably 
integrated short hairpin RNA.
Results: Approximately two‑thirds of sites showed demethylation as expected, with one‑third showing hypermeth‑
ylation, and targets were shared between the three independently derived lines. Enrichment analysis indicated sig‑
nificant losses at promoters and gene bodies with four gene classes most affected: (1) protocadherins, which are key 
to neural cell identity; (2) genes involved in fat homoeostasis/body mass determination; (3) olfactory receptors and 
(4) cancer/testis antigen (CTA) genes. Overall effects on transcription were relatively small in these fibroblasts, but CTA
genes showed robust derepression. Comparison with siRNA‑treated cells indicated that shRNA lines show substantial
remethylation over time. Regions showing persistent hypomethylation in the shRNA lines were associated with poly‑
comb repression and were derepressed on addition of an EZH2 inhibitor. Persistent hypermethylation in shRNA lines
was, in contrast, associated with poised promoters.
Conclusions: We have assessed for the first time the effects of chronic depletion of DNMT1 in an untransformed, dif‑
ferentiated human cell type. Our results suggest polycomb marking blocks remethylation and indicate the sensitivity 
of key neural, adipose and cancer‑associated genes to loss of maintenance methylation activity.
Keywords: DNMT1, EZH2, Protocadherin, Body mass, Cancer/testis antigen
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Background
DNA methylation is an important mechanism for epige-
netic regulation of genes in both mouse and human [1]. It 
occurs mainly at the CpG dinucleotide, and methylation 
at this symmetrical site is efficiently maintained during 
replication by the action of the DNA methyltransferase 
1 (DNMT1) enzyme [2]. Methylation is known to play 
an important role in regulating imprinted loci [3], genes 
on the inactive X chromosome [4] and germline-specific 
genes [5] in mouse.
Where methylation occurs at the promoter of a gene, it 
is strongly associated with the silencing of transcription, 
particularly if there is a high density of CpGs, a so-called 
CpG island (CGI). However, studies have shown that 
most CGI are intrinsically protected from methylation [6, 
7] and only a small number shows dynamic changes dur-
ing development, mostly in the three classes mentioned
above [5, 8], though there may be others which have not
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yet been clearly defined. As you move outward from an 
island, the shores and shelves show higher levels of meth-
ylation and greater dynamic response [9], though here the 
link to changes in gene activity is less clear [10]. Methyla-
tion is also associated with larger regions of inert chro-
matin, such as the inactive X, pericentromeric repeats 
and regions rich in transposable elements [1], generally 
consistent with a repressive role. Recent genome-wide 
surveys have also indicated that high levels of methyla-
tion are found in the bodies of active genes, where they 
may facilitate transcription [11, 12]. In keeping with this, 
we and others recently showed that artificially decreasing 
intragenic methylation levels reduced steady-state tran-
script levels, consistent with a positive role for methyla-
tion in the gene body [11–13].
Another major system for epigenetic repression is via 
histone modification, particularly by the polycomb group 
of proteins, with EZH2 being one of the main enzymes 
involved [14]. A number of studies suggest an interplay 
between polycomb- and DNMT-mediated repression, 
with a generally negative correlation between DNA meth-
ylation and the H3K27me3 mark deposited by EZH2 [15, 
16]. Supporting this, a loss of DNA methylation caused 
a reshaping of the histone landscape and derepression of 
some polycomb targets in mouse ES cells [17], suggesting 
that DNA methylation helps to determine where poly-
comb marks are deposited.
While DNMT1 is the main maintenance methyltrans-
ferase, there also appears to be an important role for the 
de novo enzymes DNMT3A and DNMT3B in comple-
menting that activity at some loci [18, 19]. In order to 
clarify which genes are most sensitive to DNMT1 loss 
in human, a number of studies have been carried out 
using mutations within the gene to assess the effects of 
loss of methylation [19–22]. While this has been a fruitful 
approach in mouse embryonic stem (ES) cells, where null 
mutants are tolerated, differentiation of the mouse cells 
leads to cell death [20, 22, 23], whereas DNMT1 disrup-
tion in human ES cells is not tolerated even in undifferen-
tiated cells [24]. Genetic ablation in adult differentiated 
cells also leads to cell death within a few cell cycles, 
before passive demethylation of the genome can occur 
[23, 25]. One of the best-studied systems in humans con-
sists of HCT116 colon cancer cells carrying a hypomor-
phic allele in the DNMT1 gene together with a DNMT3B 
knockout (HCT116 DKO cells) [26–28]. Blattler et  al. 
[29] found that there was widespread and relatively uni-
form demethylation across the genome in the DKO cells,
with small effects at CGI (most of which are normally
unmethylated anyway) and relatively few genes showing
derepression. There was no enrichment by gene ontol-
ogy (GO) analysis, but some effect at enhancers: how-
ever, this is complicated by the presence of the DNMT3B
knockout alleles. Acute depletion of DNMT1 using an 
siRNA-mediated approach in embryonal carcinoma cells 
also found regions of low CpG density (open sea, shelf ) to 
be the most affected by loss of methylation [70]. Among 
the small number of dysregulated genes, there was some 
enrichment for cell morphogenesis and phosphorylation 
pathways.
Neither of these cancer cell lines, however, are a good 
model for the normal differentiated cell as they are trans-
formed, aneuploid, hypermethylated, and contain a 
number of different mutations in key regulatory genes. 
Additionally, acute depletion of DNMT1 results in cell 
cycle delay, triggering of the DNA damage response and 
increased rates of cell death [24, 25, 30], making it diffi-
cult to separate acute and chronic effects.
To circumvent some of the difficulties outlined above, 
we generated a series of isogenic human cell lines derived 
from the hTERT-immortalised normal fibroblast line 
hTERT1604 as previously described [30]. These are nor-
mosomic and non-transformed, and by using a stably 
incorporated plasmid with an shRNA targeting DNMT1 
we were able to isolate a number of clonally derived lines 
to allow identification of any cell line-specific effects. 
While these showed initially the range of shared features 
indicative of a global response to the loss of this criti-
cal regulator, including cell cycle delay, demethylation 
of imprinted genes and others, they could be cultured 
for longer under selection [30], allowing identification 
of loci with particular sensitivity for decreased main-
tenance methyltransferase activity. Here we set out to 
completely characterise the methylation changes seen in 
the cell lines using the Illumina Infinium HumanMeth-
ylation450 BeadChip (450k) array platform [31] and sub-
sequent analysis using the RnBeads pipeline [32]. These 
approaches were chosen due to their high reproducibil-
ity and low inter-operator variability, ensuring the reli-
able and sensitive detection of alterations in methylation. 
A sample of the observations was then further verified 
using locus-specific assays. In addition and for the same 
reasons, we used the HT-12 Expression v4 BeadChip 
array, to assay changes in transcription in our cell lines.
Methods
Cell culture
The parental or wild-type (WT) adherent hTERT1604 
lung fibroblast cell line [33] was cultured in 4.5  g/l glu-
cose DMEM (Thermofisher, Loughborough, UK) sup-
plemented with 10% FBS and 2× NEAA (Gibco/
Thermofisher). Generation of the hTERT1604 cell lines 
stably depleted of DNMT1 using a pSilencer construct 
(Thermofisher) has been previously described [30]. 
Knockdown (KD) cells were maintained as for WT, but 
medium was supplemented with 150 μg/ml hygromycin 
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B (Invitrogen/Thermofisher, Paisley, UK), which was 
removed at least 48 h before any experimental procedure. 
Treatment of cells with siRNA for 24 h was as previously 
described [34]: for the pulse-chase experiment cells were 
afterwards allowed to recover in normal media and pas-
saged as required for up to 36  days. The siRNA (Dhar-
macon ON-TARGETplus SMARTpool) for DNMT1 and 
DNMT3B, as well as scrambled control, was obtained 
from Invitrogen/Thermofisher. HCT116 and double 
knockout (DKO) cells [27] were cultured in 1 g/l glucose 
DMEM (Gibco) supplemented with 10% FBS and 1× 
NEAA (Gibco). DZNeP (Sigma-Aldrich, Dorset, UK) was 
used at a final concentration of 1 μM.
DNA extraction and bisulphite conversion
Genomic DNA was harvested from cells in log phase of 
growth. Samples were incubated overnight at 55  °C in 
lysis buffer [50 mM Tris pH 8, 0.1 M EDTA (both Sigma-
Aldrich), 0.5% SDS, 0.2  mg/ml proteinase K (Roche, 
West Sussex, UK)], with rotation, and DNA was subse-
quently isolated using the standard phenol/chloroform/
isoamyl alcohol (25:24:1 pH8, Sigma-Aldrich) extraction 
method. DNA quality was verified using gel electropho-
resis and UV absorbance measurements at 260/280 and 
260/230  nm using a Nanodrop UV spectrophotometer 
(Labtech International, Ringmer, UK). Bisulphite conver-
sion of 500 ng of DNA was carried out using the EpiTect 
bisulphite kit (Qiagen, Crawley, UK) according to the 
manufacturer’s instructions.
Hybridisation to 450K array and bioinformatic analyses
Three samples from each cell line were used to pre-
pare DNA, with at least one biological repeat in each 
set. DNA was assessed for purity and integrity as above 
prior to quantification using the Quant-iT PicoGreen 
dsDNA assay kit (Thermo Fisher Scientific) as per man-
ufacturer’s instructions. In total, 500  ng of high-quality 
bisulphite-converted (Zymo Research) DNA was checked 
for purity and fragmentation on a bioanalyser and then 
loaded on the Infinium HumanMethylation450 BeadChip 
[31] and imaged using an Illumina iScan (Cambridge 
Genomic Services). Output files in IDAT format were 
processed using the RnBeads [32] methylation analysis 
package (v1.0.0) which carries out all the analysis from 
import to differential methylation within the R platform 
(3.2.0). Briefly, quality control used the built-in probes 
on the array and included filtering out of probes contain-
ing SNPs, and checking for hybridisation performance. 
Normalisation was then carried out using the SWAN 
method in minfi [35] after background subtraction with 
methylumi.noob. The exploratory analysis module was 
used to generate probe density distributions and scatter 
graphs. The differential methylation analyses was based 
on a combined ranking score, which combined absolute 
effect size, relative effect sizes and p-values from statisti-
cal modelling into one score where rank is computed as 
the most conservative value among mean difference in 
means, mean in quotients and combined p value across 
sites in the region: the enrichment analysis used the com-
bined rank among the 1000 best-ranking regions and a 
hypergeometric test to identify GO terms in the AmiGO 
2 database [36]. Pairwise comparison of triplicate samples 
from each cell line against WT hTERT was also made to 
determine change in beta value and associated combined 
p-value, adjusted for multiple comparison using false dis-
covery rate (FDR). Some tailored analyses were also car-
ried out using custom scripts in R. Additional GO studies 
were performed using DAVID (v6.7) [37].
We used the GALAXY platform [38] to map sites 
showing highly reproducible changes (FDR < 0.05) against 
the locations of RefSeq genes or ChromHMM regions 
on the UCSC genome browser [39] for each cell line. GO 
category genes which showed changes in methylation at 
multiple sites in more than one KD cell line were scored 
as true hits (Yes in the FDR column), while GO catego-
ries with few or no sites reproducibly altered across rep-
licates (FDR > 0.05) or where methylation changes were 
small (< 0.1 β), inconsistent in direction, or not found in 
more than one KD cell line, were scored as false positives. 
Absolute β levels were used to measure median methyla-
tion across genes of interest using custom workflows in 
GALAXY, with further statistical analyses in Statistical 
Package for the Social Sciences software (SPSS) version 
22.0 (SPSS UK Ltd).
Locus‑specific methylation analysis
Amplification was carried out using the PyroMark PCR 
kit (Qiagen) with 2 μl bisulphite-converted DNA, 12.5 μl 
MasterMix, 2.5  μl CoralLoad Concentrate, 1.25  μl each 
primer (10  μM) and 5.5  μl nuclease-free  H2o using the 
following conditions: 15  min at 95  °C followed by 45 
cycles of 94 °C for 30 s, 56 °C for 30 s, 72 °C for 30 s and a 
final elongation step of 72 °C for 10 min. Pyrosequencing 
was carried out on the PyroMark Q24 System, accord-
ing to the manufacturer’s instructions (Qiagen). Most 
assays were designed in-house using the PyroMark Assay 
Design software 2.0 (LEP, MAGEA12, OR10J5, OR51E2, 
OR2AG1, PCDHA2, PCDHC4, UGT1A1, UGT1A4) prior 
to synthesis (Metabion, Germany): see Additional file 1: 
Table S1 for details: DAZL, SYCP3, D4Z4 and NBL2 
were as described [34, 40]. In some cases, pre-designed 
pyrosequencing primers were obtained from Qiagen 
(GABRQ PM00133483, GHSR PM00014350, SNRPN 
PM00168252). Clonal analysis was carried out as previ-
ously described [30].
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Hybridisation to HT‑12 microarray and bioinformatic 
analyses
Total RNA was extracted using the RNeasy minikit 
(Qiagen) as per manufacturer’s instructions, including a 
DNase step. RNA integrity was verified via gel electro-
phoresis, and quality and quantity were verified using a 
SpectroStar (BMG Labtech, Aylesbury, UK) and a bioana-
lyser (Agilent Technologies, Cheadle, UK). Two hundred 
nanograms of total RNA underwent linear amplification 
using the Illumina TotalPrep RNA Amplification Kit 
(Life Technologies/Thermofisher, Paisley, UK) follow-
ing the manufacturer’s instructions. Microarray experi-
ments were performed at Cambridge Genomic Services, 
University of Cambridge, using the HumanHT-12 v4 
Expression BeadChip (Illumina, Chesterford, UK). After 
scanning the data were loaded in GenomeStudio (Illu-
mina) and then processed in R (version 3.2.2). The data 
were filtered to remove any non-expressed probes using 
the detection p-value from Illumina, transformed using 
the variance stabilization transformation (VST) from 
lumi and normalised using the quantile method. Com-
parisons were made using the limma package with results 
corrected for multiple testing using false discovery rate 
(FDR) testing.
RNA and protein analysis
Transcriptional assays at individual loci using RT- and 
RT-qPCR were carried out essentially as in [34]: primer 
sequences are listed in Additional file  1: Table S1. Pro-
tein was extracted from cells growing in log phase 
using protein extraction buffer (50  mM Tris–HCl, 
150 mM NaCl, 1% Triton-X, 10% glycerol, 5 mM EDTA; 
all Sigma-Aldrich) and 0.5  µl protease inhibitor mix 
(Sigma-Aldrich). For Western blotting, 30  μg protein 
was denatured in the presence of 5  μl 4× LDS sample
buffer (Invitrogen) and 2 μl 10× reducing agent (Invitro-
gen) in a total volume of 20 μl nuclease-free water (Qia-
gen) via incubation at 70 °C. Proteins were separated by 
SDS-PAGE and then electroblotted onto a nitrocellulose 
membrane (Invitrogen) and blocked in 5% non-fat milk 
for 1 h at room temperature (RT). Membranes were incu-
bated with anti-DNMT1 (a kind gift from Guoliang Xu) 
and anti-β-actin (Abcam ab8226) overnight at 4  °C, fol-
lowed by HRP-conjugated secondary antibody incuba-
tion at RT using ECL (Invitrogen).
Statistical analysis
Statistical analysis was performed by the RnBeads pack-
age, or separately in Excel (Microsoft Office Professional 
Plus 2013), Prism (Graphpad) or SPSS (v22.0). Experi-
ments were carried out in triplicate and included at least 
one biological replicate. PCR results were analysed using 
Student’s paired t-test. Pyrosequencing results were ana-
lysed by ANOVA within representative runs and using 
Student’s t-test on the average of multiple runs. Error 
bars on all graphs show standard error of the mean 
(SEM) or in the case of HT12 array data, 95% confi-
dence interval (CI), unless otherwise stated. Asterisks are 
used to represent probability scores as follows: *p < 0.05; 
**p < 0.01; ***p < 0.005 or n.s. not significant.
Results
Generation of isogenic hTERT1604 fibroblast cell lines
Isogenic lines carrying an shRNA construct targeting 
DNMT1 were generated by transfecting the hTERT-
immortalised human lung fibroblast cell line hTERT-
1604 with pSilencer plasmid containing an shRNA 
(Fig.  1a). The generation and initial characterisation of 
these isogenic cell lines have been previously described 
[30]. Here we took two sublines typical of the intermedi-
ate levels of knockdown (KD) seen (d8 and d10) as well 
as one line (d16) with relatively low levels of mRNA, with 
good agreement between reverse transcription quanti-
tative PCR (qPCR) and array results (Fig. 1b; all p < 0.05 
except d8 array). We also confirmed knockdown at the 
protein level using Western blotting, with HCT116 cells 
mutated in DNMT1 and DNMT3B [27] as controls 
(Additional file 3: Fig. S2A).
(See figure on next page.) 
Fig. 1 Cell line generation and overall changes seen in methylation levels. a Experimental approach: WT hTERT1604 fibroblasts were transfected 
with shRNA‑containing plasmid and grown in selective medium; colonies of resistant cells were expanded, and three (d8, d10, d16) showing 
reduced DNMT1 levels were then analysed using genome‑wide methylation and transcription arrays on the Illumina platform. b Levels of DNMT1 
mRNA in cell lines from array and qPCR: error bars represent 95% confidence intervals around median, and standard error of the mean (SEM), 
respectively. All three knockdown (KD) lines were significantly depleted at p < 0.05 for both assays (except d8 array). c Overall methylation levels in 
WT and KD cells as measured by 450K: a β value of 1 equates to 100% methylation. Median values are indicated by the line, and whiskers represent 
interquartile range. The positions of the medians are also indicated at right (arrowheads). d The difference in median β value between each KD cell 
line and WT is shown first for all sites assayed (see c above) and then for each type of genomic element. CGI, CpG island; shore, region adjacent to 
CGI; shelf, adjacent to shore; sea, all other. See also Additional file 3: Fig. S2B. e Probe density distributions; in KD there is a decrease in the number of 
fully methylated sites (β closer to 1) and an increase in the number of unmethylated sites (β closer to 0), as well as in probes showing intermediate 
levels of methylation (arrow). f Numbers of sites (×104) showing significant changes in methylation (FDR < 0.05) compared to WT: the set of com‑
mon sites is largest in each case, with close to twice as many sites commonly losing methylation in comparison with those gaining
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Characterisation of overall changes in absolute 
methylation levels in depleted lines
Using the 450K array [31] and processing in RnBeads [32] 
to assess methylation levels across the genome (Fig. 1c), 
there was still a wide range of methylation values (given 
for the array as a value β ranging from 0 to 1) in KD 
lines as compared to WT, but the median values were 
decreased as expected in all three with d8 being compa-
rable to d10, while d16 was lower (arrowheads at right). 
Principle components analysis and examination of the 
sites showing greatest differences in methylation between 
the stable lines confirmed that d8 and d10 were most 
similar (Additional file  2: Fig. S1). Probes on the array 
were annotated by location relative to genomic features, 
and while all regions showed a decrease in methylation, 
the difference in median values was smallest for CGI, 
which were unmethylated anyway in parental cells (β < 0.1 
in WT), while the separation in medians was greatest at 
shelves and shores, where methylation levels were higher 
(Additional file 3: Fig. S2B). This can most clearly be seen 
by plotting the difference in medians (Fig. 1d). Both WT 
and the KD cell lines showed the typical bimodal probe 
density distribution pattern reported in most cell types 
[31] (Fig. 1e). Overall, there was an increase in the num-
bers of less methylated probes (β < 0.25) in the KD cell
lines and a decrease in the numbers of highly methyl-
ated probes (β > 0.65). For individual regions CGI again
showed the smallest change, while gene bodies (genes)
appeared most altered (Additional file 3: Fig. S2C).
To determine whether methylation was lost stochasti-
cally in each KD cell line given the variation seen (Addi-
tional file 2: Fig. S1), or was more targeted, we determined 
the degree to which affected sites were shared between 
the three cell lines (Fig.  1f ). The largest set of sites los-
ing methylation (17.2 × 104) was that shared between all
three KD lines, supporting a non-random loss. A spike in 
numbers of probes showing intermediate levels of meth-
ylation (β ~ 0.50) in KD cell lines in the density profile 
plot (Fig. 1e, arrow) had indicated that a possible gain in 
methylation might also be occurring at some sites. Analy-
sis showed that a substantial number (9.1 × 104) of sites
gaining methylation are shared between all three KD 
lines, indicating reproducible gains in methylation at par-
ticular CpGs.
Overall pattern of sites showing significant differential 
methylation on DNMT1 depletion
We compared WT cells to all three KD lines using the 
RnBeads package in R and combined rank scoring (see 
methods). This confirmed that d16 has the greatest num-
ber of demethylated sites using a false discovery rate 
(FDR) cut-off of p < 0.05, but at p < 0.001 all three lines 
have comparable numbers of hypo- and hypermethylated 
sites (Additional file 4: Fig. S3A), with more sites losing 
than gaining. An analysis of the 1000 best-ranking sites 
highlights sites common to all three KD lines (Additional 
file 4: Fig. S3B), confirming that there are large numbers 
of sites which respond in the same way in each KD, with 
an excess of probes showing loss over gain.
We then looked to see whether shared probes were 
enriched in any particular gene region. As we were inter-
ested in changes which might cause altered transcrip-
tion, we focussed on CGI, promoters and gene bodies 
(hereafter genes) rather than shores, shelves or open sea, 
where correlations with transcriptional output are harder 
to assess. Using a hypergeometric test in RnBeads, both 
promoters and genes, but not CGI, showed significant 
enrichment in demethylated probes for particular gene 
ontology (GO) terms. Table 1 indicates the top 3 ontol-
ogy classes under biological process (BP) and molecular 
function (MF). For loss of methylation, examining com-
mon genes and processes suggested that three classes of 
genes were common to the enriched GO terms, which 
we grouped as follows: (1) genes involved in neuroepi-
thelial differentiation; (2) genes involved in fat homoe-
ostasis/body mass (FBM); and (3) olfactory receptor 
genes (groups 1–3 in Table 1), all of which will be dealt 
with below. The only orphan GO term whose mem-
bers had multiple high-confidence demethylated sites 
was GO:0007506 gonadal mesoderm formation, which 
largely consists of members of the TSPY gene family on 
the Y chromosome. For gain of methylation, the same 
was true in that a relatively small number of histone 
modifier genes (group 4), represented under several GO 
terms, were responsible for many of the hits. In addi-
tion, the GO terms for glucuronosyltransferase activity 
(GO:0015020) and for regulation of megakaryocyte dif-
ferentiation were also represented (Table 1). These were 
then curated by looking for sites showing reproducible 
changes (FDR < 0.05) in all KD lines (described more fully 
in “Methods” section), which indicated strong support 
[Yes (Y) in confirm column, Table 1] for all GO categories 
showing loss, but only in two showing gain (GO:0015020 
and GO:0004984). We then set about verifying these 
targets.
Loss of methylation at the protocadherin gamma gene 
cluster particularly affects the A and B class variable genes
A main contributor to the enrichment of neuroepithelial 
genes are the protocadherin genes. Protocadherin α, β 
and γ (PCDHA, PCDHB and PCDHG) genes are located 
in three linked clusters on chromosome 5 and give rise to 
neural cell–cell adhesion proteins, with significant loss of 
methylation across the whole region in all three cell lines 
(Additional file 4: Fig. S3C). The α and γ proteins have a 
variable extra-cellular recognition domain, either A, B 
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or C-type, attached to a constant transmembrane and 
intracellular domain. This is achieved at the gene level by 
alternative 5′ exons encoding the variable region being 
spliced to the constant region exons. Figure  2a shows 
the tracks containing sites with significant (FDR < 0.05) 
methylation differences between KD and WT cells for the 
PCDHG cluster. These reveal loss of methylation (in red 
in Fig. 2a) at most A and B class variable exons in all three 
KD cell lines, but not at the C class variable or the con-
stant exons. Array probes were present in this region, and 
examination of the absolute rather than relative methyla-
tion (amber, top track in Fig.  2a) confirmed high levels 
of methylation in WT, where median β values were high 
for all variable exons (Fig.  2b). Methylation decreased 
in all three KD lines, with d10 showing the least effect 
(Fig.  2b). Methylation was substantially altered at all A 
and B class variable exons, but not at the C class (Fig. 2c). 
We could experimentally verify the loss of methylation at 
A2 (Fig. 2d), and no change at C4 (Fig. 2e), using pyrose-
quencing assays (pyroassay).
Some demethylation of other neuroepithelial genes in 
this GO category was also seen from the array, such as 
S100P, ROBO1 and PAX6, with significant (p < 0.05) dem-
ethylation of S100P in two-thirds of KD cell lines con-
firmed by pyrosequencing (not shown).
Loss of methylation at other targets including fat 
homoeostasis/body mass (FBM) genes
Another class of genes showing enrichment all appear 
to be involved in some aspect of triglyceride processing, 
Table 1 Gene ontology analysis for differentially methylated sites
BP biological process, MF molecular function, GO FID gene ontology family identification code, P probability value, OR odds ratio, Ex expected number of hits, Obs 
observed number, Total total number of genes in that family, Grp-see below; confirm Y/N, confirmation given by FDR tracks Yes/No
Groups (Grp): 1 = neuroepithelium; 2 = Fat homoeostasis/body mass (FBM); 3 = olfactory receptor; 4 = histone modifier
Type GO FID P OR Ex Obs Total GO Term Grp confirm
Loss
Promoter
 BP 0098609 0.0011 3.0454 4.2148 12 189 Cell–cell adhesion 1 Y
0007156 0.0011 3.4722 3.0998 10 139 Homophilic cell adhesion via plasma membrane 1 Y
0010982 0.0015 88.2036 0.0669 2 3 Regulation of high‑density lipoprotein particle clearance 2 Y
 MF 0004888 0.0001 1.9709 24.2681 44 1055 Transmembrane signalling receptor activity 3 Y
0005509 0.0001 2.2488 14.3768 30 625 Calcium ion binding 1 Y
0004871 0.0003 1.7441 33.6302 54 1462 Signal transducer activity 3 Y
Gene
 BP 0007506 0 130.3775 0.1339 5 7 Gonadal mesoderm development Y
0032375 0.0001 25.9783 0.2295 4 12 Negative regulation of cholesterol transport 2 Y
0045409 0.0001 77.705 0.0956 3 5 Negative regulation of interleukin‑6 biosynthetic process 2 Y
 MF 0008083 0.0009 3.5742 3.0015 10 158 Growth factor activity 3 Y
0004984 0.0014 2.5939 6.136 15 323 Olfactory receptor activity 3 Y
0038023 0.0014 1.7776 22.9102 38 1206 Signalling receptor activity 3 Y
Gain
Promoter
 BP 0035574 0 443.1106 0.4729 14 15 Histone H4‑K20 demethylation 4 N
0045653 0 147.6833 0.5359 14 17 Negative regulation of megakaryocyte differentiation N
0016577 0 26.4022 1.0404 15 33 Histone demethylation 4 N
 MF 0035575 0 452.3692 0.4637 14 15 Histone demethylase activity (H4‑K20 specific) 4 N
0032451 0 21.0879 1.1747 15 38 Demethylase activity 4 N
0015020 0 10.1109 0.8965 7 29 Glucuronosyltransferase activity Y
Gene
 BP 0035574 0 280.0725 0.4039 14 16 Histone H4‑K20 demethylation 4 N
0045653 0 140.0181 0.4544 14 18 Negative regulation of megakaryocyte differentiation N
0006335 0 31.0869 0.8078 14 32 DNA replication‑dependent nucleosome assembly 4 N
 MF 0035575 0 287.2955 0.3942 14 16 Histone demethylase activity (H4‑K20 specific) 4 N
0032451 0 24.654 0.9856 15 40 Demethylase activity 4 N
0004984 0 4.4768 7.9586 31 323 Olfactory receptor activity 3 Y
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energy homoeostasis and body weight regulation 
(Table  1), including leptin (LEP), ghrelin/growth hor-
mone secretagogue receptor (GHSR) and genes encoding 
the very low density lipoproteins APOC1, APOC2 and 
APOC3. Median levels of methylation in the gene bod-
ies were approximately 45% in WT (β = 0.45) and showed
significant (p < 0.05) decreases in the KD lines (Fig.  3a). 
Most individual genes also showed substantial loss, with 
the exception of the ANXA genes (Fig. 3b). Loss of meth-
ylation at the LEP and GHSR promoters was confirmed 
using pyroassay (Fig. 3c).
Olfactory receptor (OR) genes appeared in a number 
of GO categories as having lost methylation, though 
some gains in the gene body were also indicated 
(Table 1). ORs encode G protein-coupled receptor pro-
teins and are members of a large gene family, many of 
which are grouped into major clusters, particularly 
on chromosome 11 [41]. To buffer against stochastic 
effects due to the large gene family involved, we car-
ried out a second analysis starting instead with sites in 
promoters showing reliable methylation loss compared 
to WT (FDR < 0.05) in the triplicates of each KD line 
Fig. 2 Loss of methylation at the protocadherin γ (PCDHG) cluster of neuroepithelial identity genes. a Structure of the PCDHG cluster showing the 
5′ variable exons (A, B and C classes) which are spliced to the 3′ constant exons (right). The top track (amber) shows absolute β values in the WT 
fibroblast cells from the 450K array, which range from 1(fully methylated) to zero (unmethylated). Only the sites showing significant differences 
from WT (FDR < 0.05) in each cell line are shown in the three tracks below, with decreases in red representing loss of methylation, and gains in blue. 
The size of the bar is proportional to the magnitude of change: maxima and minima are indicated on the scales at left. The locations of CpG islands 
(CGI) are also shown. Pyroassay locations are boxed. b Median β values for all variable exons. Significant differences (Mann–Whitney U) are indicated: 
*p < 0.05; **p < 0.1; n.s., not significant. c Methylation at each exon in WT and d16 cells obtained by taking the median of the absolute β value for all 
probes at that exon. The variable class C exons are underlined. d Average methylation values in WT and KD cells obtained from a pyrosequencing 
assay (pyroassay) designed to cover CpGs in the A2 exon. Bars represent SEM; ***p < 0.001, t‑test. e Methylation at the C4 variable exon by pyroassay, 
shown as a control
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and then overlapping these (Fig. 3d) to see which sites 
were common to all three KD cell lines (Additional 
file  5: Table S2). Ontology analysis of these common 
sites using DAVID independently highlighted signal-
ling receptor genes and more particularly olfactory 
receptors (n = 21). This group of OR genes also showed 
significant demethylation compared to WT (Kruskal–
Wallis, p < 0.05) across the genes when median meth-
ylation at all available probes was analysed (Additional 
file  4: Fig. S3D). We chose three of these genes—
OR10J5, OR51E2 and OR2AG1—located on different 
chromosomes and could verify loss of methylation in 
all KD lines (Fig. 3e).
The final GO category of genes (GOFMID:0007506) 
showing loss of methylation (Table 1) consists largely of 
the TSPY gene family (TSPY1-4, 8 and 10) located on 
the Y chromosome and thought to be implicated in both 
normal gonadal development and in gonadoblastoma 
[42]. These also showed clear evidence of demethylation 
(Fig. 3f ).
Gains in methylation affect the UGT1A locus
As indicated above, with respect to gains in methylation 
only two of the GO classes identified in the genome-wide 
screen (Table 1) contained multiple sites showing signifi-
cant gains in methylation (FDR < 0.05, > 0.1 gain in β). One 
of these was the olfactory genes, discussed above: the other 
GO term GO:0015020 was largely comprised of mem-
bers of the UGT1A family. This gene family has a similar 
structure to the PCDHG cluster, where unique alternate 
5′ exons splice to common 3′ exons, but in this case codes 
for a series of nine UDP-glucuronosyltransferase enzymes 
(UGTs). Substantial gains in methylation can be seen at 
the upstream promoters controlling the 5′ exons (Fig. 4a), 
most of which lack CGI. Median methylation levels also 
showed clear increases overall in the KD lines (Fig.  4b), 
though these did not reach significance. Most individual 
exons also showed a sharp increase (Fig. 4c), with A1 being 
a clear exception in all lines. We confirmed a significant 
gain in methylation in each cell line at A4 (Fig. 4d) but no 
alteration at A1 (Fig. 4e). In contrast to the clear gains in 
Fig. 3 Loss of methylation at fat homoeostasis/body mass (FBM) genes, olfactory receptors and the TSPY genes. a Median β values for all FBM 
genes (following curation) in WT and KD cell lines; significant differences (Mann–Whitney U) are indicated. b Median methylation values at each 
FBM gene in WT and d16 cells. c Average methylation levels obtained from pyroassays at the Leptin (LEP) and Ghrelin/growth factor receptor secre‑
tagogue (GSHR) promoters. d CpG located in promoters which showed highly reproducible loss of methylation (FDR < 0.05) were identified. The set 
of sites common to all three KD cell lines (n = 1185) was found to be enriched for olfactory receptors (such as the three indicated) using the DAVID 
tool. e Pyroassays designed for the three olfactory receptor genes from (d) confirmed methylation was consistently reduced across all KD cell lines. f 
Browser view showing loss of methylation (red) at the CGI‑containing promoters for members of the TSPY family on the Y chromosome
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all three lines for UGT1A, the histone modifier group also 
identified as gaining methylation (Table  1, group 4) con-
tained few FDR-supported sites and these often did not 
overlap between cell lines, with median β levels also not 
differing significantly (Additional file 4: Fig. S3E).
A cluster of loci showing gain of methylation on the X 
chromosome
Given that there were considerable numbers of probes 
showing gain in methylation, but few of the GO classes 
from the RnBeads analysis contained testable targets by 
our criteria, we tried an alternative analysis as for the 
OR above. Sites associated with promoters and which 
showed reliable (FDR < 0.05) gains were identified in each 
KD line, and then the lists of cognate genes were com-
pared to find those which were common to all three cell 
lines (Fig.  5a). Examination of the 201 promoters from 
this analysis (Additional file  5: Table S2) failed to show 
any significantly enriched terms in DAVID. However, sev-
eral of the genes showing the greatest gain in methylation 
were located on the X chromosome, including GABRQ 
and members of the MAGE family of cancer/testis anti-
gens such as MAGEA12. Mapping of FDR sites to the X 
chromosome showed that adjacent domains could vary 
in methylation level by more than 80% in either direction 
(Fig.  5b). Pyroassays for GABRQ and the neighbouring 
Fig. 4 Gains in methylation at the clustered UGT1A locus. a Structure of the UGT1A cluster showing the 5′ variable exons (UGT1A1–UGT1A10) which 
are spliced to the 3′ exons (right). Key to tracks as before; pyroassay locations (UGT1A1 and UGT1A4) are boxed. b Median β values for all first exons: 
though medians are higher in KD lines these failed to reach statistical significance. c Median absolute β values at individual first exons in WT and 
d16 cells. d Average methylation values in WT and KD cells obtained from a pyrosequencing assay (pyroassay) designed to cover CpGs in the A4 
exon. e Methylation by pyroassay at the A1 exon, shown as a control
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MAGEA12 gene confirmed significant gains in methyla-
tion at the GABRQ promoter and in the MAGEA12 gene 
body (Fig.  5c). Clonal analysis for GABRQ indicated a 
uniform increase in methylation (78 vs. 16%) across all 
adjacent CpG at this locus (Fig. 5d). Both direction and 
degree of change in methylation were highly correlated 
between pyrosequencing and the 450K array across all 
sites which were covered by both types of assay (r = 0.916 
for loss of methylation r = 0.818 for gain in methylation).
Transcriptional changes are enriched at cancer/testis 
antigen genes on X and Y
To see whether methylation changes were accompanied 
by large-scale changes in transcription, we carried out a 
genome-wide screen using the HT12 array which assays 
most RefSeq genes. Figure  7a shows the distribution of 
changes comparing d8 and WT: genes which showed > 2 
fold change (FC) and with scores of p < 0.05 are high-
lighted, with the greater spread to the right indicat-
ing a greater tendency to derepression. Relatively small 
numbers of genes were affected (Fig.  6b), particularly 
at higher stringency (FDR < 0.01), and d16 showed few-
est dysregulated genes. To determine common targets, 
we looked for shared genes (Fig. 6c). DAVID analysis on 
the genes common to all three (n = 70; Additional file 6: 
Table S3) indicated significant enrichment for genes cod-
ing for MAGE domains (Fig.  6d). MAGE genes on the 
X chromosome were previously identified as showing 
large changes in methylation (Fig. 5): also appearing here 
was a TSPY family member (Table 1, Fig. 3f ). Upregula-
tion of members of these gene classes could be verified 
by RT-PCR (Fig.  6e) and showed similar direction of 
change to the array, and greater magnitude, by RT-qPCR 
(Fig.  6f ). Consistent with the transcriptional upregula-
tion, median methylation levels at the promoters of these 
genes were lower than WT (Fig. 6g). Interestingly, there 
was an overall increase in intragenic (as opposed to pro-
moter) methylation in the larger group of transcription-
ally dysregulated genes common to d8 and d10 (n = 764, 
see Fig.  6h and Additional file  6: Table S3), which may 
Fig. 5 Gains in methylation on the X chromosome. a Sites reliably showing gain in methylation and located in promoters were analysed to identify 
those common to all three KD lines (n = 201). Some of these sites showing the greatest change in methylation were located on the X chromo‑
some including MAGEA12 and GABRQ. b Schematic showing the locations of the two genes adjacent to each other on X in a region showing gain 
in methylation. Tracks indicate the locations of all 450K probes and CGI; the positions of the pyroassays are also indicated; the scale bar pertains to 
the bottom part of the schematic; ∆β, change in beta value. c Methylation as determined by pyroassay at the two genes indicated in a, b. d Clonal 
analysis of GABRQ in WT and d8. Filled circles represent methylated sites, open circles unmethylated. The CpG which were also analysed by the 
pyroassay (pyro) and the 450K array (asterisk) are indicated
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Fig. 6 Transcriptional dysregulation of genes on the X and Y chromosomes correlates with methylation changes. a Volcano plot showing log fold 
change (FC) in transcription as measured by HT12 array versus FDR‑corrected significance values: genes with > 2FC and FDR < 0.05 are highlighted 
in red. b Numbers of dysregulated genes at different FDR thresholds for the different KD lines. c Genes common to more than one KD line at 
FDR < 0.05; total numbers in each cell line are indicated in brackets. d Ontology enrichment output from DAVID for the genes common to all KD 
lines. e RT‑PCR analysis of the three MAGE genes on X and a member of the TSPY gene family on Y highlighted in DAVID analysis (C). ACTB is a load‑
ing control; −ve, negative control lacking cDNA. A 100‑bp ladder is shown at left with the 200‑bp band indicated by an arrowhead. f Transcrip‑
tion levels of indicated MAGE genes from the HT12 array or by qPCR. Error bars are 95% CI for the array, SEM for qPCR; fold change was significant 
(p < 0.05) in all cases. g Median β values on 450K array for probes at MAGE promoters were decreased, though failed to reach significance. h Gene 
body methylation was increased in transcriptionally upregulated genes
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reflect increasing gene body methylation accompanying 
transcription.
Regions hypomethylated in shRNA lines correlate 
with polycomb repression
To investigate why losses in methylation occurred at the 
same positions in all KD lines, we used ENCODE data to 
look at chromosomal distribution, replication timing and 
chromatin features which might be important, since the 
DNMTs have no DNA sequence specificity themselves. 
Of these, the chromatin marks were most informative, 
in particular the ChromHMM dataset on lung fibro-
blasts which partitioned the genome into different types 
of chromatin based on a set of distinguishing histone 
marks and other features [43]. This indicated that probes 
significantly losing methylation in our shRNA lines are 
most densely distributed across regions which are nor-
mally polycomb-repressed or are heterochromatic/low-
signal regions in lung fibroblasts (Fig.  7a). Specifically, 
many regions show a striking correlation between poly-
comb marking and methylation loss, such as the LEP 
and neighbouring PRRT4 genes (Fig. 7b): in contrast, the 
intervening MGC27345 and RBM28 genes at that locus, 
which are highly methylated in WT cells (top track), 
show little or no loss of methylation and have chromatin 
marks associated with transcription.
These data suggested that polycomb-repressed regions 
might be more susceptible to demethylation than oth-
ers. To test whether these regions lost methylation more 
readily than others, we treated hTERT1604 with siRNA 
for 72  h, which led to acute depletion of the DNMT1 
mRNA (Fig.  7c). We found, however, that there was lit-
tle difference between polycomb-repressed and other 
regions in terms of demethylation in the siRNA-treated 
lines (Fig.  7d), in contrast to the shRNA lines where 
losses were concentrated at the former (Fig.  7d). This 
could also be seen at the LEP locus, where MGC27345 
and RBM28 now showed loss of methylation following 
siRNA treatment (Fig.  7b, siRNA track). Also of note, 
almost no probes showed gains in methylation relative to 
WT in the siRNA cells (Fig. 7e), indicating that this effect 
is associated exclusively with chronic treatment. These 
results suggested that gains of methylation had occurred 
only in shRNA lines and had effectively restored methyla-
tion to near WT levels at most regions outside of those 
marked as polycomb-repressed.
Since transcriptional analysis did not highlight dys-
regulation of polycomb regions in shRNA cells (Fig. 6d), 
we tested to see whether polycomb-mediated repression 
was being maintained there in the absence of DNA meth-
ylation. To do this, we treated with DZNep, an inhibitor 
of EZH2, and confirmed the upregulation of a positive 
control gene SLCA4 (Fig. 7f ) as previously reported [44]. 
Likewise, HOXC13—a known polycomb target—showed 
derepression (Fig.  7f ). The FBM genes marked by poly-
comb including LEP showed reactivation to a compara-
ble degree to SLCA4, whereas the MAGEA12 gene which 
is in a heterochromatic region not marked by polycomb 
showed little effect (Fig. 7f ).
To further investigate the difference between acute and 
chronic DNMT1 depletion in these cells, we first exam-
ined the effects of acute depletion by siRNA on the loci 
identified in the stable lines: this confirmed that loci 
such as the clustered protocadherins and the fat/body 
mass genes also lose methylation on short-term deple-
tion by siRNA (Fig. 7g). Following treatment, cells were 
then allowed to recover in the absence of siRNA for an 
extended period (36  days). DNMT1 levels returned to 
normal rapidly (Fig.  7h). Examination of the methyla-
tion response at various gene classes was very instructive. 
Germline genes (SYCP3, DAZL), which are known to 
become de novo methylated to high levels during somatic 
differentiation [5, 34], showed initial loss versus a scram-
bled control (Scr), followed by remethylation over time 
to near WT levels (Fig.  7i), confirming that the hTERT 
cells possess sufficient de novo activity to remethylate 
(See figure on previous page.) 
Fig. 7 Methylation loss is concentrated at regions normally repressed by polycomb. a Distribution of probes showing significant loss per chromatin 
state—numbers of probes are shown at left, chromatin states below: tcn, transcription; heterochrom/Lo, heterochromatin or low signal; repeti‑
tive, repeat DNA. b Region around the LEP gene: tracks as before, with the addition of data from cells treated with siRNA for 72 h (top). A track 
showing ChromHMM chromatin states from NHLF foetal lung fibroblasts is shown at bottom: grey, polycomb‑repressed; green, transcriptionally 
active (full colour key at top right). c DNMT1 mRNA levels by qPCR following treatment with siRNA (+) for 72 h compared with scrambled control 
(Scr). ACTB is shown as a control; ladder as above. d Median β values for all regions (WT) compared to medians for polycomb‑repressed regions 
(Polycomb), or all other regions (Other) in the cell lines indicated at top; remeth, remethylated. e Numbers of probes showing loss and gain in 
methylation in hTERT cells following treatment with siRNA for 72 h compared with the shRNA lines (averaged); #, number. f mRNA levels for the 
indicated genes in shRNA lines treated with the EzH2 inhibitor DZNeP; UNT, untreated; bars represent SEM, experiment carried out in duplicate. g 
Median β values for all variable exons at the PCDHG locus (left) and for fat/body mass genes (FBM, right): compare d16 shRNA lines with cells treated 
with siRNA. h DNMT1 mRNA levels in WT cells exposed to siRNA for 48 h, then allowed to recover in normal medium; comparisons were made to a 
scrambled siRNA negative control (Scr). i Methylation levels by pyroassay at the loci indicated during the transient KD and recovery shown in (h); 
timepoints are in days. All loci showed significant loss of methylation: LEP and SNRPN showed no significant gain versus lowest methylation level, 
while PCDHGA2 showed no significant gain between d22 and d36
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the genome, as already suggested (Fig. 7b–e). Imprinted 
genes are normally unable to regain methylation somati-
cally [45], and we could confirm that the SNRPN imprint 
control region failed to remethylate (Fig.  7i). The poly-
comb-marked genes LEP and PCDHGA2 were also 
refractory to de novo methylation, either showing no 
gain (LEP) or reaching a plateau at an intermediate level 
of recovery only (PCDHGA2) (Fig. 7i).
Gain in methylation is associated with poised promoters 
in shRNA lines
Having established that loss of methylation in shRNA 
lines is linked to polycomb repression, we wished to 
determine what features are associated with gains in 
methylation in these chronically depleted cell lines. As 
indicated, gains were not seen genome-wide following 
acute depletion using siRNA (Fig.  7e) and specific loci 
such as UGT1A showed instead loss of methylation on 
acute treatment (Fig.  8a, siRNA track), suggesting that 
hypermethylation is associated with longer-term culture 
of the shRNA-containing cell lines. To investigate what 
features might be associated with such loci, we looked 
to see which chromatin states in shRNA lines showed 
the highest median β for probes which gained methyla-
tion and the largest difference in methylation (Fig.  8b). 
This identified weak and poised promoter categories, and 
comparing shRNA lines to WT (Fig. 8c), the median val-
ues were more different for poised than for weak promot-
ers (0.4 vs. 0.2, Cohen’s D test). These results suggested 
that poised promoters attract de novo methylation par-
ticularly strongly. Consistent with this, hypermethylation 
in the shRNA lines is centred around the UGT1A pro-
moters and not the common 3′ exons (Fig. 8a). A hetero-
chromatic location may contribute to over-methylation, 
since genes in adjacent active chromatin show restora-
tion of normal methylation (Fig.  8a, compare siRNA to 
d10, d16 for DGKD), but not hypermethylation. While 
UGT1A transcription levels were very low compared to 
expressing cells by RT-qPCR (not shown), available HT12 
array data showed a consistent decrease in transcription 
in all three shRNA lines (Fig.  8d, left), correlated with 
gains in methylation at the cognate promoters (Fig.  8d, 
right).
Further analysis confirmed that while gains in meth-
ylation were seen across all the UGT1A exons in all 
shRNA lines (Fig. 8e), all of these exons showed a loss of 
methylation following acute depletion with siRNA. We 
took advantage of our transient depletion and recovery 
experiment (Fig.  7h, i) to examine levels of methylation 
at UGT1A4 using pyrosequencing: this showed that while 
the region indeed loses methylation on acute depletion, 
it undergoes steady de novo methylation following recov-
ery and at day 36 was the only gene examined whose 
methylation exceeded that seen in the scrambled control 
(32.4 vs. 31.3%), suggesting that these genes are indeed 
susceptible to hypermethylation.
One possible reason for the gains in methylation seen 
in the shRNA lines could be over-expression of a de novo 
enzyme. Previous reports have indicated that between 
them, DNMT3B and DNMT1 account for the major-
ity of methylation in cultured adult human cells and 
that there may be a role for DNMT3B in maintenance as 
well as de novo methylation [27]. We saw little change in 
DNMT3B levels in the DNMT1 KD lines from the HT12 
transcriptional array (Additional file 7: Fig. S4A) or RT-
PCR (not shown), indicating that gains in methylation 
are not due to DNMT3B over-expression. To investi-
gate a possible role in maintenance methylation, we car-
ried out a transient siRNA treatment and could achieve 
robust knockdown of DNMT3B in the cells (Additional 
file 7: Fig. S4B). While some germline genes showed little 
effect, loci previously shown to require DNMT3B includ-
ing D4Z4 and NBL2 did show loss of methylation (Addi-
tional file 7: Fig. S4C), confirming that we had achieved 
a functional depletion. Examination of the loci identified 
in our DNMT1 shRNA clones showed that these loci also 
showed loss of methylation in DNMT3B KD cells (Addi-
tional file 7: Fig. S4C), suggesting that loci which remain 
hypomethylated in the shRNA clones also require input 
from DNMT3B to retain WT methylation levels.
Discussion
Summary and model
We and others have previously shown that acute deple-
tion of DNMT1 using siRNA triggered the DNA dam-
age response and cell cycle perturbations in human 
cell lines, making it difficult to identify genes which are 
directly controlled by methylation. Here we used iso-
genic shRNA-containing derivatives of a normosomic 
lung fibroblast cell line to look at the effects of chronic 
depletion of the protein. We characterised the altera-
tions in methylation and transcription using microar-
rays in three different cell lines, processing them using a 
highly reproducible pipeline, and verified changes using 
locus-specific pyrosequencing or RT-qPCR assays. Addi-
tionally, we compared the effects on methylation of this 
chronic depletion to the effects of acute depletion using 
siRNA, as well as investigating possible contributions 
by DNMT3B. Finally, we investigated the correlations 
between chromatin state and DNA methylation and 
showed a role for polycomb-mediated repression at some 
of the loci.
Our results show that while both siRNA and shRNA-
treated cells lose methylation overall as would be 
expected, only the latter show gains in methylation, most 
likely reflecting selection against the deleterious effects 
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of hypomethylation during clonal expansion and cul-
ture. Figure 8e shows what we propose to have occurred: 
shRNA treatment gave initial widespread demethylation 
in all three clonal lines, since each line shows the pres-
ence of some highly demethylated sites distributed across 
the genome, but methylation seems to have recovered 
at most CpGs (Fig.  8e red line). Comparison to normal 
chromatin patterns in human lung fibroblasts indicated 
that remaining hypomethylation in the expanded cells 
was concentrated at regions normally marked for repres-
sion by polycomb (Fig. 8e purple line), while the smaller 
number of regions becoming hypermethylated relative to 
the parental cell line are associated with poised promot-
ers (green line). TET expression was not detected, and 
the cells had little or no 5-hydroxymethylation (5hmC; 
data not shown), in keeping with other reports [46], sug-
gesting that the hypermethylation does not represent 
5hmC. Likewise, no over-expression of DNMT3B was 
detected.
In terms of what type of gene was particularly affected 
by chronic DNMT1 KD, the enrichment analyses and 
laboratory verification consistently pointed at the same 
small group of gene categories, namely (1)neuroepi-
thelial genes, and in particular the protocadherins; (2) 
fat homoeostasis/body mass genes; (3) olfactory recep-
tors; (4) the cancer/testis antigens; and (5) the UGT1A 
complex.
Protocadherins are major targets of DNA methylation 
in human cells
Emerging evidence suggests that the clustered proto-
cadherin genes may be central to specifying individual 
neural cell identity [47, 48] and they have been shown to 
become heavily methylated during embryonic develop-
ment in mouse [49], suggesting that stable repression of 
non-transcribing copies is a programmed event during 
development. Recent work has shown that DNMT3B is 
important for de novo methylation at these loci and sug-
gested that dysregulated expression may contribute to the 
phenotype in immunodeficiency, chromosome abnor-
malities and facial anomalies (ICF) syndrome [50], where 
DNMT3B is frequently mutated [51], and we found that 
depletion of DNMT3B was accompanied by loss of meth-
ylation at PCDHGA2. The PCDHA and PCDHB loci are 
heterochromatic and show persistent loss of methyla-
tion, as does the 5′ end of the PCDHG locus which is 
polycomb-repressed, but not the 3′ end which shows lit-
tle loss of methylation and has instead chromatin marks 
associated with weak transcription (Additional file 3: Fig. 
S2B). Meehan and co-workers recently showed that long-
term loss of DNA methylation in mouse Dnmt1 −/− ES 
cells led to spreading of polycomb marks (in particular 
H3K27me3): their analyses singled out the Pcdh genes, 
which were heavily methylated in WT but not mutant 
ESC, as also shown by others [52]. Reddington et  al. 
[17] also showed an increase in H3K27me3. A similar 
sequence of events in our human cells would cause an 
increase in H3K27me3 on PCDH genes and potentially 
help block remethylation. The sensitivity of the proto-
cadherin cluster to methylation changes may explain 
why these genes are frequently identified in screens for 
differentially methylated loci in cancer [53]. The lack of 
derepression in our stable fibroblast cells is unsurpris-
ing here since expression of these genes is restricted to 
neurons [54]: they are also, with the exception of part of 
the PCDHG complex, heterochromatic rather than poly-
comb-repressed and may as such be harder to reactivate.
Fat/body mass genes can be repressed by DNA 
methylation and polycomb
Currently, there is much interest in the possibility that 
altered diet, folate status or exposure to environmental 
toxins may lead to stable changes in the human methyl-
ome which particularly affect metabolic processes, as this 
offers an attractive mechanism by which it may be possi-
ble to partly explain the foetal origins of adult disease [55, 
56]. Enrichment analysis in our cells identified the FBM 
genes involved in the common processes of lipid storage 
and body mass homoeostasis, including LEP, GHSR and 
the APOC cluster. These loci are readily demethylated 
on acute DNMT1 depletion and remain demethylated 
in chronically depleted cells where many other loci have 
(See figure on previous page.) 
Fig. 8 Methylation gain is concentrated at poised promoters. a UGT1A locus showing siRNA treatment data (top), shRNA lines (middle) and chroma‑
tin states (bottom); grey, heterochromatin/low signal; green, transcriptionally active (for full key see previous fig). b Median β levels for probes gain‑
ing and losing in shRNA lines (bottom) and median changes in methylation (∆β) versus WT for different chromatin states. c Boxplots of methylation 
values for probes falling within weak and poised promoter chromatin regions in WT or shRNA lines (averaged). d Transcription at the UGT1A3 and 
UGT1A6 genes decreases (relative to WT, set to 1) in all three shRNA lines as methylation (β value) increases, as indicated by HT12 and 450K arrays, 
respectively. e Median methylation (β) across all UGT1A exons decreases in siRNA‑treated cells, but shows gains in all shRNA lines. f Methylation at 
UGT1A2 during the transient KD and recovery experiment shown in Fig. 7h, i; differences are significant between control (Scr) and d4, but not Scr 
versus d36. g Model for methylation changes which occurred over time following chronic (shRNA) depletion of DNMT1: while polycomb‑marked 
regions (purple) resisted remethylation, most regions (“other”, red) regained normal or near‑normal levels, while poised promoters (green) tended to 
become hypermethylated
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recovered methylation. These loci are heavily marked by 
polycomb in normal fibroblasts, rather than being het-
erochromatic, which can potentially explain both their 
resistance to remethylation and their lack of transcrip-
tional depression in the stable lines. In keeping with this, 
inhibition of the polycomb repressor EZH2 which gener-
ates H3K27me3 marks could reactivate these genes, as 
well as the canonical polycomb targets the HOX genes. 
These results suggest that in cells which have both DNA 
methylation and polycomb-mediated repression, both 
layers of repression must be removed to achieve gene 
activation. Interestingly a recent report by Hajkova and 
colleagues showed that reprogramming of germ cells in 
mouse also required both removal of DNA methylation 
and alteration of polycomb marks [57].
Olfactory genes are methylated and largely inert
Olfactory receptors are also involved in specification 
of neural cell identity, where individual receptors are 
expressed in only a small group of cells in the olfac-
tory epithelium [58]. They are largely monoallelically 
expressed, and methylation has been implicated as play-
ing a role in their control [59, 60]. The OR gene fam-
ily is the largest in the genome, with approx. 380 active 
members, many organised into “gene factories” where 
they are flanked by many more pseudogenes and repeats, 
such as the large cluster on chr11 [41]. These regions are 
often transcriptionally inert and heterochromatic, which 
together with the requirement for tissue-specific factors 
may explain their lack of derepression.
Cancer/testis antigen genes are particular targets 
for demethylation and activation
The TSPY and MAGE genes fall into a function-
ally defined group known as the cancer/testis antigen 
(CTA) genes ([61, 62]; http://www.cta.lncc.br/) which 
are expressed during testis development normally, but 
which are aberrantly expressed in some tumours, such 
as melanoma and gonadoblastoma (e.g. TSPY2). This 
latter property makes them of particular interest for 
cancer immunotherapy, and monoclonal antibodies 
against some CTA members have already gained clinical 
approval [63]. CTA genes have been shown previously 
to lose methylation and become derepressed in several 
cancer cell types after treatment with the methyltrans-
ferase inhibitor 5′aza-2-deoxycytidine (Aza) [64–66] 
and in the HCT116 DNMT1 mutant line [66, 67] using 
locus-specific approaches. Our study (1) shows in an 
unbiased genomic screen that CTA genes are the genes 
most affected by loss of maintenance activity, (2) shows 
this for the first time in a normal, differentiated cell 
line and (3) highlights the subset of CTA genes which 
are particularly dependent on maintenance activity to 
keep them repressed. It is noteworthy that the majority 
of these genes are on the X chromosome, which shows 
major fluxes in methylation in our stable lines. The genes 
are largely associated with heterochromatin, rather than 
polycomb repression, and do not respond to EZH2 inhi-
bition, but rather directly to loss of methylation, which 
may reflect some difference in heterochromatin mark-
ing on the X. Strategies to demethylate and turn on these 
genes in tumour cells (e.g. with Aza) to facilitate cancer 
vaccine development may be worthwhile to pursue, given 
that these genes are the most responsive to loss of meth-
ylation in our cell lines.
UGT1A genes and other poised promoters are susceptible 
to hypermethylation
From the enrichment analysis, the UGT1A gene clus-
ter was highlighted in terms of genes gaining methyla-
tion. These genes are known to be highly expressed in 
skin fibroblasts postnatally, and to be repressed in non-
expressing tissues by methylation [68, 69]. The WT cells 
already had substantial levels of methylation but the 
increased methylation in the stable cell lines led to small 
but consistent decreases in transcription on the HT12 
array, though levels were so low these could not be con-
firmed by Taqman qPCR (data not shown). It may be that 
the particular marks associated with a recent inactivation 
of the UGT1A cluster in the fibroblasts during adaptation 
to cell culture led to an increased de novo activity here, 
and in our transient KD experiment we saw the greatest 
gains in methylation at UGT1A4. Consistent with this, 
hypermethylation relative to the WT cells was associated 
with weak and poised promoters genome-wide, and the 
latter showed the greatest tendency to gain methylation 
above normal WT levels in the shRNA-containing lines.
Lack of transcriptional changes in part due to polycomb
It is notable that while there was widespread changes in 
methylation in the KD cell lines, this was not accompa-
nied by large-scale transcriptional derepression, with 
only a few hundred genes showing dysregulation, and 
the fold change in transcription being small. Of the four 
gene classes identified as most affected in terms of meth-
ylation, only one—that containing the TSPY and MAGE 
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genes—showed robust transcriptional derepression. A 
lack of global changes in transcription, also reported by 
others [29, 70], is likely due to in part to the absence of 
transcription factors in fibroblasts needed to transcribe 
neural or adipocyte genes at high levels. However, many 
of the regions showing most persistent hypomethylation 
are polycomb-marked and this is likely to be sufficient 
in itself, as it is for example in Drosophila, to main-
tain repression of these genes. However, we could show 
that in the presence of an EZH2 inhibitor, polycomb-
marked loci which lacked DNA methylation, such as 
those involved in fat homoeostasis/body mass regulation, 
became upregulated, along with canonical polycomb tar-
gets such as the HOX genes. Our results therefore indi-
cate both that the polycomb system is sufficient in itself 
to repress and also that polycomb-repressed regions 
appear to be refractive to remethylation, which may be 
due to the action of FBXL10 [71]. It has previously been 
proposed that the two systems work in parallel, with their 
own sets of targets and a degree of mutual exclusivity 
[15–17]: our results would support such a conclusion.
Comparison to other recent work
Two recent studies have also examined the effects of 
DNMT1 mutation on DNA methylation and gene 
transcription in human, albeit in cancer cells [29, 70]. 
Acute depletion of DNMT1 using an siRNA-mediated 
approach found, as we did, regions of low CpG density 
(open sea, etc.) to be most affected, but differed in find-
ing more evidence for cell morphogenesis and phospho-
rylation pathways being affected [70]. This might reflect 
differences between acute and chronic depletion and the 
high levels of cell death during acute depletion. Blattler 
and colleagues [29] also found that relatively few genes 
were dysregulated in DNMT1/3B double KO HCT116 
cells, but some cancer/testis genes (the related GAGE 
genes) were upregulated, along with Krüppel-associated 
box genes, while chaperonins figured prominently among 
down-regulated genes. The latter two gene classes may 
therefore be more dependent on DNMT3B, or the com-
bination of DNMT1 and 3B, for their maintenance; alter-
natively the differences may be due to the experiment 
being carried out in colon cancer cells rather than, as 
here, in non-transformed fibroblasts.
Conclusions
In conclusion, our study sheds new light on the loci 
which are most sensitive to sustained loss of mainte-
nance activity in humans and shows an interplay between 
polycomb and DNA methylation-mediated repression in 
these differentiated cells.
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Additional file 1: Table S1. Details of the primers used in this study.
Additional file 2: Figure S1. Variation between shRNA clonal lines. (A) 
Relative similarities between cell lines based on principal component 
analysis (PCA) of the 450K data; three independent cultures of each line 
were analysed. Note the clustering of lines d8R and d10R. The fraction of 
total variance explained by each component is indicated in brackets. (B) 
The 1000 sites most variably methylated between cell lines were used for 
hierarchical clustering. The location of sites with respect to CpG island is 
indicated at left. Beta values are depicted as shades from red (low) to blue 
(high).
Additional file 3: Figure S2. Changes in methylation levels by genomic 
element. (A) Protein levels in knockdown lines by western blotting. As a 
control HCT116 colon cancer cells which are WT or have a homozygous 
mutation in DNMT1 (KO) are shown: the DNMT1‑specific top band is 
indicated by the arrowhead at right. (B) Median levels of methylation are 
shown for each genomic element (listed at top). The positions of medians 
are also indicated at right (arrowheads). The differences between WT and 
KD medians were used to plot Fig. 1d. (C) Density distribution of methyla‑
tion at the three main elements involved in gene regulation, shown by 
cell line. Demethylation seems most marked at gene bodies (Genes), 
indicated by increased density of probes at low methylation (β) values.
Additional file 4: Figure S3. Further analysis of enriched genes. (A)Total 
numbers of sites showing significant changes in methylation at different 
false discovery rates (FDR). Some sites showing gain were found in each 
KD cell line alongside the more numerous sites showing loss. (B) Differen‑
tial methylation between WT and all KD lines using the 1000 best‑ranking 
sites as identified by RnBeads (red). The majority of high‑scoring sites 
common to all three lines lost methylation, but approx. one‑third showed 
gain. (C) Methylation changes at neural identity genes on chromosome 
5. Protocadherins in the α and γ families (PCDHA and PCDHG genes) 
have a clustered arrangement, while genes for the β family members are 
arranged individually. Tracks are as in Fig. 3. The position of the C class 
variable exons in the PCDHA and PCDHG clusters are also shown: gain in 
methylation relative to the siRNA‑treated cells can be seen in the boxed 
regions, which includes the PCDHG constant exons, corresponding to 
transcriptionally active chromatin (green). (D) Median β values for gene 
bodies for olfactory receptors identified by DAVID: differences were signifi‑
cant by Mann‑Whitney U (MWU). (E) Median β values for the promoters 
of genes in the histone modifier group identified by enrichment analysis 
in Table 1. No significant differences between WT and KD were found by 
MWU.
Additional file 5: Table S2. Details of the hypomethylated and hyper‑
methylated genes from Figs. 3d and 5a, respectively.
Additional file 6: Table S3. Details of the genes showing transcriptional 
changes in KD cell lines from Fig. 6c.
Additional file 7: Figure S4. Role of DNMT3B in hTERT1604. (A) DNMT3B 
mRNA levels from the HT12 transcription array (3 probes) did not differ 
substantially in DNMT1 shRNA cell lines from WT cells. (B) Successful 
depletion of DNMT3B mRNA using siRNA for 48hr, versus a scrambled 
control (Scr). (C) Methylation levels by pyroassay at the indicated loci: KD, 
knockdown. Methylation levels at 72hr were similar (not shown).
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The main aims of this paper were to: 
1. Identify gene targets specifically sensitive to DNMT1 inhibitors in normal human cell
lines by pharmacological depletion of DNMT1 using Aza.
2. Compare the depletion of DNMT1 using Aza to that of a transient knockdown of
DNMT1 using DNMT1 targeting siRNA.
3. Identify any novel effects of DNMT1 depletion on global methylation and on specific
genomic regions.
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I performed all of the bioinformatic analysis on the transiently and pharmacologically DNMT1 
depleted human fibroblastic cell lines (created by co-author Karla O'Neill) using a modular 
methylation analysis package called RnBeads with some tailored script in the R interface. 
Using the differential methylation results from the initial bioinformatic analysis, I performed 
all the downstream gene enrichment, and subsequent statistical analysis of differentially 
methylated gene classes, in addition to screening the same gene classes in complementary 
transcription array data of the same cell lines. I created all the figures for the manuscript using 
either RnBeads or Adobe Illustrator and I wrote the majority of the manuscript and created the 
GEO submission to deposit all of the 450k methylation data and associated metadata sheets 
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Summary of the major findings; 
1. Treatment of non transformed hTERT cells with Aza, and DNMT1-targeting siRNA both
caused an overall hypomethylation event. 
2. The hypomethylation caused by Aza was particulary enriched at the promoters of histone
genes. 
3. A common set of genes enriched for proteins involved in phosphorylation & acetylation
were affected by both treatments. 
4. Gains of methylation were observed in Aza-treated hTERTs particulary at GPCRs.
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Aim: 5-aza-2′deoxycytidine (Aza) is used to treatmyelodysplastic syndrome and is in trials for other cancers.
It acts chiefly as a hypomethylating agent inhibiting DNMT1. A lack of understanding of off-target effects
in normal cells hinders wider usage. Materials & methods: We compared treatment of the same normo-
somic, nontransformed fibroblast cell line with Aza and SMARTpool siRNA against DNMT1. Methylation
and transcription were assayed using Illumina 450k and HT12 arrays. Results: Both Aza and DNMT1 siRNA
caused overall hypomethylation, with siRNA more efficient at demethylating gene bodies. Hypomethyla-
tion at the promoters ofmany histones, and hypermethylation atmultiple sites genomewide, were unique
to Aza treatment. Conclusion: Aza had important unique effects and targets compared with DNMT1 in-
hibition via siRNA.
First draft submitted: 19 December 2017; Accepted for publication: 23 February 2018; Published online:
31 July 2018
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Aberrations inDNAmethylation are amajor characteristic of cancer progression [1,2] and in particular of some hema-
tological malignancies such as myeloid dysplastic syndromes (MDS) [3]. DNA methylation is a post-translational
modification which serves as an epigenetic method to regulate transcription, modulate chromatin structure and
repress transposable elements [4]. DNA methylation is established through the addition of a methyl group from
a donor molecule of S-adenosyl-methionine to the 5′ position on a cytosine within a cytosine-guanine (CG)
dinucleotide [5]. Current epigenetic treatments are thought to mainly affect DNMT1, one of the three functional
methyltransferases in human and chiefly responsible for the maintenance of DNA methylation and ensuring the
integrity of methylation post replication [6,7].
There are currently a range of knownDNMT1 inhibitors such as the nucleoside inhibitors 5-aza-2′ deoxycytidine
(Aza), 5-azacytidine and zebularine [7,8], all of which are modified at the 5′ position of their pyrimidine ring. Aza
in particular has been found to be the best nucleoside inhibitor to promote DNA demethylation [9] and in this role
as a hypomethylating agent it has become US FDA- and UK NICE -approved (as decitabine or dacogen) for the
treatment of MDS [3,10], and is currently under clinical trial for use in acute myeloid leukemia (AML) patients who
are ineligible for intensive chemotherapy [11]. Around 15% of confirmed patients with MDS respond to epigenetic
therapy through an improved blood cell count, particularly a smaller count of malignant cells [12,13]. This epigenetic
treatment with Aza has been shown to prolong the overall survival while lowering the risk of progression to the
leukemic stages in patients with higher risk MDS, in comparison to MDS that is treated conventionally [7,14].
However, despite clinical success with use of this pharmacological agent the mode of action behind Aza and its
effect on myeloid malignancy remains unclear.
Aza functions so well as a hypomethylating agent because it acts as a cytosine analog and can be easily incorporated
into the replicating DNA in proliferating cells and acts as a suicide substrate. This phenomenon is due to the
irreversible covalent bonding of the cytosine analog, chiefly with the DNAmethyltransferase DNMT1 [15,16], which
is the main activity present in almost all cells, althoughDNMT3A andDNMT3B, which are present at low levels in
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most adult tissues [17]may also be affected.WithDNMT1nowunable to function asmaintenancemethyltransferase,
normal methylation is prevented at CG dinucleotides of newly synthesized DNA and the enzyme becomes targeted
for premature degradation [18]. This ultimately leads to a hypomethylation, most likely through excision of the
enzyme: analog: DNA conjugate by DNA repair enzymes and synthesis of a new, unmethylated replacement [16].
The widespread demethylating effect of Aza on multiple genes across many cell lines and tissues, as shown both
by ourselves [19–21] and others [7,9,15,22] is therefore well established. The nucleoside inhibitor 5-azacytidine on the
other hand becomes preferentially incorporated into the RNA [23,24]. Genome-wide demethylation in cancerous
cells at promoter regions in particular is one of the primary aims of oncological epigenetic therapy. In cell lines,
methylation levels at transcription start sites can be pharmacologically altered to cause hypomethylation and
consequent transcriptional re-activation of epigenetically silenced tumor suppressor genes (TSGs) [7,22,25].
However, despite clinical success in the treatment ofMDS by prolonging the time to leukemic transformation [24]
specificDNMT inhibitors that are both efficient and have clearly elucidated gene targets have not yet been identified:
this is in part due to different genetic backgrounds in distinct cancers [26]. There is a real need for baseline data
in a normal cell which can be compared with direct DNMT1 inhibition. Here we aimed to investigate the exact
gene targets that were particularly sensitive to changes in methylation post-treatment with Aza in the normosomic,
nontransformed human fibroblast cell line hTERT-1604, comparing directly to a transient knockdown of DNMT1
in the same cell line. To allow quantitation of smaller effects, we used the Infinium HumanMethylation 450k
BeadChip Array, which can very reliably measure small effects [27].
Material & methods
Cell culture
hTERT-1604 fibroblasts were cultured as previously described [21] in 4.5 g/l glucose Dulbecco’s Modified Eagle’s
Medium (D-MEM) supplemented with 10% Fetal Bovine Serum (FBS) and 2× Non-Essential Amino Acids
(NEAA). Pharmacological inhibition of DNMT1 with Aza (sold as 5-aza-2′ deoxycytidine [Sigma-Aldrich, Dorset,
UK] and resuspended in medium) and transient DNMT1 depletion using siRNA (SMARTpool, Thermo Fisher
Scientific, Loughborough, UK) in hTERT-1604 fibroblasts were also carried out as described therein, along with
subsequent validation. Briefly, for Aza treatment 1 × 106 hTERT-1604 cells were seeded onto a 90 mm plate in
complete medium and allowed to attach overnight, before replacing with medium containing 1 uMAza, or medium
alone (untreated [UT]). Medium +/- Aza was replaced at 24 and 48 h, and cells harvested at 72 h. For siRNA,
1 × 106 cells were resuspended in 2 ml of medium containing 0.2 uM final concentration of targeting siRNA or
a scrambled control (Thermo Fisher Scientific), then allowed to attach in the well for 24 h before replacing with
fresh medium without siRNA; cells were harvested at 72 h.
DNA extraction & pyrosequencing
DNA was extracted from each of the cell lines in log phase using the Genomic DNA Purification Kit (Fermentas,
now Thermo Fisher Scientific) as per manufacturer’s instructions. The concentration and purity of the DNA
extracted from each cell line were measured using a Nanodrop ND-1000 spectrophotometer (Labtech, Ringmer,
UK). Integrity of the DNA samples was determined by running 3 μl of each sample on a 1% agarose gel with 1 kb
ladder (Invitrogen, Paisley, Scotland) by gel electrophoresis and imaged using UV light in the Kodak Gel Logic 200
imaging system (CarestreamHealth UK Ltd, Hemel Hempsted, UK) . An initial aliquot (500 ng) of DNA was used
to test the effectiveness of the treatments by bisulfite conversion using the EpiTect Bisulfite Kit (Qiagen, Crawley,
UK) according to the manufacturer’s instructions followed by pyroassay, as was described previously [21]: briefly,
an initial PCR was carried out using the PyroMark kit (Qiagen) before pyrosequencing on the PyroMark Q24
according to the manufacturer’s instructions. Details of assays are given in Rutledge et al. [21]: average methylation
across all CpG (DPEP-5CpG, SYCP3- 4CpG, DAZL- 4CpG) is shown; experiments were carried out in triplicate
with at least one biological repeat.
Illumina Human Methylation 450k BeadChip Array
Prior to array analysis the DNA underwent additional quantification using PicoGreen R© dsDNA quantification
assay (Thermo Fisher Scientific). For this, 2.5 μl PicoGreen and 497.5 μl 1 × TE buffer (10mM Tris (pH 8),
1mM EDTA) were added together and combined to a solution of 3 μl DNA and 497 μl 1 × TE buffer. This
combined 1 ml solution was left to incubate for 5 min. Following incubation, 150 μl of the solution was aliquoted
into six wells of a 96-well plate (Orange Scientific, Braine-l’Alleud, Belgium) per DNA sample and fluorescence
10.2217/epi-2017-0171 Epigenomics (Epub ahead of print) future science group
Targets of 5-aza-2′deoxycytidine Research Article
read on the plate reader at 485–520 nm. The subsequent fluorescence values were incorporated into a calculation
that included information gained via the generation of a standard curve using λ DNA (effectively the R2 value
from the slope of the line). The DNA at a concentration of 50 ng/μl was sent to Cambridge Genomic Services
(CGS; Cambridge, UK) who bisulfite converted the DNA in-house (Zymo Research kit, Cambridge Bioscience,
Cambridge, UK) prior to assessing methylation levels on the Infinium Human Methylation 450k BeadChip Array
(Illumina, Chesterford, UK). The outputs from the DNA methylation array were subsequently scanned using an
Illumina iScan (Illumina) by CGS.
RNA extraction & reverse transcription quantitative PCR
RNA was extracted from each sample using the RNeasy Mini Kit (Qiagen) as per the manufacturer’s instructions:
concentration and purity was checked using the Nanodrop ND-1000 spectrophotometer (Labtech International,
Ringmer, UK) and integrity by running on a 1% agarose gel and imaged as before. Prior to sending the samples
the RNA was quantified using the RiboGreen R© quantification assay (Thermo Fisher Scientific). The reverse
transcription quantitative PCR protocol used for the test loci (DAZL,DPEP3, SYCP3) andDNMT1 was described
in Rutledge et al. [21], primers as detailed therein except DNMT1 F: GTGGGGGACTGTGTCTCTGT and R:
TGAAAGCTGCATGTCCTCAC (204 bp).
HT12 transcription array
The RNA extracted from each sample was concentrated using a SpectroStar (BMG, Labtech, Aylesbury, UK) and a
Bioanalyzer (Agilent Technologies, Cheadle, UK) by CGS before using the HumanHT-12 v4 Expression BeadChip
(Illumina) to examine gene expression. Two hundred nanogram of RNA was required as an input per reaction
and was subjected to linear amplification with the Illumina TotalPrep RNA Amplification Kit (Life Technologies,
Paisley, UK). The resultant cDNA was screened for concentration, integrity and purity using the above mentioned
SpectroStar and Bioanalyzer. Screened cDNAwas then hybridized to the BeadChip overnight, followed by washing,
staining and scanning using the BeadArray Reader (Illumina) as per manufacturer’s instructions.
Bioinformatic analysis of methylation & transcription array data
The methylation array was analyzed by calculating the β-value. The β is calculated as the signal of the methylation-
specific probes over the sum of the signals from both the methylation- and unmethylated-specific probes [28].
Total methylation of a nominated CG dinucleotide is given as a β of one, whereas total absence of methylation
is represented by a β of zero. Generally probes that have signals where the p-value >0.05 are removed before
downstream analysis is conducted. GenomeStudio (Illumina v3.2) was used by CGS after scanning the methylation
and transcriptional array data for initial data processing. Subsequently the RnBeads (v1.2.2) package [28] was used
to further process the methylation array data using R (version 3.2.2 [2015–08–14]) in R Studio (version 0.99.903).
The package offers a tailored pipeline approach for preprocessing, normalization, quality control, exploratory
analysis, differential methylation and enrichment analysis. Each analysis module populates an interactive html to
facilitate analysis. An initial principal component analysis using three siRNA- and three Aza-treated samples was
used to obtain the most tightly clustered samples and data was then renormalized with using two siRNA and two
Aza samples.
The sample, and control probes belonging to the HT12 transcription array data were also analyzed in R in
RStudio using the lumi (2.22.0) and the limma package (3.26.3). Probes that failed to have intensity values in
this case that were not significantly different (p > 0.01) from the allocated negative controls were removed. Lumi
Variance Stabilization Transformation was used to transform the data, followed by quantile normalization. Limma
was used to perform false discovery rate (FDR) testing.
Gene ontology
Functional classification of enriched gene lists identified through either methylation or transcription array analysis
was performed using the enrichment module in RnBeads, and in some cases also using the online tool DAVID
(Database for Annotation, Visualization and Integrated Discovery) v6.8 [29] and the PANTHER v12.0 classification
system [30].
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Data visualization in Galaxy
To allow comparison of gene features aligned with their associated probes browser extensible data (BED) and
bedGraph files were generated. Methylation values were visualized by converting the decimal β-value (0.0–1.0)
into integers (1–1000) by multiplying by 1000, then intervals were compared using custom scripts in Galaxy, an
open-source web-based platform [31]. The interface allowed the mapping of probes to the Refseq human reference
genome (hg38) in the University of California at Santa Cruz (UCSC) genome browser [32] and quantification
of average β-levels across genomic regions, etc.: tables of data were extracted and further statistical analysis and
boxplots generated using SPSS (v22.0, IBM UK Ltd, Portsmouth, UK). In addition to plotting actual β-scores,
β was plotted to show the changing methylation levels across the assembly.
Results
Overall hypomethylation was greater in cells treated with siRNA than Aza
In the present investigation, methylation changes after treatment with 5′-aza-2-deoxycytosine (Aza) or with a more
specific inhibitor of DNMT1 were compared in hTERT-1604 cells. We availed of cells which we had previously
treated with Aza and siRNA, where we had shown that both treatments cause demethylation and reactivation of
key indicator genes known to be transcriptionally repressed by DNA methylation as described [21]. This cell line is
normosomic, nontransformed and differentiated, making it a better model for normal tissue than the majority of
cell lines. Briefly, cells were treated with Aza (1 μM) in fresh medium each day for 3 days, or with siRNA against
DNMT1 once on day 1, then harvested at 72 h for DNA and RNA (Figure 1A). We found both demethylation
and reactivation for specific germline genes including DAZL, SYCP3 and DPEP3 with both Aza and DNMT1
siRNA using locus-specific assays (Figure 1B) as described previously [21]. Here, we extended our study to examine
genome-wide methylation levels using the Illumina 450k array, with data processing using the RnBeads pipeline
in R. Principal component analysis of probes passing the quality control steps confirmed the tight clustering of
samples according to treatment, with PC1 and PC2 explaining 55.33 and 25.47% of the variance, respectively
(total 80.80%) (Figure 2A). It can be seen that siRNA samples are more different from UT than the Aza samples
are to the UT samples. To further investigate the pattern of methylation change across the distinctly segregated
sample groups, hierarchical clustering was first performed across the 10,000 most variable sites (Figure 2B) followed
by 3000 of the most variable promoters that experienced a change in methylation (Figure 2C). The quantitative
output from the BeadChip array is given as a decimal value β ranging from 0.0 to 1.0, representative of methylation
at each CpG assessed, with high values indicating high levels of methylation and vice versa. Both clustering maps
employ Euclidean distance as their dissimilarity metric and in each case the DNMT1 siRNA-treated samples show
a greater density of probes with lower methylation in comparison to either the UT or Aza-treated samples. This
pattern was echoed in the regional methylation profiles in Figure 2D where the siRNA samples showed increased
numbers of probes with lower β-values across gene bodies, CpG islands and promoters, and reduced numbers of
probes with high β-values. There was a small plateau effect visible in gene body probes around 25% methylation in
the siRNA samples where many more probes exhibited an intermediate level of methylation in comparison to that
of the UT or Aza-treated samples. As expected Aza-treated samples also exhibited hypomethylation across all three
of the regions (Figure 2D) but the overall profile shape remained similar to that of the UT, with the demethylating
effect less pronounced than that of the DNMT1-targeting siRNA.
Distinct gene classes are most affected by the different treatment types
Differential methylation analysis was carried out between UT and both the siRNA- and the Aza-treated samples.
Scatter plots showing probes with FDR-adjusted p-values <0.05 were generated as part of this analysis (Figure 3A)
and indicated that treatment with siRNA caused more individual probes to significantly lose methylation than
treatment with Aza (Figure 3A), and that there were a large number of probes that also gained methylation in the
Aza-treated cells. This was also evident when examining methylation at the promoters, in particular when volcano
plots were generated using the change in β (β) values (equivalent to difference in methylation vs UT) between
treatments (Figure 3B). For samples treated with siRNA, the promoters were seen to mostly lose methylation on the
whole (from β 0.00 to -0.4) with only some gaining methylation (from β 0.00 to +0.3). We noticed, however, that
with Aza there is nearly an equal spread of promoters that are both gaining and losing methylation when compared
with UT β-values (0.0). In addition to the differences in direction of methylation change the magnitude (y-axis)
also differed with siRNA more potent at inducing hypomethylation at the promoters than Aza (adj. p-values up to
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Figure 1. Schematic of experimental approach for comparative treatment of hTERT-1604 with 5-aza-2′deoxycytidine and DNMT1 siRNA,
and confirmation of effects. (A) The normosomic, nontransformed fibroblast cell line hTERT-1604 was treated over 3 days with
5-aza-2′deoxycytidine, or once on day 1 with SMARTpool siRNA targeting DNMT1 respectively, and untreated hTERT-1604 used as a
control. DNA was collected for analysis of methylation levels using Illumina 450k BeadChip methylation arrays. Output IDAT files were
analyzed in R using the RnBeads pipeline and in-house scripts. (B) Methylation at three indicator genes showed decreases after both
treatments compared with untreated cells as measured by pyrosequencing assay (left) and mRNA levels increased in reverse transcription
quantitative PCR assays consistent with derepression (right). Methylation is the average across all CpG assayed; error bars are standard
error of the mean; all differences were significant at p < 0.05 except DPEP3 mRNA levels for siRNA (C) Reverse transcription-PCR showing
effectiveness of siRNA targeting DNMT1. Scr, scrambled control siRNA; ACTB is a control gene; a 100 bp ladder was used (D)
Quantification of DNMT1 decrease using reverse transcription quantitative PCR: Scr, scrambled siRNA control. Difference was significant
by t-test (p < 0.01).
(B) Reproduced with permission from [21].
10-4 vs 10-2) (Figure 3B). We then wanted to explore if any of these probes experiencing hypomethylation were
enriched in any particular gene class.
A hypergeometric enrichment analysis was carried out in RnBeads and the top three enriched gene ontology
(GO) terms for both biological process and molecular function identified for promoters and genes experiencing
hypomethylation in each treatment (Figure 3C). The three enriched GO terms for promoters following siRNA
treatment showed considerable overlap, that is, detection/sensory perception of chemical stimulus. Many of the
targets in these categories are olfactory receptors, a large class of G protein-coupled receptors. When looking at
which gene bodies are enriched in probes losing methylation, related terms also surface (odorant binding, GDP
metabolic activity), but other terms are also identified including tyrosine phosphorylation of STAT protein and
cytokine receptor activity. Interestingly there was no overlap between the top enriched categories affected by the
Aza treatment among both promoters and genes. Instead two themes appeared evident – terms associated with
DNA replication and histone interactions.
To help visualize these changes in methylation across the genome, we created user-defined tracks viewable on the
UCSC genome browser with the use of the Galaxy interface. Figure 3D shows an example locus with significant
methylation changes between siRNA-treated cells andUT atTLR2, which belongs to the enriched group ‘Detection
of Chemical Stimulus’ and exhibits demethylation (minimum -11%) at multiple probes spanning the CpG islands
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Figure 2. 5-aza-2′deoxycytidine and DNMT1 siRNA both caused overall hypomethylation, with the latter proving more efficient. (A)
Principal component analysis presented in a scatter plot showing how the cells clustered by treatment. This principal component analysis
is exclusive of one anomalous Aza sample, and one siRNA sample. Variance for principle component one and two are as labeled on the x
and y axis, respectively. (B) Hierarchical clustering was performed using 10,000 most variable sites using Euclidean distance as a
dissimilarity metric. Blue represents high methylation values, white intermediate and red low values, showing how the methylation
patterns differ between treatments, with siRNA showing more low and intermediate values. (C) Hierarchical clustering was used to map
the 3000 most variable promoters, with Euclidean distance employed as above. Again siRNA appeared to more probes showing low and
intermediate methylation as indicated by the dense band of red respective to the siRNA samples, with more variability seen between the
two Aza samples. (D) Methylation value densities of each sample group across gene bodies, CpG islands and promoters were graphed to
demonstrate the different profiles of methylation change across the respective probes, with all the treated and untreated cell lines
graphed for comparison. The siRNA samples showed a distribution markedly shifted toward the left (less methylated), particularly for
gene bodies. The most noticeable change in Aza-treated samples was a decrease in numbers of highly methylated probes at CpG islands.
Aza: 5-aza-2′deoxycytidine.
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Figure 2. 5-aza-2′deoxycytidine and DNMT1 siRNA both caused overall hypomethylation, with the latter proving more efficient (cont.).
(A) Principal component analysis presented in a scatter plot showing how the cells clustered by treatment. This principal component
analysis is exclusive of one anomalous Aza sample, and one siRNA sample. Variance for principle component one and two are as labeled
on the x and y axis, respectively. (B) Hierarchical clustering was performed using 10,000 most variable sites using Euclidean distance as a
dissimilarity metric. Blue represents high methylation values, white intermediate and red low values, showing how the methylation
patterns differ between treatments, with siRNA showing more low and intermediate values. (C) Hierarchical clustering was used to map
the 3000 most variable promoters, with Euclidean distance employed as above. Again siRNA appeared to more probes showing low and
intermediate methylation as indicated by the dense band of red respective to the siRNA samples, with more variability seen between the
two Aza samples. (D) Methylation value densities of each sample group across gene bodies, CpG islands and promoters were graphed to
demonstrate the different profiles of methylation change across the respective probes, with all the treated and untreated cell lines
graphed for comparison. The siRNA samples showed a distribution markedly shifted toward the left (less methylated), particularly for
gene bodies. The most noticeable change in Aza-treated samples was a decrease in numbers of highly methylated probes at CpG islands.
Aza: 5-aza-2′deoxycytidine.
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Figure 3. Differential methylation analysis highlights distinct gene classes which are affected by each treatment.
(A) Scatterplots comparing treated with untreated at the site level, looking only at probes with FDR-adjusted p-value
<0.05. Samples treated with siRNA have more hypomethylated probes than Aza-treated samples. (B) Volcano plots
for promoter differential methylation comparing treatment with siRNA to that of Aza (using FDR-adjusted p-value). A
negative value for the difference between means (mean.diff) signifies a loss of methylation, for which siRNA-treated
samples have a greater population of probes compared with Aza. Aza-treated samples show a more nearly similar
spread of probes which have both negative and positive mean.diff. (C) Top gene ontology categories enriched for
hypomethylated probes using ‘combined rank among the 1000 best ranking regions’ for both promoters and gene
bodies for both treatments and color coded to show similar functional annotation. The gene classes’ enriched
intertreatment are distinct from each other, but within treatment groups show substantial commonality. (D) Map of
the TLR2 locus from the accession group ‘Detection of Chemical Stimulus’ enriched in demethylated probes following
siRNA treatment, showing the first exon and intron at bottom, and location of CpG islands (green). Above are shown
the locations of probes on the array and whether these gained (blue) or lost (red) methylation; a scale bar is shown at
left, with maximum and minimum methylation changes as labeled. The chromosomal location and span are shown at
top. (E) CHAF1B belongs to the accession group ‘DNA replication-dependent nucleosome assembly’ enriched in
demethylated probes following Aza treatment: legend as in D.
Aza: 5-aza-2′deoxycytidine; BP: Biological process; ExpCount: Expected count; MF: Molecular function.
located at the promoter. Aza-treated samples also experienced demethylation here (min -22%) but across fewer
probes in the region, and also showed probes gaining methylation here. CHAF1B is an example from the accession
group ‘DNA replication-dependent nucleosome assembly’ enriched in the Aza-treated cells (Figure 3E), which
showed the opposite pattern.
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Figure 3. Differential methylation analysis highlights distinct gene classes which are affected by each treatment (cont.). (A) Scatterplots
comparing treated with untreated at the site level, looking only at probes with FDR-adjusted p-value <0.05. Samples treated with siRNA
have more hypomethylated probes than Aza-treated samples. (B) Volcano plots for promoter differential methylation comparing
treatment with siRNA to that of Aza (using FDR-adjusted p-value). A negative value for the difference between means (mean.diff)
signifies a loss of methylation, for which siRNA-treated samples have a greater population of probes compared with Aza. Aza-treated
samples show a more nearly similar spread of probes which have both negative and positive mean.diff. (C) Top gene ontology categories
enriched for hypomethylated probes using ‘combined rank among the 1000 best ranking regions’ for both promoters and gene bodies
for both treatments and color coded to show similar functional annotation. The gene classes’ enriched intertreatment are distinct from
each other, but within treatment groups show substantial commonality. (D) Map of the TLR2 locus from the accession group ‘Detection of
Chemical Stimulus’ enriched in demethylated probes following siRNA treatment, showing the first exon and intron at bottom, and
location of CpG islands (green). Above are shown the locations of probes on the array and whether these gained (blue) or lost (red)
methylation; a scale bar is shown at left, with maximum and minimum methylation changes as labeled. The chromosomal location and
span are shown at top. (E) CHAF1B belongs to the accession group ‘DNA replication-dependent nucleosome assembly’ enriched in
demethylated probes following Aza treatment: legend as in D.
Aza: 5-aza-2′deoxycytidine; BP: Biological process; ExpCount: Expected count; MF: Molecular function.
A common set of genes coding for proteins involved in phosphorylation & acetylation are affected
by both treatments
To quantitatively address the numbers of probes losing and gaining methylation we looked at all of the probes
with either a positive or negative β per treatment (Figure 4A). Cells treated with DNMT1-targeting siRNA had
considerably more probes losing methylation than those treated with Aza, but there were more losses than gains
with each treatment, as expected. Notably, while some probes belonging to the siRNA-treated samples experienced
gains in methylation there were close to three-times as many probes gaining methylation in Aza-treated cells, which
was unexpected (Figure 4A).
Due to the comparable nature of both of the treatments with respect to hypomethylation we wanted to
examine if Aza treatment did demethylate the same targets as siRNA and so examined the overlap in genes (and
promoters) that were demethylated through each treatment. Differentially methylated regions were ranked in
RnBeads according to a combination of both statistical significance and effect size, where the latter was composed
of the absolute difference in DNA methylation (between UT and treatment) in addition to the relative ratio of
mean DNA methylation levels (β) between sample groups, that is, Aza and siRNA. There were 1173 overlapping
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Figure 4. Common targets experience demethylation in both treatments. (A) Column graph showing the number of
total probes that show an absolute loss and gain in (methylation) β scores overall for each treatment when compared
with the untreated hTERT-1604 cells. Probes belonging to the siRNA-treated samples predominantly show
demethylation, while there were a substantial number of probes in Aza-treated cells which showed gains in
methylation too. (B) The overlap between the 3000 top-ranked hypomethylated promoters between sample groups is
shown in a Venn diagram. Of this group, 1173 promoters were hypomethylated by both treatments, and an exactly
equal number of unique probes (1827) were seen for each treatment. (C) Analysis as for B but with genes (gene
bodies) showed 605 hypomethylated genes in common between the respective treatments, but greater numbers of
uniquely targeted genes. (D) DAVID was used to perform functional annotation for the 605 commonly
hypomethylated genes between siRNA and Aza treatments. Benjamini, p-value corrected by Benjamini–Hochberg
method. (E) Commonly hypomethylated genes from D, which also showed upregulation on the HT12 array (a fold
change of >1.0 on the HT12 and an adjusted p-value of < 0.01) were analyzed by DAVID, which further highlighted
phosphoprotein and acetylation terms. (F) Transcriptional fold change for the enriched ‘acetylation’ targets seen in
Figure 4E was calculated using data generated from the HT12 transcription array. Wilcoxon signed rank test indicated
a significant upregulation of these genes overall in the Aza samples when compared with untreated (p < 0.001). (G)
Functional annotation was also carried on the 605 commonly hypomethylated promoters seen in (B) using DAVID.
Acetylation appears to be the only enriched gene class that appears to show up as hypomethylated for both
promoters and gene bodies (D above).
Aza: 5-aza-2′deoxycytidine; DAVID: Database for Annotation, Visualization and Integrated Discovery.
hypomethylated promoters (Figure 4B) while there were only 605 common hypomethylated genes (Figure 4C). To
further investigate the enriched common genes (605) in particular, their IDs were extracted and added to the GO
pipeline in DAVID, which functionally categorized the enriched genes into classes such as phosphorylation, rRNA
binding and acetylation (Figure 4D). Very similar results were obtained when analyzing GO terms in PANTHER
(data not shown).
To explore if methylation changes at these enriched hypomethylated genes had any downstream transcriptional
effects, we assessed transcription using the HT12 array. With the strongest Benjamini score of 9E10–07, acetylation
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Figure 5. Promoters targeted by 5-aza-2′deoxycytidine but not DNMT1 siRNA. (A) DAVID was used to examine the 1827 uniquely
hypomethylated Aza promoters from Figure 4B, with results ranked according to Benjamini score. (B) The annotation of the uniquely
hypomethylated Aza promoters was further explored using PANTHER to determine functional categorization specifically for molecular
function where ‘binding’ and ‘catalytic activity’ were the most populated gene classes. (C) A boxplot was generated for the uniquely
hypomethylated Aza-treated promoters and gene bodies for the ‘nucleosome’ category highlighted in (B). Thirty-two histones were
identified as enriched under the ‘nucleosome’ accession and are significantly hypomethylated when compared with untreated
hTERT-1604. (D) A schematic of three of the enriched histones belonging to the nucleosome accession from UCSC with Aza β tracks
showing methylation loss (red probes) across the region, with the maximally demethylated probe at -13% occurring inside a CpG island
which spans parts of all three histones.
Aza: 5-aza-2′deoxycytidine.
was the first common enriched term to appear with nearly 70 genes hypomethylated and upregulated (Figure 4E).
The Wilcoxon signed rank test was performed on the transcriptional fold change of the genes treated with Aza that
fell under the acetylation category and these were also significantly upregulated compared with the UT (p < 0.001)
(Figure 4F).
Using the same approach, DAVID functional categorization was performed on the commonly affected 1173
promoters. While some similar enriched gene terms appeared, there were distinct categories enriched in this analysis
of common hypomethylated promoters such as alternative splicing/splice variant (Figure 4G). Overall we show
here that a relatively small number of common gene classes are affected by both treatments and many of these
showed transcriptional effects after being treated with Aza.
Aza uniquely targets histone genes through promoter hypomethylation
We decided to examine the 1827 hypomethylated promoters initially that are unique to Aza treatment (Figure 5A).
Through functional categorization of the uniquely hypomethylated promoters in DAVID, gene terms such as
nucleosome, phosphorylation and nucleosome core were significantly enriched (Figure 5B). Further exploration of
the same 1827 hypomethylated promoters in PANTHER for molecular function highlighted two key categories
affected, catalytic activity and binding (Figure 5C). Consistent with the functional annotation analysis, binding is
one of the main terms of enrichment that overlaps with phosphoprotein in Figure 5B. Using an analysis workflow
in Galaxy we could confirm that methylation levels of the gene targets belonging to the nucleosome family in
particular are significantly lower than that of the UT hTERTs (Figure 5D). A cluster containing three histone
genes, which belong to the nucleosome category, is shown in Figure 5E with the user defined track indicating β
against UT hTERT. HIST2HAC showed the maximum decrease in methylation of 12% at its promoter here, but
with consistent hypomethylation across this region (Figure 5E).
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Observed gains of methylation is a phenomenon almost exclusively caused by Aza
To investigate the gains in methylation in treated cells noted in Figure 4A we compared all the genes and promoters
which had a positive β for each treatment (Figure 6A & B, respectively) using Venn diagrams. These showed
that the majority of gains are observed as an effect of the Aza treatment at both genes and promoters, while only
a few are observed in the siRNA-treated cells. Enrichment analysis in RnBeads for Aza was able to assign some
functional categorization of the gains in both genes and promoters for biological process and molecular function
(Figure 6C) with overlap present at, for example, sensory perception of chemical stimulus and signaling receptor
activity. Throughmatching the 2471 genes that were uniquely hypermethylated upon Aza treatment to information
provided on the HT12 transcription array for the same clones, 26 genes were shown to also be downregulated
(Figure 6D & E). RnBeads generated a word cloud made up of the 100 best ranking probes that are gaining
methylation according to their molecular function (Figure 6F) showing that G-protein-coupled receptors (GPCRs)
are most affected, with many being olfactory receptors. One of the other GPCRs is DRD5, a dopamine receptor
that shows maximum gains of 24% when treated pharmacologically (Figure 6G).
Discussion
Epigenetic therapies are being taken up in the clinic, with the use of pharmacological DNMT inhibitors such as Aza
showing some success in the treatment of MDS and the deferment of subsequent progression to AML [33]. However
what genes are specifically affected by such epigenetic therapies remains unclear. In the present investigation, target
genes susceptible to a change in methylation levels after Aza treatment as compared with siRNA were identified.
We found that siRNA was more effective at causing loss of methylation; both treatments targeted genes coding
for proteins which become phosphorylated or acetylated, and the genes show transcriptional dysregulation in Aza
samples; Aza uniquely targeted histone genes for promoter hypomethylation; and gains of methylation were also
seen only in Aza-treated samples.
While both treatments caused overall hypomethylation in the treated cells in both gene bodies and promoters,
siRNA proved more efficient at demethylation within the transcription units. These results are in agreement with
those of others [34] who observed that pharmacological treatment with Aza caused hypomethylation in the gene
bodies of HCT116 cells and subsequently altered the expression of cancer-associated genes. Together this confirms
that a drop in methylation in the gene body could be a previously unrecognized but important therapeutic target
for DNMT inhibitors. An important role for gene body methylation in contributing to transcription levels has also
been indicated by a number of recent studies in other systems [20,35]. This type of methylation has an important
function in regulating alternative splicing [36] and this is particularly noteworthy in the context of MDS given the
latter’s abundance of spliceosome gene mutations [37].
The enriched hypomethylated ‘acetylation’ genes were significantly upregulated compared with the UT hTERT-
1604 cells. This suggests a negative correlation between methylation and expression levels in gene bodies. This novel
finding shows that pharmacological treatment with Aza also operates under a different system than traditionally
thought by causing transcriptional dysregulation. It has been reported that the methylation present in gene bodies
of some leukemic subtypes may have both a functional and clinical impact on disease progression [38] and this may
suggest further research is needed in this area.
Methylation at promoter regions is known to silence genes, and often aberrant hypermethylation at these regions
is associated with cancer and inappropriate gene silencing [9,39]. Here, however, we saw that Aza uniquely targeted
histone transcription units for promoter hypomethylation including some 32 histones including HIST1H2AJ,
HIST1H1E and HIST2H2AC, which all fell under the ‘acetylation’ accession. We observed that the histones were
hypomethylated by three separate approaches: using enrichment analysis in RnBeads, DAVID and PANTHER;
comparing methylation levels versus UT using Galaxy workflows and statistical analysis in SPSS; by manual
curation on UCSC with the use of user-defined interactive tracks against the human genome (hg38). Therefore,
it is concluded that Aza can specifically target histones. Interestingly histone deacetylase (HDAC) inhibitors, for
example, valproic acid [40] have been used clinically for some time and these can also revert closed chromatin to a
more open conformation and in doing so provide an additional mechanism for gene silencing. Some reports have
indicated an element of cross-talk betweenDNA and histone methylation to reduce gene expression, due potentially
to the recruitment ofHDACafter a 5-methylcytosine-binding protein has attached to the gene promoter [41].HDAC
inhibitors are now used clinically with DNMT1 inhibitors as a combination therapy. This form of combination
therapy has shown success with respect to the antineoplastic response in AML both clinically [42,43] and in the
laboratory [44].
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Figure 6. Observed gains of methylation is a phenomenon almost exclusively caused by 5-aza-2′deoxycytidine. (A) Common gains in
methylation across the probes annotated as in gene bodies (genes) are presented in a Venn diagram. Gains were taken to be anything
with a positive difference (not FDR corrected). Aza-treated samples experienced considerably more hypermethylation than the
siRNA-treated samples, with only 84 genes commonly hypermethylated between the two treatment groups. (B) As for (A) but
promoter-associated probes; 120 promoters were commonly gaining methylation between the treatment groups. (C) Enrichment table
from the RnBeads differential methylation output showing the top enriched hits for Aza (biological process/molecular function) for all of
the genes, and promoters that were identified as hypermethylated when compared with the UT. Enriched gene classes ‘sensory
perception of chemical stimulus’ and ‘signaling receptor activity’, however, were enriched at both probes associated with genes and
promoters, and contains many intron-less olfactory receptor genes. (D) Venn identifying the hypermethylated Aza probes (p-value < 0.05)
which are also downregulated on the HT12 transcription array (fold change <1.0 when compared with UT hTERT-1604). (E) For the 26
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Aza: 5-aza-2′deoxycytidine; UT: Untreated.
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The hypomethylation seen in the gene bodies here has been argued elsewhere to increase the accessibility of
chromatin [44]. The enrichment for hypomethylated histones with Aza treatment may partly explain known clinical
interactions [45] that take advantage of combining the DNMT inhibitors and HDAC inhibitors [46] in the treatment
of myeloid neoplasms. This form of dual combination treatment approach reduced DNMT activity to create a
net demethylation while the HDAC inhibitors are responsible for an overall gain in histone acetylation – this
synergistic approach maintains an active and open chromatin state to promote transcriptional activation of, for
example, TSGs. The absence of TSGs themselves in the enrichment analysis may reflect the absence of GO terms
specifically matched with TSGs, which have a range of different molecular functions and process involvement.
We could not rule out that perhaps the gains in methylation observed in the enriched GPCRs contribute to
the relapse in AML in sufferers as key TSGs could be silenced. GPCRs are known to act as oncogenes and tumor
suppressors through their regulation of oncogenic signaling networks (reviewed in [47]). To support this point
there have been several largescale genome-wide association studies (GWAS) in multiple human tumor samples that
have uncovered novel GPCRs altered in cancer [47]. GPCRs may be a suitable therapeutic target as personalized
medicine begins to diminish the clinical dependency on nonspecific pharmacological or chemotherapeutic agents.
In our study, we were able to identify GPCRs that were hypermethylated including MAS1 (on oncogene involved
in leukemia [48], USP33 and PARD3 – candidate and identified TSGs, respectively in lung cancer and in lung
squamous cell carcinoma [49,50].
Among the other targets experiencing demethylation, some hypomethylated promoters were unique to Aza
treatment and therefore potentially off-target with respect to the reduction in DNMT1 such as phosphoprotein,
histone-fold and nucleosome core. These demethylated targets, and the gains in methylation seen at other loci,
may be a result of effects of Aza on DNMT3A or DNMT3B, or through a more indirect mechanism such as the
reported effects of Aza on the histone modifier G9a [51].
Conclusion
In conclusion, our use of 450k to study the comparative effects of a pharmacological knockdown using Aza, and
DNMT1 targeting siRNA in the immortalized hTERT-1604 cell line has confirmed many observations from
previous literature with respect to demethylating effects. However, there was also a notable hypermethylating effect,
particularly at some GPCRs. Our results suggest Aza is also having an important effect on methylation unrelated
to the direct inhibition of DNMT1, thus suggesting further avenues for therapeutic improvements.
Summary points
• 5-aza-2’deoxyctidine (Aza) is a DNA methyltransferase (DNMT) inhibitor used to treat some cancers
• We know relatively little about targets and off-target effects, particularly in normal cells.
• Here we compared drug treatment to siRNA knockdown of the main methyltransferase DNMT1 in
non-transformed cells.
• Both caused hypomethylation, particularly at genes for proteins involved in phosphorylation and acetylation, but
siRNA was more efficient.
• There were distinct gene classes affected by each, histones being particularly affected by Aza.
• Gains of methylation were uniquely seen in Aza-treated cells, with G-protein coupled receptors common targets.
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Abstract
There have been a number of recent insights in the area of genomic imprinting, the phenomenon whereby one of two autosomal 
alleles is selected for expression based on the parent of origin. This is due in part to a proliferation of new techniques for interrogating 
the genome that are leading researchers working on organisms other than mouse and human, where imprinting has been most 
studied, to become interested in looking for potential imprinting effects. Here, we recap what is known about the importance of 
imprints for growth and body size, as well as the main types of locus control. Interestingly, work from a number of labs has now 
shown that maintenance of the imprint post implantation appears to be a more crucial step than previously appreciated. We ask 
whether imprints can be reprogrammed somatically, how many loci there are and how conserved imprinted regions are in other 
species. Finally, we survey some of the methods available for examining DNA methylation genome-wide and look to the future of this 
burgeoning field.
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Introduction
Genomic imprinting is a classic epigenetic phenomenon, 
and after X-inactivation, one of the best understood. In its 
simplest form, imprinting refers to genes showing mono-
allelic expression depending on their parent of origin 
(Bartolomei & Ferguson-Smith 2011, Barlow & Bartolomei 
2014). There is however considerable variation seen in 
where in the body and when the imprinted expression 
is seen. Imprints need to be set up when the alleles are 
separated during germ line development and then the 
imprints need to be interpreted by the transcriptional 
machinery in the target tissues. Recent work has advanced 
our understanding of (1) the processes behind establishment 
of imprints as well as (2) how the imprinting mark is 
maintained and interpreted. For the former, there is an 
excellent review by Kelsey (Hanna & Kelsey 2014). Here, 
we wish to focus on the latter process of maintenance, as 
well as ask what we have learned from species other than 
mouse, and touch on the technical difficulties, which arise 
when working in organisms other than mouse and human, 
where the most resources are available.
Importance of known imprints for body mass 
and feeding
Effects on growth and body size
One of the most enduring explanations for why 
imprinting may have arisen is the parental conflict 
hypothesis (Haig & Graham 1991, Moore & Haig 1991). 
Many imprinting phenomena involve effects on growth, 
nutrition or metabolic balance, and this theory was partly 
based on observations from uniparental conceptuses 
where the paternal contribution seemed particularly 
important for the embryo, while the maternal genome 
was important for placental development (Barton et al. 
1984). This turned out to be partly due to the paternal 
expression of the major growth factor insulin-like growth 
factor-2 (IGF2), and the maternal expression of an 
antagonistic binding partner insulin-like growth factor-2 
receptor (IGF2R), one of the first observations leading 
to the idea of parental conflict in imprinting. Several 
imprinted genes were also shown to be dysregulated 
in the placentas of these mouse conceptuses (Walsh 
et  al. 1994), including genes specifically imprinted 
only in placenta such as Mash2 (Guillemot et al. 1995). 
Indeed, the placenta is generally considered to have a 
higher number of imprinted genes than in other tissues 
(Court  et  al. 2014); though in the mouse and human, 
many of these are maternally expressed. An alternative 
to the parental conflict hypothesis, called coadaptation 
theory, also stresses the importance of interactions 
between offspring and parents for nutrient provision and 
acquisition (Keverne & Curley 2008).
Much of the support for these theories has been 
gleaned in mouse systems. Interestingly however, a 
single nucleotide substitution in a non-coding region of 
IGF2 underlies a major QTL in pigs that affects muscle 
growth, heart size and fat deposition (Jeon et al. 1999, 
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Van Laere et al. 2003). The mutation disrupts the binding 
of a recently evolved nuclear protein ZBED6 that appears 
to be acting as a repressor of IGF2 transcription, not only 
in pigs but potentially in all placental mammals, where 
it is highly conserved (Markljung et  al. 2009, Younis 
et al. 2018). A more general defect called large offspring 
syndrome (LOS) in livestock (namely sheep and cattle) 
also involves perturbed imprinted gene expression, 
thought to be due to preimplantation disturbances. LOS 
is associated with an increase in gestational length, 
50–80% increase in birth weight, hypoglycaemia and 
an enlarged tongue (Chen et al. 2013). The phenotypic 
characteristics of LOS are reminiscent of those exhibited 
by Beckwith–Wiedemann syndrome in humans, which 
can be driven by defects at the IGF2 imprint control 
region (ICR) or the nearby KvDMR (Weksberg  et  al. 
2010). Rivera and colleagues found however that LOS 
was not characterised by loss of imprinting at any 
one locus, but seemed instead to be accompanied by 
misregulation of multiple imprinted genes, with greater 
dysregulation seen in the largest offspring (Chen et al. 
2015). The requirement for delivery of large offspring by 
caesarean section, the frequent post-natal mortality, and 
other complications, mean that LOS restricts the full use 
of modern reproductive strategies in ruminants.
The callipyge muscle hypertrophy phenotype 
observed in sheep is also caused by a SNP, in this 
case located intergenically between known imprinted 
genes, the paternally expressed DLK1 and maternally 
expressed MEG3 long non-coding RNA (lncRNA) within 
the telomeric region of chromosome 18. This region 
is known to share a high degree of homology with 
other mammals including cattle and humans (Freking 
et al. 2002a,b). Callipyge syndrome can cause adverse 
changes to normal muscle development, body shape and 
even changes to meat quality (Freking et al. 2002a) and 
the composition of their carcass (Bidwell  et  al. 2014). 
Interestingly, the expression of this unique phenotype is 
the only distinctive example of polar overdominance in 
mammals (Freking et al. 2002a). Heterozygous callipyge 
sheep have a normal maternal allele while carrying the 
callipyge SNP on the paternal allele (Bidwell et al. 2014).
Neurological effects involving feeding and weight gain
Another general feature of imprinted genes is that 
many are transcribed primarily in the neurons and in 
some cases only show imprinted expression there. 
While initially this posed difficulties for the parental 
conflict hypothesis, which was originally proposed 
on the basis of imprinting affecting placentation and 
embryonic growth, with the discovery that some of 
the genes controlled feeding behaviour or weight gain 
later in life, these results could be reconciled with the 
hypothesis. Thus, Prader–Willi syndrome in humans 
(OMIM176270), where transcription of the neuronal 
genes at the SNRPN cluster are affected, involves 
excessive eating (hyperphagia), while the Peg3 gene 
in mouse is crucial for feeding behaviour (Curley et al. 
2005). Likewise, loss of expression of the Gnas and 
Gnasxl genes in mice can give hypo- and hyperphagia 
respectively, while a number of other imprinted genes 
also have effects on fat/body mass ratios (Peters 2014).
Furthermore, the aforementioned LOS or large calf 
syndrome can often cause a reluctance to suckle in 
young cattle. This may be due to the dysregulation of 
a number of imprinted genes reported in these animals 
(Zhang et al. 2004, Chen et al. 2015). However apart 
from these few studies, little work appears to have been 
done to date investigating imprinted genes and feeding 
behaviours outside of the mouse and human systems.
Imprinting disorders in hybrid species: the case of 
the hinny
A classic example of parent-of-origin effects in livestock 
is the horse–donkey cross: when the horse is the sire, 
the resultant offspring is a mule; if the donkey is the sire, 
then a hinny results, and these are quite distinguishable 
animals even though their genomic complements are 
the same. Initially, it was argued that this may be due to 
differences in uterine environment and the placental–
uterine exchange. Early investigation identified that 
serum concentrations of the placental hormone equine 
chorionic gonadotrophin were considerably higher in 
mule than in hinny pregnancies, suggestive of paternal 
genome-specific expression (Allen 1969). Recent use 
of RNA sequencing of trophoblast tissue from embryos 
derived from each reciprocal cross of horse and donkey 
(Wang et al. 2013) identified 15 ‘core’ imprinted genes 
that are conserved in equids, mouse and human, 
including genes such as SNRPN, H19 and PEG3. 
Interestingly, paternal expression seems favoured, as 
10/15 core imprints – and all of the larger group of 78 
genes identified in that study – showed paternal bias, 
but with many only imprinted in placenta. Additionally, 
some of the genes in the second, larger group showed 
incomplete or variable silencing. The authors speculate 
that this variability may reflect the flexibility of the 
structure and function of the placenta, which varies 
widely between mammals. Interestingly, XIST does not 
seem to be one of the imprinted genes, and X-inactivation 
in the placenta is random in both the horse parent and 
the hybrids (Wang et al. 2012).
Establishment of parental-specific methylation 
at imprints
It was recognised already from early studies that 
imprints would most likely be established in the germ 
line, where each allele of the diploid pair is separate 
and therefore can be separately marked. While studies 
on germ cell development were long hampered by the 
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difficulty of access to the early stages of development of 
this migratory cell population, and the small numbers 
of cells involved, recent advances in cell labelling and 
separation, coupled with the refinement of sequencing 
techniques and single-cell approaches (see below) have 
meant that we now have a much deeper understanding 
of the process of imprint establishment. This area has 
been dealt with very expertly by others in a recent 
review (Hanna & Kelsey 2014). We will concentrate 
here on insights gained in some studies published since 
then, confining ourselves first to a brief recap of the 
varied imprinting mechanisms.
The main types of imprinted loci and their structures
Current studies suggest that there are three main types 
of imprinted locus, controlled by different mechanisms. 
This has implications for where the imprint controllers 
are located and what they look like, as well as how the 
locus might respond to different perturbations.
Insulator
The archetype here is the cluster of genes around the 
H19 locus (Bartolomei & Ferguson-Smith 2011): these 
are controlled by an intergenically located ICR that 
is not a CpG island (CGI) (Bird 1987) but is relatively 
CG rich, making it sensitive to DNA methylation. The 
ICR contains several repeats of a sequence that binds 
the insulator protein CTCF. Methylation blocks CTCF 
binding on the paternal allele at the locus (Bell & 
Felsenfeld 2000, Hark  et  al. 2000), preventing H19 
transcription but facilitating expression of Igf2 and, in 
mouse, the Insulin 2 gene expressed in the yolk sac. The 
mark on the ICR that is set up in the germ cells is called 
a primary differentially methylated region (1° DMR) or 
gametic DMR (gDMR). Methylation that occurs post 
implantation, for example, on the H19 promoter after it 
has already been silenced, is known as a secondary (2°) 
DMR or somatic DMR (sDMR). There are a number of 
other imprinted loci with CTCF-binding sites, in some 
cases lacking CGI, where this protein is thought to play 
an important role (Prickett et al. 2013).
Long non-coding RNA promoter
Here the index locus is Igf2r that, unlike H19, is an 
orphan imprinted gene. The DMR at the Igf2r promoter 
was, against expectation, the secondary DMR, and 
the primary DMR and functional ICR were found to 
be located at an intragenic island. This turned out to 
control transcription of an antisense lncRNA, whose 
transcription blocked the sense transcript in cis 
(Sleutels  et  al. 2002). This type of arrangement is also 
seen at the Kcnq1, Grb10 and Dlk1 loci among others 
(Barlow & Bartolomei 2014) and as more lncRNA are 
uncovered, this is becoming the largest group.
Promoter
For some imprinted loci such as Snrpn, Plagl1 and 
Grb10, transcription appears to be directly regulated by 
methylation of the promoter. Here, a promoter CGI is 
methylated to block transcription rather than any indirect 
mechanism. Although there is no antisense transcript, 
the Snrpn promoter does drive the production of a long 
RNA called Snurf/Snrpn that extends far downstream and 
contains multiple small RNA species that are processed 
from it (Buiting 2010), so it could be argued that it falls 
into the lncRNA category. However, for other genes in 
this group such as Grb10, no associated lncRNA have 
so far been found.
Recent insights into imprint establishment
Seminal work from the Bestor lab (Ooi  et  al. 2007) 
showed that the methyltransferase cofactor DNMT3L, 
which is only required in germline, bound to CGI but 
was blocked by methylation of the fourth lysine on the 
histone 3 tail (H3K4me3), and further that imprinting was 
disrupted in the knockout (KO) mice. This link seemed 
strengthened by the finding that KDM1B, a histone 
demethylase, was required to establish DNA methylation 
at imprints (Ciccone et al. 2009). However, the idea that 
DNMT3L might be specific to imprints was weakened 
by studies charting the establishment of methylation in 
oocytes, which showed that not only did many thousands 
of non-imprinted CGI became hypermethylated during 
oocyte maturation in a DNMT3L-dependent fashion, 
but DNMT3L was also required for methylation of 
many other non-CGI sequences (Kato  et  al. 2007, 
Smallwood et al. 2011, Kobayashi et al. 2012), suggesting 
that DNMT3L was in fact more of a general cofactor 
for the de novo methyltransferases, required primarily 
in the germline. What appeared instead to distinguish 
imprinted loci from other genes was that they could 
maintain their DMR in the face of the two main waves 
of remodelling in the early embryo, namely active and 
passive demethylation in the first few cell divisions and 
then the widespread de novo methylation seen post 
implantation. While few imprints are established in the 
male germ line, indications are that here too it is the 
maintenance of these DMR in the face of remodelling 
that separates them from other loci (Wang et al. 2014).
In effect, this marks a real shift in thinking with 
regards to imprinting, moving the emphasis away from 
the mechanisms that might target regions to become 
imprinted and towards identifying factors that are 
responsible for maintaining methylation differences 
at specific loci in the face of extensive epigenomic 
remodelling. Since this is a crucial new insight, we 
wish to expand on these findings below and begin by 
looking in more detail at the protein factors that may be 
involved prior to implantation, and then look at events 
post implantation.
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Maintenance of imprints pre implantation
Methylation marks are applied in a sex-specific manner 
during gametogenesis at the gDMRs and several proteins 
play important roles at various stages in this process. In 
particular, Pgc7 (also referred to as Stella) is a critical 
component required in early maternal development 
and encodes a protein that has a SAP-like domain and 
a splicing factor-like domain (Aravind & Koonin 2000). 
It has an important role in protecting the methylation 
status of imprinted genes by limiting demethylation 
in early embryogenesis (Nakamura  et  al. 2007) and 
as such is crucial for normal development. PGC7 has 
been experimentally shown to be actively expressed 
in primordial germ cells (PGCs) in mouse from E7.25 
to E15.5 (Sato et al. 2002) but more importantly in the 
immature ovaries of the neonate females (Payer  et  al. 
2003). Through depletion of the protein in the oocytes, 
Payer et al. (2003) found there was a reduction in the 
number of blastocysts, successful implantations and a 
reduction in the number of viable offspring. Nakamura 
et  al. (2007) initially showed that PGC7 was required 
to maintain methylation on most imprinted loci in the 
preimplantation embryo, and later went on to show 
that PGC7 bound to H3K9me2 at both paternally 
and maternally marked loci protects against active 
demethylation by TET3, a finding confirmed by others 
(Nakamura et al. 2012, Szabó & Pfeifer 2012).
Another factor necessary for DNA methylation 
maintenance at ICRs in both mouse and human is 
ZFP57 (Kruppel-like zinc finger protein). Removal 
of the protein from the mouse zygote by use of both 
maternal and zygotic deletions caused embryonic death 
mid-gestation with a loss of all maternally methylated 
imprints (Li  et  al. 2008). In humans too, mutations in 
ZFP57 causes hypomethylation at multiple imprinted 
loci (Mackay  et  al. 2008). ZFP57 binds to a target 
hexanucleotide found at imprinted gDMRs, but only 
when methylated, and recruits DNMT1 and its cofactor 
UHRF1 to maintain methylation on the marked alleles 
(Quenneville et al. 2011). Additionally, through KAP1, it 
recruits SETDB1 that modifies the chromatin by adding 
H3K9me3. Indeed, loss of KAP1 also causes a failure 
to maintain imprints in the preimplantation embryo 
(Messerschmidt et  al. 2012). Following this protective 
step in early development, DNA methylation is thought 
to be maintained along with this chromatin mark 
throughout the offspring’s life at the respective ICRs 
(Proudhon et al. 2012).
Post-implantation changes at transient and 
stable imprints
The small number of known imprinted loci 
characteristically show (1) methylation differences 
between gametes (gDMRs), (2) dependence on 
DNMT3L (Kato et al. 2007) and (3) an ability to maintain 
differential methylation during preimplantation 
development (Hanna & Kelsey 2014). However, the 
genome-wide studies of the methylation landscape in 
germ cells mentioned earlier found that a relatively large 
number of loci (>1000) were methylated in a DNMT3L-
dependent fashion in oocytes, but not sperm, and that 
many of them maintained high levels of methylation 
on the maternal allele until at least the blastocyst stage 
(Borgel et al. 2010, Smallwood et al. 2011, Shirane et al. 
2013). Initial work by Michael Weber and colleagues 
(Borgel et al. 2010), suggested that not only imprinted 
loci, but also genes that were specifically expressed 
in the germline showed these features. Work from 
our own lab confirmed this (Rutledge et al. 2014) and 
further uncovered a class of genes expressed in brain 
showing these characteristics, suggesting three classes of 
genes with DNMT3L-programmed gDMRs: imprinted, 
germline and brain-specific genes (Fig.  1A). However, 
in stark contrast to the canonical imprinted loci, most 
of the brain and germline genes examined lost their 
differential methylation in adult tissues tested due to 
gains in methylation on the paternal, unmethylated 
allele. However, it was possible that among these latter 
two classes there were some true imprinted genes, 
which would show allele-specific expression in a tissue- 
or stage-specific fashion.
To identify such genes, Ferguson-Smith and colleagues 
used ZFP57 binding as an extra criterion in addition to 
the three indicated above (Strogantsev et al. 2015). Using 
this approach, they could confirm recently identified 
imprints such as Cdh15 and Gpr1, and also uncovered 
evidence for imprinting at the Fkbp6 gene. Fkbp6 
showed methylation in oocytes but not sperm in their 
study (Strogantsev et al. 2015), and maternal methylation 
was maintained in placenta at e16.5. In keeping with 
this, there was also predominant expression from the 
paternal allele as assayed using a transcribed SNP in 
interspecific mouse crosses, and this allele also carried 
H3K4me3 marks. Notably, in brain, both transcription 
and H3K4me3 continued to be associated with the 
paternal allele, even though the DNA methylation 
was assayed at 80%, rather than the expected 50%. 
This suggests that (1) either a subset of cells in brain 
continues to maintain the DNA methylation difference 
(in keeping with the low levels of transcription in this 
tissue); (2) some of the methylation being assayed may in 
fact be 5-hydroxymethylation (5hmC- see below), which 
is more prominent in brain and may cloud the picture, or 
most intriguingly (3) the DNA methylation difference is 
not as important as the histone marks. In addition to this 
complexity, Fkbp6 may show differences in imprinting 
due to genetic variation, since sperm methylation varies 
between mouse strains (Rutledge et al. 2014), and there 
have been reports of polymorphic imprinting in humans 
(Hanna et al. 2016). ZFP57 is also capable of mediating 
such strain-specific effects (Strogantsev et al. 2015).
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Using one of the other three criteria above, namely 
dependence on DNMT3L, the Bourc’his lab also 
identified novel imprinted gDMRs including Cdh15, 
AK008011, Zfp777 and Zfp787 (Proudhon et al. 2012). 
The Cdh15 gDMR was found to control transcription of 
an allele-specific RNA in the hypothalamus, but there 
was no evidence for imprinted expression at the other 
three loci. All four gDMRs again lost their parental 
mark through gains in methylation in most adult tissues, 
highlighting the crucial role of protection from de novo 
methylation for imprint stability. They proposed that such 
genes, which would include Fkbp6, Cdh15, Gpr1 and 
others, should be referred to as transient imprints. The 
subtlety of regulation of these loci led to the question 
of how functionally important this was. In a subsequent 
paper, they showed however that for the Gpr1 locus, 
DNA methylation did indeed play an important role in 
fine-tuning transcription levels (Duffie  et  al. 2014). At 
this locus, interestingly, the histone marks seem to play 
a secondary role.
In contrast to these transient imprints, the canonical 
imprinted loci maintain methylation differences at the 
gDMR even in tissues that do not express the associated 
gene (Woodfine et  al. 2011, Court et  al. 2014, Wang 
et al. 2014), highlighting the existence of mechanisms 
to (1) prevent demethylation of the methylated (usually 
maternal) allele and (2) protect the unmethylated 
(usually paternal) allele from gaining methylation. 
Studies comparing the sizes of DMR concluded that 
a certain degree of shrinkage occurs from the gametic 
state as the embryo matures (Court  et  al. 2014) but 
that the boundaries do not markedly shift upstream or 
downstream, consistent with a mechanism centred on 
the sequence determinants in the gDMRs.
Possible role of other cytosine modifications at 
imprinted loci
The dynamic changes in DNA methylation seen during 
early development are now known to be driven both 
by passive dilution through replication in the absence 
of maintenance activity, as well as active demethylation 
via the action of the three ten-eleven translocation (Tet) 
enzymes (Guo et al. 2014, Wang et al. 2014). The Tets 
have been shown to catalyse the oxidation of normal 
5-methylcytosine (5mC), first to 5-hydroxymethylation 
(5hmC), then to 5-formlycystosine (5fC) and 
5-carboxycytosine (5caC), at which stage the modified 
nucleotide is excised from DNA by the base excision 
repair enzyme thymidine DNA glycosylase (TDG) or 
possibly removed through an as-yet uncharacterised 
Figure 1 Some experimentally observed dependencies for imprint and imprint-like genes in mouse. Three classes of genes have gametic 
Differentially Methylated Regions (gDMR): testis, brain and imprinted genes (see key at bottom right: filled bar, 100% methylation). Genes that 
acquire methylation post implantation (somatic or sDMR) are also represented. (A) Germline: All three classes of gDMRs lose methylation in 
oocytes lacking DNMT3L. (B) Blastocyst/ESC: The gDMRs retain their methylation aided by DNMT1 and by DNMT3A/B, with other possible 
contributors indicated. Loss of methylation on imprints in Dnmt1 knockout (1KO) cells cannot be rescued with Dnmt1 cDNA (1Ko+1). In 
contrast, imprints in Dnmt3a/b KO (3abKO) can recover following rescue with Dnmt3a2 (3abKO+a2). (C) Adult: Unlike true imprints, the testis 
and brain gDMRs cannot maintain the unmethylated allele in the face of the wave of de novo methylation after implantation. Likewise, they are 
more sensitive to inhibitors such as 5′-aza-2′deoxycytidine (Aza).
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decarboxylase activity (reviewed in Hahn et al. 2014). 
Active demethylation explains the rapid loss of 5mC 
in the pronuclei of the fertilised egg in the absence of 
replication, particularly notable for the male pronucleus, 
and lies behind much of the swift demethylation seen at 
some other time points such as germ cell specification 
and preimplantation development (reviewed in Hill et al. 
2014). Blocking the action of the Tets thus prevents 
the demethylation at ICR in the germ cells required to 
reset the imprints, and it is only through the protective 
action of PGC7 (Nakamura et al. 2012, Szabó & Pfeifer 
2012) that imprints can be maintained pre implantation 
when Tet activity drives rapid demethylation at other 
methylated regions (Guo et al. 2014, Wang et al. 2014).
In addition to being an intermediate in the active 
demethylation pathway, however, there is some 
evidence that 5hmC may also act as a stable epigenetic 
mark in itself (Hahn et al. 2014). Support for this derives 
from the observations that 5hmC levels in brain are 
too high to be consistent with being an intermediate in 
active demethylation in the non-replicating neurons and 
that proteins with high affinities for 5hmC, which may 
represent specific readers of this modification, appear 
to exist (Iurlaro  et  al. 2013, Spruijt  et  al. 2013). Thus, 
5hmC is frequently detected at high levels in neural 
tissues in the absence of 5fC and 5caC and may play an 
instructive role. Since it cannot be distinguished from 
5mC by standard bisulfite modification and sequencing, 
it may contribute a substantial proportion of the DNA 
methylation reported at some loci. Examination of 
imprinted genes using methods that detect 5hmC have 
indicated however that the majority of methylation seen 
at ICR is indeed 5mC in adult tissues, though 5hmC is 
relatively enriched at imprinted loci compared to the 
levels elsewhere in the genome (Hernandez Mora et al. 
2005). The 5hmC was present on the same allele as 
the 5mC, suggesting to the authors that it might be a 
stable mark here and not a sign of active demethylation. 
However, it is possible that this might reflect a dynamic 
turnover of methyl groups here, since Zhang and 
colleagues recently showed that G9a/GLP was required 
to recruit de novo methyltransferases to counteract TET 
activity at imprinted ICR (Zhang et al. 2016). However, 
levels of oxidised methyl cytosine products at ICR were 
not measured directly in the latter experiments. Much 
of the 5hmC that was detected by Hernandez Mora 
and colleagues was in transcribed regions of imprinted 
genes, not ICR, in keeping with an earlier report for H19 
(Nestor  et  al. 2012). Intriguingly, an association has 
been reported between 5hmC levels in H19 and small-
for-gestational-age babies (Piyasena et al. 2015).
Thus, while there is good evidence for high levels 
of 5hmC and other modified cytosines being seen at 
imprints during reprogramming, levels appear to be 
much lower in adult tissues except brain, and may be 
more related to transcription in the latter, since found in 
the gene bodies.
Can somatic reprogramming of imprints occur?
One of the key features of imprinted regions is their 
programming in the germ line, when the parental alleles 
are separated. Early work showed that in Dnmt1−/− ES
cells (1KO – Fig. 1B), imprints lost DNA methylation and 
could not recover it even when DNMT1 was restored 
using a cDNA (1KO + 1), unlike the rest of the genome. 
However, when the rescued ES cells were used to make 
mice, the imprints were restored following passage 
through the germline (Tucker et al. 1996). This is thought 
to be due to the imperviousness of imprints to the 
normal reprogramming events seen in the soma. Indeed, 
the inability to reprogram in somatic tissues is a key 
difference between the imprinted gDMRs and the other 
two classes of gDMR, namely those found in germline 
and brain genes (Borgel et al. 2010, Rutledge et al. 2014), 
whose methylation can be restored in 1KO + 1 cells 
(Fig.  1B). We and others have confirmed these results 
both in ES cells (Chen et al. 2003, Thakur et al. 2016) 
and in adult cell lines (Chen et al. 2003, Wernig et al. 
2007) (Fig. 1B and C). Interestingly, imprints appear to 
be resistant to demethylation as well as remethylation: 
treatment of cells with 5′Aza-2′deoxytidine (Aza) results
in robust demethylation of most targets, but not imprints 
(O’Neill et al. 2018).
However, recently two ES cell systems have been 
described in which imprints can apparently be restored, 
breaking one of the main rules of imprinting. Wong 
and colleagues, working with UHRF1-deficient ES cells 
(Qi et al. 2015), found that most imprinted gDMRs lost 
methylation, as expected, since UHRF1 appears to be a 
vital cofactor for DNMT1 in somatic cells (Bostick et al. 
2007, Sharif  et  al. 2007). Surprisingly however, they 
found that when they rescued these cells using a UHRF1 
cDNA that not only was methylation restored on bulk 
DNA, but also is a subset of the imprinted loci showed 
recovery. In particular, the H19, Nnat and Dlk1 gDMRs 
showed some recovery of methylation, though not to 
WT levels, and ZFP57 binding was restored at 2/3 loci 
(Qi et al. 2015). While it would be reasonable to assume 
that an underlying chromatin mark might be retained, 
allowing restoration of methylation, there was no clear 
correlation between recovery and chromatin marks at 
the loci (Qi et al. 2015).
Using a different ES cell system, we too found 
somatic recovery of imprints could occur under some 
conditions. In cells lacking DNMT3A and DNMT3B 
(3abKO), imprinted gDMRs lost their parental allele-
specific methylation to almost the same extent as in 
DNMT1-deficient cells. However, in contrast to rescue 
experiments in 1KO cells, when DNMT3A2 was added 
back to the 3abKO cells, we found that DNA methylation 
was restored at most gDMRs examined (11/14), with 
many achieving levels similar to the WT cells (Fig. 1B). 
Results were confirmed using up to three different 
techniques (Thakur et al. 2016).
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Taken together, these two sets of results independently 
confirm that in some ES cell types, methylation can be 
restored on imprinted gDMRs outside of the germline 
opening the way for further exploration of the factors 
and signals that may be involved.
Implications for reproductive biology
How many imprinted loci are there?
In the index species mouse, where most data are 
available and there have been some dedicated 
searches, the number of verified imprinted loci remains 
relatively steady at around 150. Despite a few high-
profile studies suggesting more may exist, the number 
of genes with confirmed uniparental expression has 
not increased greatly. Many of the known imprinted 
genes in mouse (http://www.mousebook.org/imprinting-
gene-list (accessed 24/1/2018)) are also imprinted in 
human (http://igc.otago.ac.nz/1601summarytable.pdf 
(accessed 24/1/2018)). A recent study by Wang et  al. 
(2014) identified a small number of new germline DMR, 
for which uniparental methylation has been verified by 
ourselves or others (Thakur et al. 2016), but the effects on 
transcription are yet to be confirmed. Likewise a study 
in human by Court et al. (2014) using a combination of 
arrays and whole-genome bisulfite sequencing (WGBS 
– see below) added some new DMR. These were largely
confined to known imprinted loci, although some were
novel placenta-specific DMR. One caveat with the latter
is that the differential methylation appears to have been
established postnatally, which would require a radical
rethink of mechanisms. However, some evidence exists
to suggest that this may also occur in mouse (Wagschal
& Feil 2006).
In addition to the ‘true’ imprints, there are a number 
of ‘transient’ imprinted genes that show widespread 
imprinting in the early embryo that later becomes 
confined to one tissue (see ‘Post-implantation changes’ 
section above). This larger group of neuronal and 
germline genes have gDMRs in the early embryo that 
become erased post-implantation, largely through the 
de novo methylation of the unmethylated paternal allele 
(Borgel et al. 2010, Proudhon et al. 2012, Rutledge et al. 
2014). These loci have not all been tested for uniparental 
expression in early development, but may contribute to 
parent-of-origin effects in early embryogenesis.
How conserved are imprints in other species?
Initial reports of imprinting in mouse were quickly 
followed by the investigation of corresponding human 
loci, and the subsequent discovery that at least one 
of the index loci IGF2R was not imprinted in all 
humans, but may instead show polymorphic imprinting 
(Xu  et  al. 1993). As the number of well-characterised 
imprinted loci in mouse grew, the general trend was for 
the homologous locus in human to be imprinted, but 
with a number of notable exceptions (Hanna & Kelsey 
2014, Peters 2014). In general, though, the emerging 
complexity of imprint locus control has tended to 
discourage attempts to verify in detail in the second 
species, with an assumption of similarity being adopted 
on the whole unless forced to be re-evaluated due to 
clinical or experimental evidence.
Some early studies also tried to map the index 
imprinted loci in marsupials in order to test parental 
conflict theories as well as to investigate evolutionary 
mechanisms. This met with some success, despite 
the difficulty of the exercise. There is now support 
for an origin for imprinting at the time of divergence 
of marsupials (metatheria) and egg-laying mammals 
(montremes), which lack imprinting (Renfree  et  al. 
2013). The oldest imprinted loci with a conserved 
DMR are H19 and PEG10, though a number of other 
imprinted genes such as IGF2R and PEG1 are also 
imprinted, but lack a conserved DMR. Many other 
loci appear to have acquired imprinting in eutheria 
(Renfree  et  al. 2013). PEG10 is a retroposon-derived 
gene, and it has long been suggested that there 
is a link between methylation at newly acquired 
retrotransposons and imprinting (Yoder et al. 1997). It 
is interesting in this context that rodentia are notable 
for having the highest number of imprinted loci and 
also a unique methyltransferase locus Dnmt3c, initially 
thought to be a pseudogene based on an early draft 
of the rat genome (Lees-Murdock et al. 2004) but now 
shown to produce a functional enzyme confined to 
the male rodent germline that appears dedicated to 
retroposon methylation (Barau et al. 2016).
ART and imprints
In livestock species, there has also been a lively interest 
in imprinted loci (O’Doherty et al. 2012), partly due to 
the widespread use of artificial reproduction techniques 
(ART), which are thought to be particularly associated 
with perturbed methylation and development including 
syndromes such as the aforementioned LOS (see 
above), enlarged placenta and perinatal death. These 
have been tied to changes in methylation at imprinted 
loci in a number of studies in cattle (O’Doherty et al. 
2012, 2014). While studies in mouse have found 
substantial support for ART-induced alterations in 
imprints (Rivera et al. 2008, Denomme & Mann 2012), 
in humans, any link between methylation changes at 
imprinted loci and standard IVF has been controversial, 
with most reviews of the area not able to fully 
exclude an effect on imprints or other epigenetically 
regulated loci (Grafodatskaya  et  al. 2013). However, 
the addition of large enough concentrations of 
inhibitors such as aphidicolin have conclusively been 
shown to alter the programmed demethylation of the 
genome (Guo  et al. 2014) at the pronuclear stage, so 
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environmental perturbations of imprinting remain at 
least theoretically plausible.
Use of sequencing technologies to investigate 
known and potential imprinted regions
There have been a number of approaches taken to 
identify potentially imprinted genes and to more closely 
define the size of the imprint, partly dictated by the tools 
and approaches available in the differing species. In 
humans for example, microarrays have made assessing 
methylation easier, but low heterozygosity levels and 
incomplete data make assignment of parental allele and 
gametic imprints – even with resequencing approaches – 
problematic, whereas in mice, no methylation arrays are 
available but interspecific crosses can be generated to 
maximise heterozygosity. Ruminants on the other hand 
have a long reproductive cycle and inter-strain hybrids 
are not commonly used, and with some exceptions, there 
are no arrays here either. For these reasons, resequencing 
approaches offer the most widely applicable tool 
(Table 1). While sequencing can be restrictive in cost, it 
represents a powerful discovery platform.
Wang and colleagues for example used WGBS to 
investigate the methylation status of the 54 imprinted 
DMR in the mouse genome (Wang et  al. 2014), and 
in particular to sort unclassified DMR into gametic or 
somatic categories. They compared oocyte, sperm and 
early embryo, and began by confirming they could 
correctly sort all the DMR whose status was known (29) 
into gametic vs somatic types. They then used the same 
criteria to classify 25 imprinted DMRs whose status 
was unknown into gametic or somatic DMR, which 
is essential for determining where primary control of 
each locus is being exerted. At least four of these newly 
classified DMRs could subsequently be independently 
confirmed using a pyrosequencing-based assay 
(Thakur et al. 2016).
In humans, microarray technologies and in particular 
the Illumina EPIC array, have become so reliable in 
terms of assessing methylation levels quantitatively 
that confirmation by a second technology has become 
almost redundant. The low relative cost of the array 
makes it an attractive approach for initial screening and 
a comparison of uniparental disomies could correctly 
identify all 30 DMRs for which the array had probes (one 
DMR at MEG3/DLK1 is not covered). They additionally 
identified 21 novel putative imprints, 15 specific to 
placenta, albeit a number of them were at known 
imprinted loci already (Court  et  al. 2014). However, 
the low relative resolution of the array meant that they 
needed to use WGBS to accurately delineate the DMR.
Reliable standardised methylation microarrays are 
largely confined to humans, though the success of 
the 450K and EPIC platforms has meant that Illumina 
appears to be considering a similar BeadChip array 
for mouse. An exception is cattle, where the EDMA 
array has been developed for assessing genome-wide 
methylation (Shojaei Saadi et  al 2014), though this is 
based on cutting with methylation-sensitive restriction 
enzymes rather than oligos. While the array gives good 
internal consistency and technical reproducibility and 
could correctly identify methylation status at a number 
of imprinted regions in this species, it gives relative rather 
than absolute levels of methylation and is therefore 
difficult to correlate with outputs from many other 
assays (Desmet et al. 2016), though not all (Ispada et al. 
2018). Whole-genome sequencing represents the gold 
standard for exploratory work and can definitively assess 
methylation across all sites. Confirming parental origin 
of the methylation mark requires heterozygous SNPs 
Figure 2 Schematic comparison of reduced representation bisulfite 
sequencing (RRBS) vs post-bisulfite adaptor tagging (PBAT). In RRBS 
(left), the DNA is initially fragmented by a methylation-insensitive 
restriction endonuclease such as MspI to an optimal fragment size of 
between 400 and 600 bp, and this fraction isolated following gel 
electrophoresis or similar. Adaptors are ligated to these DNA 
fragments that are subsequently treated through bisulfite conversion 
to convert unmethylated cytosines to thymines for the differential 
readout. Amplification is carried out using primers specific to the 
adaptor sequences, but there is substantial loss of sample at this point 
due to strand breakage (flashes) between adaptors caused by bisulfite. 
PBAT (right) skips the initial enzyme digestion and instead takes 
advantage of the bisulfite-induced breakage to fragment the DNA 
here. Instead of PCR, the adaptors are used for two rounds of random 
primer extension, which serves to produce numerous reads from a 
small amount of input genomic DNA.
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however. While Liu and colleagues could find sufficient 
variation in an inter-strain cross for mice (Wang et  al. 
2014), generating cross-bred cattle is not trivial given 
cost implications and slow reproductive times and most 
reported work in the area does not feature such animals.
An alternative, more widely applicable and cost-
effective approach for assessing methylation is to 
subset the genome and do targeted resequencing. 
Reduced representation bisulfite sequencing has been 
the most extensively used method in this category so 
far (Meissner  et  al. 2005), but is being superseded by 
post-bisulfite adaptor tagging (PBAT) (Miura  et  al. 
2012), which appears to offer improvements in yield 
and efficiency, particularly when starting with small 
amounts of material such as oocytes (Smallwood et al. 
2014) (Fig.  2). Apart from cost considerations, a 
significant bottleneck for resequencing-based analyses 
is the extensive bioinformatic analysis required, with 
concomitant need for higher-specification computing 
hardware, local network clusters and data warehousing, 
all adding substantial capital and human resource costs 
to the equation (Lewitter  et  al. 2009). While this has 
resulted in the majority of such work being undertaken at 
large central institutes that have developed the required 
infrastructure, often with national support, there remains 
a niche for smaller players out-sourcing the sequencing 
to larger centres with surplus capacity and who may in 
future also be able to avail of cloud-based storage and 
analysis capabilities (Liu et al. 2014).
Another point to consider here is that some species that 
may be of interest for biologists wishing to understand 
the origins or phylogenetic reach of imprinting may not 
be sequenced yet. In cases where a reference genome 
framework is unavailable, assembling sequence reads 
and defining variation become considerably more 
challenging (Cahais et al. 2012).
Finally, the impact of third-generation sequencing 
technologies is yet to be fully felt, given that this market 
is currently in flux and no clear front-runner appears 
yet to have emerged. Current technologies require a 
separate sequence library for each type of cytosine 
modification for example (meC, 5hmC, 5fC, 5caC) 
(Yu et al. 2012), whereas certain new approaches (Table 1) 
such as PacBio’s technology have the capability to also 
call methylated bases while sequencing, obviating the 
need for multiple sequence sets (Lister & Ecker 2009).
Conclusions and future prospects
Imprinting clearly plays an important role in body size 
determination and nutrient transfer to the young, making 
assessment of methylation at key loci a useful tool for 
reproductive biologists and breeders alike. Despite 
the improvement in technologies for assessing and 
delineating imprinting, the number of verified imprinted 
loci has not increased very significantly. However, our 
understanding of the mechanisms by which these regions 
are established and maintained in early life, as well as 
the contexts in which some plasticity in imprinting may 
occur, have greatly increased. We can look forward to 
further insights from comparative genomic approaches 
based on the increasing application of sequencing 
technologies to an ever-expanding range of organisms, 
including the so far rather surprisingly neglected 
livestock species, which play such an important role in 
human food production and welfare.
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General Discussion 
DNA methylation involves the transfer of a methyl group from 5-adenosylmethionine to 
5’carbon of a cytosine residue, converting it to 5- methylcytosine (Gibney and Nolan, 2010) 
and it is essential for differentiation and normal mammalian development, due to its effects on 
long term stable gene repression (Cedar & Bergman, 2009). The work presented in this thesis, 
focuses on the effects of loss of key DNA methyltransferases in human model and mouse model 
systems to identify and validate genes classes sensitive to a transient and stable loss of 
methylation in an attempt to shed some light on their reprogramming capabilities and point 
towards the mechanisms, which allow this to happen.  
Identification of enriched human gene classes that are particulary sensitive to a stable 
loss of maintenance methylation and those responsive to s transient loss of methylation 
A chronic depletion of DNMT1 in the hTERT cell lines caused by either pharmacological 
treatment with Aza, transiently with siRNA or through a stable knockdown with shRNA caused 
hypomethylation at defined enriched gene classes, and interestingly not all at the same gene 
classes. The pharmacological DNMT1 inhibitor Aza in the fibroblast cell line was shown to 
cause hypomethylation of the histone genes, and genes encoding proteins, which become 
phosphorylated or acetylated (Paper III), whilst siRNA treatment resulted in hypomethylation 
of gene classes involved in the sensory perception of smell, metabolic processes and 
phosphorylation (Paper III). Interestingly, long-term KD by shRNA instead led to cell lines 
with hypomethylation concentrated atthe PCDH locus, fat/body mass genes, the CTA, and the 
Olfactory genes (Paper II). These enriched hypomethylated gene classes are described further 
below;  
PCDH 
The enriched PCDH locus (A & B) identified in Paper II for example is heterochromatic by 
nature and exhibited a persistent loss of methylation. We identified this region to be polycomb 
repressed in fibroblasts, where a transcriptionally repressive state has been established through 
interactions with H3K27me3 (van Kruijsbergen et al., 2015). A number of genome-wide 
studies in mouse ESCs established that polycomb marking and DNA methylation appeared in 
large part to cover different areas of the genome, such that genes were either marked by 
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H3K27me3 or by DNA methylation, and not usually by both, suggesting that the two systems 
of repression were mutually exclusive (Otani et al., 2013).  
There are 70 members of the PCDH family currently identified, and segregated into two broad 
groups- clustered, and non-clustered. PCDHα, -β and -γ are clustered sequentially on Chr 5q31 
in human (Hulpiau and van Roy, 2011) as shown in Figure 1. PCDH forms a gene cluster 
similar to that of the immunoglobulins and T-cell receptors. PCDH genes are highly expressed 
during neural development, as such as the brain matures the expression level of PCDH falls 
(Hulpiau and van Roy, 2011). Their role is of a transmembrane protein involved in calcium ion 
binding, synaptic formation, axonal projection and neuronal survival.  These three clusters have 
large variable (V) exons, each of which encodes an extracellular domain, as well as a 
transmembrane domain and a short cytoplasmic region. Both  and  cluster variable exons are 
spliced to a set of constant (C) exons (red shading below) which encode cluster-specific 
additional intracytoplasmic domains (ICD). The PCDHγ cluster genes however do not share 
this property with the α and β clusters, and so lack the additional ICD. Somewhat confusingly, 
there are also C-type variable exons, which have a slightly different function than the standard 
variable exons (yellow shading below). Functionally the PCDHs are involved in neural circuit 
formation and have been found to be expressed in the neurons and glia as cell-cell adhesion 
proteins (Takeichi, 2007).  
Figure 1- Schematic of the clustered PCDH family. The protocadherin locus has three different 
clusters of possible variable exons adjacent to each other. The two PCDHα and PCDHγ clusters have 
three constant exons, responsible for encoding a cluster specific intracellular domain which is combined 
through mRNA splicing of the two clusters (Image reused from Rubinstein et al., 2015). 
Interest in protocadherin structure and function has grown greatly during recent years, as it has 
emerged that they play a key role in specifying neural cell shape and identity. Knockout studies 
conducted in the laboratories of Tom Maniatis and Takeshi Yagi have shown that mice lacking 
the protocadherins either die in utero (C-class variable exon deletion) or survive to birth but 
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have severe neurological problems including gait and memory (Chen et al., 2012). The 
presence of a different “bar-code” of PCDH proteins on adjacent neural cells allows the 
neurites to distinguish self-self from self - non-self-contacts and so form functional interactions 
with its neighbours to build the neural net (Rubinstein et al., 2015).Only 1-3 PCDH promoters 
in any cluster are being expressed, while the other 65+ are inactive. Crucially with respect to 
our studies, the inactive promoters are methylated, and Yagi and others have shown that 
demethylation using Aza or cells with mutations in the methyltransferase genes can cause re-
activation of the silenced alleles (Morishita and Yagi, 2007). 
The shRNA treated cell lines showed significant DNA hypomethylation across the extended 
locus, in particular at the upstream variable exons with little difference seen in the constant 
region. Maintaining greater diversity of specific mRNAs and PCDH proteins would require 
repression of all other non-transcribing PCDHs than those being actively expressed, as such 
this is an important event in early mammalian development. The Pcdh-γ proteins have been 
found to be expressed embryonically, (mice null for Pcdh-γ die neonatally (Wang et al., 2002)) 
when neural development is very active.Pcdh-γ proteins have also been found to be expressed 
postnatally in the viable embryo until the brain has matured (Frank et al., 2005). 
Repression of Pcdh genes can be caused epigenetically through silencing by DNA methylation. 
This was shown in two mouse cells lines, where Kawaguchi et al (2008) observed that 
methylation of Pcdh-α promoters and the 5’region of each variable exon was correlated with a 
lower expression level (Kawaguchi et al., 2008). The diversity of the clustered PCDH alleles 
therefore relies upon the epigenetic regulation of promoter choice and the variety of alternative 
transcripts (Toyoda et al., 2014). The de novo methyltransferase 3B is responsible for the de 
novo methylation of some of these promoters in early development ultimately regulating the 
expression of the variety of potential Pcdh isoforms in individual cells (Toyoda et al., 2014). 
Fat Body Mass Genes 
In Paper II we were able to show that upon comparison to normal chromatin patterns in hTERT 
cell lines, the clonal stable knockdown cell lines exhibited hypomethylation at regions known 
to be marked by polycomb; for example, the hypomethylated LEP, GHSR and APOC gene 
classes are heavily marked by polycomb in normal fibroblasts. We showed that the shRNA 
lines undergo gradual remethylation at most loci throughout the genome, except for the 
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polycomb-marked regions. One reason these could be protected from a remethylation event 
might be the multidomain chromosomal protein FBXL10, and its localisation at polycomb 
repressive marks.  
Furthermore, in our study we could show that inhibition of EZH2, the main enzyme responsible 
for depositing H3K27me3 marks, was sufficient to boost transcription from some of the 
polycomb-repressed and demethylated genes, suggesting that the histone marking is sufficient 
in itself to keep these genes repressed in the absence of DNA methylation. This both supports 
the idea that polycomb and DNA methylation can act independently to repress and explains in 
part why we see so little gene reactivation in the stable cell lines.  
Cancer/Testis Antigen Genes 
In addition to the PCDH and fat/bodymass genes discussed above we also identified the 
cancer/testis antigen (CTA) genes to be targets for demethylation and transcriptional 
depression. Demethylation occurred to a greater extent in the gene bodies in the DNMT1-
depleted hTERT (Paper II), and in both the promoters and gene bodies in cells treated with 
siRNA (Paper III). In particular the TSPY and MAGE genes were shown to be enriched, some 
of over 200 CTA genes, which are characterised by being expressed at the protein level in the 
human germ line and also in tumours, but nowhere else, and by having poorly understood or 
poorly-conserved function (Simpson et al., 2005; Almeida et al., 2009). The CTA genes can be 
classified into two groups- X chromosome CTA genes and autosomal CTA. Single copy CTA 
genes such as BAGE and HAGE (Gjerstorff et al., 2015) are expressed meiotically and post-
meiotically in male germ cells, with a characteristically varied expression level in cancer cells, 
even in the same tumour (Gjerstorff and Ditzel, 2012). 
Historically, the identification of tumour antigens with cytolytic capacities was conceived to 
be an avenue for developing immunotherapy approaches for cancer. Ideally the antigen would 
be consistently and stably expressed by a tumour, not expressed by somatic tissue whilst being 
essential for the cancer cell (Simpson et al., 2005).  MAGE1 (now known as melanoma-
associated antigen A1) was the first such antigen to be identified in a patient with melanoma, 
followed by MAGE2 and MAGE3. MAGE1 was also identified in further cancer cell types, 
but interestingly not in somatic tissue except testis. The chromosomal location of the MAGE 
genes showed 12 further closely related genes, with additional MAGE clusters MAGEB, and 
C downstream. MAGEA, -B and -C clusters were all identified to be expressed in cancers and 
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testis, whilst additional clusters MAGED-MAGEL were expressed in non-cancerous normal 
tissue (Chomez et al., 2001). Many CTA genes, namely those localised to the X chromosome 
are co-expressed in tumours, with multiple CTA genes being expressed. 
We showed using both small molecule and RNA inhibitor approaches that the CTA genes were 
affected by the loss of maintenance methyltransferase activity in our normal non-cancerous 
human cell line. Promoter demethylation is considered to be the main driver in the expression 
of these genes, particularly those located on the X chromosome (Simpson et al., 2005). 
Epigenetic reprogramming is central to activation of the CTA genes, previously shown using 
the same DNMT inhibitor Aza (there termed 5-aza-dC) in cancerous cell lines (Sigalotti et al., 
2002; Karpf et al., 2004). Such reprogramming occurs in two phases where both DNA 
methylation and chromatin undergo alterations- initially in gametogenesis, and then early 
embryogenesis. The CTA genes, particularly those found on the X chromosome have 
methylated CGI in normal somatic tissue that are subsequently demethylated during 
development in spermatogenesis. Following this trend, the densely methylated CGI of CTA 
promoters can be demethylated experimentally causing cells that do not typically express CTA 
genes to express them. In tumour cells, global hypomethylation events are thought to echo this 
same effect. One important line of research is to identify whether the expression of CTA genes 
is contributory to tumorigenesis or is a functionally null by-product of the chromatin 
reconfiguration of this gene class. However, quite apart from their normal function (if any), the 
CTA have proven clinical utility as targets for anti-tumour immunotherapy.  
Ultimately, treatment with e.g. 5-aza dC can increase the expression of CTA genes, making 
them more visible to the immune system. There is a continuing effort to identify novel targets 
for immunotherapy and in particular the CTA genes as they characterised in the literature to 
have to restricted expression in somatic tissue, in addition to their depression in solid epithelial 
cancers (Thomas et al., 2018). 
The MAGE proteins have a common central MAGE homology domain (MHD) identified to 
be important for protein-protein interaction (Taniura et al., 2005). Of such proteins, the SKI-
interacting protein (SKIP) binds to MAGEA1 when there is an appropriate carboxyl terminus 
available. SKIP works by connecting DNA binding proteins to additional proteins that have a 
role in the activation or conversely the repression of transcription ultimately implicating a range 
of signalling pathways such as Vitamin D and NOTCH1 (Simpson et al., 2005). MAGEA1 has 
been found to disrupt SKIP-mediated NOTCH1 through binding to SKIP and subsequently 
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recruiting HDAC. In this functionality, MAGEA1 acts as a transcriptional repressor (Laduron 
et al., 2004). However, the role of MAGEA1 in the germline has not been fully elucidated, it 
has been postulated that MAGEA1 could repress the expression of genes that are crucially 
important to normal development and differentiation. A similar functionality of the MAGE 
genes in cancer cells would be a contributory factor to tumorigenesis and a malignant 
phenotype.  
It is important to identify the CTA genes sensitive to depression in cancer cells.  Koslowski et 
al (2004) identified that most of CTA genes were activated in gametogenesis (namely 
premeiotic stages) whilst the germline genes are expressed in gametogenesis at the late meiotic 
and postmeiotic stages (Koslowski et al., 2004). Koslowski tested the induction of CTA genes 
under the influence of DNMT1 inhibitor 5-aza dC in somatic cells, where similar to the results 
in Paper II using shRNA targeted to DNMT1 that showed that 80% of CTA genes were 
expressed, unlike those of the germline genes at only 18%. Interestingly we did not investigate 
the impact on CTA genes with depleted de novo methyltransferase 3B, but Koslowski did not 
find any induced expression of the CTA genes in human colorectal cancer cell lines collected 
from individuals. Simpson et al (2005) was able to confirm that genomic hypomethylation was 
essential and adequate for the expression of the CTA genes; in particular, DNMT1 combined 
with the activity of DNMT3B is implicated in the transcriptional repression of this gene class 
in somatic cells. 
Olfactory genes are also enriched targets of hypomethylation 
Another gene class identified as having a significant loss of DNA methylation at promoters 
and gene bodies in a DNMT1 deficient cell system as represented in Paper II, and in Paper III 
are the olfactory receptor genes (OR). Whilst being largely inert as a group both shRNA and 
siRNA targeting DNMT1 showed similar effects in this gene class in the hTERT model system. 
Treatment with Aza (5-aza dC) however conversely also caused hypermethylation in some OR 
genes in this system when compared to the untreated hTERTs. 
The OR genes are the largest gene family in the mammalian genome, part of the G-protein 
coupled receptor (GPCR) hyperfamily (Glusman et al., 2001). There are two different types of 
OR- Class I and Class II- in mammals; both classes are part of the GPCR gene family. Over 
300 OR genes have been identified and are frequently found to be located in clusters making 
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up 0.1% of the human genome. This gene family are expressed, like the imprinted genes (Paper 
I and Paper IV) in a monoallelic fashion, established early in development following the 
blastula stage (Takagi and Oshimura, 1974).  
The glomeruli that form part of the neural circuit is responsible for the olfactory input to the 
brain, and this is in turn innervated by olfactory sensory neurons. The neurons in the same 
glomerulus express the same OR. Odour discrimination is more effective when each olfactory 
sensory neuron expresses one allele of an individual OR gene. To promote the expression of a 
single OR gene the mechanism of action leading to their transcription operates through 
homeobox transcription factors e.g. Lhx2, Emx2 and Ebf (McClintock, 2010). A popular 
hypothesis suggests that epigenetic control of OR gene transcription is important for the 
repressive events necessary to ensure that only a single type of OR is produced. 
The OR genes that show substantial losses of methylation as we have shown in Paper II and 
Paper III and are made up of a single exon which follow a few noncoding exons, and the TSS 
of which can be 100s-1000s bps upstream. Methylation plays a functional role in the control 
and expression of the OR genes, this and their heterochromatic state supports the inertness of 
this gene class. The silencing of OR gene expression also complements the preferential single 
OR gene expression required to silence all of the other OR gene classes. The polycomb complex 
and chromatin remodelling elements are abundantly found in immature olfactory sensory 
neurons where the ultimate OR gene choice is confirmed. The OR gene cluster has additional 
repressive histone marks e.g. H3K9me2, in addition to low levels of histone acetylation, both 
of which are associated with poor levels of transcription. 
In summary we showed that the siRNA treatment led to widespread loss of methylation across 
the genome, as did Aza, but the unique targets of Aza likely are a result of 1) the drug affecting 
DNMT3A and DNMT3B as well as DNMT1, the only target for the siRNA/shRNA; 2) other 
side-effects such as the reported effect on G9A/GLP histone methyltransferase. On the other 
hand, the more limited pattern of hypomethylation seen in the shRNA lines is almost certainly 
due to remethylation of the genome over time as the cell lines are grown out and expanded. 
Here the profile of hypomethylation reflects instead regions which are resistant to 
remethylation. 
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Methyltransferase deficient human model systems provide evidence for gains in 
methylation upon treatment with 5-aza-2'dC offering a different response than treatment 
with DNMT1 targeting siRNA 
As previously shown by this lab group, a chronic depletion of DNMT1 in particular through 
transient siRNA mediated knockdown, revealed global losses of methylation across multiple 
candidate gene targets, in particular those with a fundamental role in early development 
(Rutledge et al., 2014). However, classical approaches were not able to reveal and identify 
enriched gene classes that experienced perturbations of methylation out with the candidate 
genes. With the introduction of microarrays such as the Illumina BeadChip 450k array and 
subsequent gene ontology, analyses of alternative DNA methylation profiles were revealed on 
a genome wide basis (Figure 2).  
166 
Figure 2- Pipeline Methylation Analysis using both wet-lab and bioinformatic techniques. The 
methodology presented in Papers I, II and III in this thesis all utilise part or all of this methylation 
pipeline. The mESCs in Thakur et al. (2016) are unsuitable for use in 450k BeadChip arrays but in-
house selective CG methylation profiling was carried out on a smaller scale with the use of 
pyrosequencing. Despite the human and mouse samples segregating with respect to their sequencing 
platform, the common outputs could be presented in multiple common bioinformatic interfaces for 
interpretation. 
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The application of such next-generation approaches revealed that DNMT1-targeting siRNA 
and shRNA-treated hTERTS cells do lose methylation globally as predicted, and for the 
siRNA-treated cells particularly at gene bodies; but uniquely only a stably mediated 
knockdown of DNMT1 using shRNA in hTERTS showed gains in methylation (Paper II). This 
pattern of hypermethylation was echoed in the pharmacologically depleted hTERT cell lines 
treated with Aza (Paper III) despite previous evidence concentrating on the widespread 
demethylating effects of Aza by us and others. The phenomenon of hypermethylation, namely 
of CG dense promoter regions has been frequently associated with the silencing of tumour 
suppressor genes in tumorigenesis or the aberrant methylation of genes fundamental to the 
regulation of DNA repair (Ehrlich, 2002; Timp and Feinberg, 2013). However, we observed 
hypermethylation of multiple gene classes in non-tumorigenic de novo methyltransferase 
depleted cells lines- that is in human normosomic lung fibroblast cell lines and mouse ESCs. 
It could be assumed that such hypermethylation is a consequence of survival in a cultured 
micro-environment against hypomethylation.  
To help solve this riddle, and to establish if short-term depletion of DNMT1 could also lead to 
gains in methylation, we examined the effects of transient or acute DNMT1 depletion in our 
hTERT cells by exposing the cells to siRNA against DNMT1 for 48-72hrs, then analysing the 
methylation state using the 450k array as before (Paper II and III). In these cells we saw little 
or no gains in methylation (Figure 3), indicating that gains are not a short-term response to 
depletion.  
Figure 3: Commonly hypermethylated genes. Genes gaining methylation that are common to all of 
the DNMT shRNA lines (d8, d10 and d16) from Paper II compared to the common hypermethylated 
genes of all the DNMT1 siRNA treated hTERTs from Paper III. 
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Instead, the cells showed more widespread demethylation across the genome, including 1) in 
regions where little demethylation is seen in the stable (shRNA) lines and 2) regions where the 
shRNA lines show gains. These results were very telling, since this indicates that the most 
likely sequence of events in the derivation of the stable shRNA lines is that the cells initially 
lose methylation everywhere, but during selection for the stable integrants and outgrowth, 
many areas become remethylated back to a normal level of methylation, and so show no 
significant difference from WT in the shRNA lines when analysed. The “hit-and-run” 
experiment described in Paper II provides solid support for this idea, since we saw initial loss 
of methylation followed by slow but steady remethylation at many genes. Regions which show 
gains in the shRNA lines are therefore likely to be the result of “overshoot” where de novo 
methylation during the outgrowth phase does not stop when the normal level of methylation is 
reached, and instead accumulates to a higher level, a good example being the UGT1 gene 
cluster. Again, we could show experimentally that a gene at the UGT1 locus initially lost 
methylation, then regained normal levels, before overshooting to a hypermethylated state in 
the “hit-and-run” experiment. We went further and looked to see what properties such regions 
have and found that the regions becoming hypermethylated are more likely to be poised 
promoters (Figure 4). We summarised our understanding of these processes in the model at the 
end of Paper II. Given these insights, it is tempting to speculate that the cells treated with the 
small molecule inhibitor may also be undergoing such a process, with an initial demethylation 
followed by a rapid overshoot at some genes. However, in order to prove this we would need 
to set up a repeat experiment where we expose cells to the agent then take samples at timed 
intervals following exposure. Examination of the methylation levels at genes which were 
identified as hypermethylated in the initial study could then establish, using this timecourse, if 
they are initially demethylated before subsequent recovery and then overshoot.  
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Figure 4- Median methylation values for weak and poised promoter categories, and comparing 
shRNA lines to WT. Cohen’s D test revealed that the median methylation value (β) value for poised 
promoters is 0.2β higher than that of the weak promoters when shRNA lines were compared to WT. 
Gains in methylation at the gene classes identified in Paper III in Aza treated hTERTs e.g. 
GPCRs could be significant in the treatment avenues of AML sufferers. GPCR methylation 
gains could contribute to the relapse in AML sufferers as key TSGs could be silenced. GPCRs 
are known to act as oncogenes and tumour suppressors through their regulation of oncogenic 
signalling networks. GPCRs may also be a suitable therapeutic target- MAS1 was 
hypermethylated, on oncogene involved in leukaemia, and USP33/PARD3 are both TSGs in 
lung cancer, and lung squamous cell carcinoma. However recent literature re-addresses the role 
DNA methylation plays in sensitising or priming e.g. AML sufferers to subsequent therapies 
following Aza treatment. As an alternative to hTERTs, Vispe (2015) used leukaemic cell line 
KG1 treated with Aza to ascertain the global methylation changes and concluded that DNA 
damage mechanisms are distinct from DNA methylation in the treated cells (Vispe et al., 2015). 
Furthermore, 450k analysis of the treated KG1 cells also exhibited distinct hypermethylation 
as we did in Paper II and III supporting the role of Aza in DNA hypermethylation. 
Despite the observation of hypermethylation in DNMT1 depleted cell lines- both normosomic 
and cancerous -through treatment with Aza, the success of such treatment for sensitising 
patients to downstream therapeutic treatment might not lie in the effects of methylation of 
tumour suppressor or other such tumorigenic genes. Recently, two research groups have been 
able to refine the response of Aza and its anti-tumour activity (Roulois et al., 2015; Chiappinelli 
et al., 2015). The research from these two groups successfully elucidated that a low dose 
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treatment of a demethylating agent such as Aza (almost 10-fold lower than we used) primes 
the immune system by stimulating the activation of ERVs and launching an anti-viral response. 
This viral response might be implicated in the induction of tumour antigen expression and the 
alteration of cell signalling pathways and/or apoptotic thresholds. However, the exact 
downstream pathway of how Aza treatment impacts myeloid malignancy is yet to be fully 
elucidated. In our study we used one higher dose Aza limited to only one cell line which may 
have masked such effects and offered a different enriched gene ontology landscape. Merit still 
exists however in the approach we have undertaken as previous work from our lab (Rutledge 
et al., 2014) using this dosage highlighted similar gene classes. Further studies in our hTERT 
system would be warranted, using different doses and timings for Aza treatment as indicated 
above and a more comprehensive sequencing approach such as WGBS, to see if this viral 
immune response occurs in normal cells as well as cancer cell lines.  
Alternatively, treatment with Aza in combination with a HDAC inhibitor such as valproic acid 
has also shown success. Histone involvement is not to be overlooked in the phenomenon of 
DNA hypermethylation presented in Paper II and III. Histones were identified as an enriched 
hypermethylated gene class in both papers.  
UGT Genes were also observed to experience gains in methylation in hTERTs 
The issue remains as to why there are gene classes more susceptible to hypermethylation than 
others. One theory is, as indicated above, that such genes exhibiting regions of 
hypermethylation e.g. UGT1A (Paper II) have poised promoters which is rendering them 
susceptible. Such promoters are frequently found in developmentally important genes (e.g. 
those on the X chromosome and in the germ line) and frequently have chromatin configured in 
a bivalent manner with high levels of repressive H3K4me3 and/or H3K27me3.  
The UGT1A genes, though not normally considered bivalent and despite their already high 
methylation levels, had further increased methylation in the stable cell lines, and showed small 
but consistent decreases on the HT12 array. Perhaps marks associated with recent inactivation 
of the UGT1A cluster in fibroblasts during adaptation to cell culture led to increased de novo 
activity, and are therefore showing the highest gains in methylation. 
The UGTs (UDP-glucuronosyltransferase) as a gene class belong to a superfamily of many 
isoforms who all share a role in metabolic activity, responsible for 35% of all phase II metabolic 
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reactions (Yang et al., 2017) and are as such a crucial gene class in pharmacogenetics 
(Barbarino et al., 2014). The UGT1A locus encodes nine isoforms through an exon sharing 
mechanism (Figure 5). This involves the transcripts of the first exon cassette being spliced to 
exons 2-5 consequentially expressing individual UGT isoforms in a tissue and age specific 
manner (Habano et al., 2015). The variety of UGT isoforms also has a pivotal role in the 
pathogenesis of neonatal jaundice, Gilbert’s syndrome and Criglerr-Najjar syndrome which are 
all closely related to a deficiency of UGT1A1, typically expressed in the liver (Bartlett and 
Gourley, 2011). 
These properties make the transcription of the UGT isoforms important for drug efficacy and 
determine adverse effects to drug treatment. It has been postulated that epigenetic mechanisms 
e.g. DNA methylation have an effect upon the regulation of this locus and as such the response
to drug therapy as has been shown previously in colorectal cancer cells treated with alternative 
DMEs (drug metabolising enzymes) (Habano et al., 2009; Belanger et al., 2010). As a gene 
class the UGTs have been documented in cancerous cell lines to be hypermethylated. 
Irinotecan is used clinically to treat colorectal cancer, particularly in metastatic cases 
(Cunningham et al., 2001; Gagnon et al., 2006), the active metabolite of this treatment is SNF2 
ultimately mediated through UGT (Gagne et al., 2002). The UGT1A gene encodes an enzyme 
which is responsible for catalysing conjugation reactions with glucuronic acid, and changes to 
this gene arising through polymorphisms or exon sharing are important for affecting toxicity 
and clinical outcome in patients treated with Irinotecan. In this instance Gagne et al. (2002) 
were able to show that DNA methylation is responsible for the repression of UGT1A1 
expression in colon cancer cells. The downstream effect of hypermethylation of this gene has 
been associated with levels of the anticancer agent SN-38 within the tumorigenic cells, 
inactivating it which can ultimately influence clinical response to Irinotecan treatment (Gagne 
et al., 2002). 
It may well be that the hypermethylation in the Aza-treated samples reflects a similar “bounce” 
or recovery following demethylation, in this case due to Aza, but in Paper II from the outgrowth 
of the shRNA-containing clones. We know that the hTERT cells (used in both studies) contain 
at least the DNMT3B de novo methyltransferase so can add methyl groups to naked DNA. It 
is unclear whether DNMT3A plays a role too: some DNMT3A transcript was detected by array 
in the cells, but we have not tested for functionality by DNMT3A-specific knockdown. 
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Figure 5: Schematic of the human UGT1A locus (not to scale). This gene locus is responsible for 
the transcription of nine UGT1 enzymes. The locus spanning a region of 200kb contains numerous 
alternative first exons with their own promoters to make up exon 1. The individual exons for the 
respective isoforms are combined with the common exons (2-5 shown in grey) by splicing out the 
intervening sequences. The alternatively spliced isoforms of UGT1A are known as UGT1As_i2 and are 
created when exon 5b is used, either with or instead of exon 5a. Image reused from Barbarino et al., 
2014. 
A number of known and putative imprinted gene loci mESCs are capable of recovery 
where methylation has been lost 
We have identified a model system depleted in the de novo methyltransferases that experiences 
methylation levels that are higher than WT values. A recovery in methylation to WT levels is 
observed upon rescue with a common isoform of the de novo methyltransferase DNMT3A.  
In the same mESCs models the de novo methyltransferases Dnmt3a/3b have a role in the 
maintenance of methylation in the mESCs 
Paper 1 showed that a loss of DNMT1, and a loss of DNMT3A/B had equivalent effects on 
methylation levels at delineated imprinted regions in mouse ESCs with both methyltransferases 
exhibiting some activity of methylation maintenance at the imprints assayed, but that only 
rescue with DNMT3A2 provided restoration of methylation at selected imprints. Whilst we 
hoped to identify the correct isoform of DNMT3B responsible for the recovery of methylation 
in imprints such as Rasgfr1 and Igf2r we were not able to delineate which domain of the e.g. 
DNMT3A2 was most active in this process. We postulated that perhaps the PWWP domain 
was most actively involved due to its known association with H3K36me3 (Ge et al., 2004). 
Since the completion of this thesis further work in the lab has attempted to investigate this 
relationship by rescuing the 3ab KO cells with five different point mutations (as shown in Table 
5) to determine which of the DNMT3A domains are crucial for the rescue of DNA methylation.
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Table 1: Mutated plasmids received from a collaborating lab with point mutations in DNMT3A. 
The point mutations in de novo methyltransferase 3A will allow us to determine which of its multiple 
domains are important for the recovery of DNA methylation if in the methylation depleted system 3ab 
KO cells (Paper 1). 
The imprints investigated in Paper I were limited to a mouse ESCs model system, however in 
the hTERT-1604 treated with DNMT1 targeting shRNA cell lines used in Paper II it has since 
been identified in the lab that there is a loss of imprinting at loci including H19, SNRPN, 
KvDMR, and GRB10. These have been identified through mining of the user defined tracks for 
these human cell lines at the co-ordinates delineated for the gDMRS of these imprinted genes 
(Court et al., 2014; Woodfine et al., 2011) using both UCSC genome browser and the Galaxy 
Bioinformatics user interface. This approach could allow for the identification of clinically 
relevant imprinted gDMRs that are sensitive to a transient loss of DNA methylation in human 
differentiated cells. Preliminary data from the lab has already shown that there are novel gains 
in methylation at specific regulatory regions of imprinted loci in the d10 and d16 cell lines 
(Paper 1 when mapped against published co-ordinates for imprinted loci in Court et al., 2014) 
e.g. a gain of methylation has been observed at a secondary DMR at the upstream promoter of
the locus involved in Silver-Russell syndrome which was particularly sensitive to the loss of 
DNA methylation. Developing new pyrosequencing assays for this novel secondary DMR and 
others like it at additional imprint DMRs could further inform diagnosis for this and other 
imprinting disorders, as existing tests may not be entirely accurate. The identification of such 
epigenomic signatures could be used to develop early intervention strategies for affected 
children.   
Plasmids with Point Mutations 
Glutamine 304 to Alanine 
Aspartic Acid 308 to Alanine 
Methionine 325 to Tryptophan 
Glutamic Acid 533 to Alanine 
Arginine 580 to Alanine 
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It would be fitting to investigate why the imprints in Paper I do recover by determining which 
chromatin marks are associated with imprinted regions and whether or not this correlates with 
the ability of these imprints to recover DNA methylation in a methylation depleted system. 
Through alteration of these chromatin modifications and/or histone marks through e.g. Epi-
CRISPR (Vojta et al., 2016) we could identify if these would prevent recovery in these cell 
lines, or in fact have no effect at all on recovery. Recovery could be instigated in the Dnmt3a2-
rescued cells by their ability to ‘remember’ that the maternal copy of e.g. Snrpn must be 
methylated. Conversely when Dnmt1 was stably depleted in the mouse ESCs, this may have 
resulted in the indirect loss of the H3K9me3 repressive histone mark from the known germline 
imprints such as Snrpn and it may be this loss that could be preventing the ESCs from 
remembering that methylation must be placed on the maternal allele. If this hypothesis about 
the importance of the presence of histone marks at imprinted loci proves to be correct this 
mouse model system may help us to understand the conditions which are required for imprint 
establishment in other mammalian species such as human. 
A paper published by the Stancheva group in 2016 (Zhang et al., 2016) aimed to identify a 
mechanism responsible for the imprints and discover why some imprints are capable of 
regaining methylation whilst others are unable to; and investigate the histone marks associated 
with imprinted regions to examine whether or not they were essential for the stable 
maintenance of genomic imprint in a ESC model system. Zhang et al. (2016) concentrated 
much of their efforts on the G9a/GLP complex, a knockdown of which reduced DNA 
methylation at maternally and paternally methylated ICRs in mouse ESCs. This complex was 
required to stabilise imprinted DNA methylation in the ESCs through DNMT1 recruitment. In 
turn, this has the effect of counteracting TET dioxygenase-dependent demethylation pathways. 
Furthermore, the G9a/GLP complex was observed to stabilise imprinting by the recruitment of 
de novo DNA methyltransferases to ICRs of the ESCs, in turn antagonising TET recruitment 
at these regions. 
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Conclusion 
Through the use of both bioinformatic and wet-lab experimental approaches, gene classes 
sensitive to a transient loss of methylation have been identified in methyltransferase depleted 
human hTERTs and mouse ESCs. We have provided evidence for the i) recovery of 
methylation in putative imprinted regions; ii) maintenance activity of Dnmt3a/b in mouse ESCs 
iii) identification of the loci most sensitive to a stable loss of maintenance methylation and their
interaction with polycomb marks and; iv) the novel discovery of gains in methylation of genes 
following the 5-aza-dC treatment of hTERTS. It is evident from the data presented in this thesis 
that DNA methylation plays a clear role in the regulation and control of a range of gene classes 
in mouse and human systems. 
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Achievements  
Published Abstracts 
1. Mackin, S.J., Walsh, C.P. (2015) Differential responses of clinically important gene
classes to transient loss of DNA methylation in human differentiated cells. Ulster Medical 
Journal 84(3): 200 2014. 
2. Mackin, S.J., O’Neill, K.M., Irwin, R.E., Walsh, C.P. (2016) Identifying clinically
relevant imprinted gDMRs sensitive to a transient loss of DNA methylation in human 
differentiated cells. Ulster Medical Journal 86(1): 55-68. 
3. Mackin, S.J., O’Neill, K.M., Walsh, C.P. (Pending Date) Comparison of DNMT1
inhibitors by methylome profiling identifies unique epigenetic signature of Dacogen. Ulster 
Medical Journal. 
4. Thakur, A., Mackin, S.J., R.E. Irwin., O’Neill, K.M., Pollin, G., Walsh, C.P (Pending
date) Widespread recovery of methylation at gametic imprints in hypomethylated mouse stem 
cells following rescue with DNMT3A2. Ulster Medical Journal. 
5. O’Neill, K.M., R.E. Irwin, Mackin, S.J., Thakur, A., Thursby, SJ., Bertens, C., Masala,
L., Loughery, J., McArt, D., Walsh, C.P (Pending date) Depletion of DNMT1 in differentiated 
human cells highlights key classes of independent genes. Ulster Medical Journal. 
Additional Research Training 
22/09/2014 Effective Researcher: Let's Get Started with your Doctorate. 
23/09/2014 An Introduction to Strategic Career Planning Workshop.  
23/09/2014 Optimising Your Professional Development. 
24/09/2014 Planning your Research.  
08/10/2014 Workplace Experience/Learning: Presentation of a Research Paper at Journal 
Club of the Genomic Medicine Research Group. 
10/10/2014 Developing Information Skills for Effective Research (Life and Health 
Sciences).  
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13/10/2014 Introduction to Refworks v2 Tutorial. 
16/10/2014 Workplace Experience/Learning: Introduction to the Sanger Sequencing 
Protocol and Analysing Sequencing Results from ABI Prism. 
16/10/2014 Introduction to Learning and Teaching for Postgraduate Tutors and 
Demonstrators. 
17/11/2014 Workplace Experience/Learning: Introduction to Pyrosequencing and Using 
Pyromark Q24 Assay Design Software. 
12/12/2014 Workplace Experience/Learning: Galaxy 101 Tutorial. 
22/12/2014 Completion of the Research Integrity Ulster University Online Course. 
01/01/2015 Demonstrator for Medical Cell Biology (BMS104) (January-April 2015). 
17/02/2015 Workplace Experience/Learning: Illumina Biobanking Interactive Webinar. 
11/03/2015 Workplace Experience/Learning: Health & Safety Induction in Gut and Blood 
Lab. 
23/03/2015 Effective Researcher: Let's Carry on with your Doctorate. 
25/03/2015 Strategically Planning your Career. 
27/03/2015 Workplace Experience/Learning: Introduction to DAVID Bioinformatic 
Analysis. 
22/04/2015 Workplace Experience/Learning: Research and Consent under the Human 
Tissue Act Training. 
07/05/2015 Work-place experience/learning: Journal Club presentation on the non-germline 
restoration of genomic imprinting. 
08/05/2015 Holding Pyrosequencing Tutorials - for undergraduate students ahead of final 
year research projects. 
20/06/2015 Soapbox Science Volunteer: Women in Science, Belfast. 
23/07/2015 Effective Researcher: 2nd Year Doctoral Skills. 
18/08/2015 Athena Swan Focus Group meeting on ‘Women in Media.’ 
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04/09/2015 Poster presentation at Irish Society of Human Genetics, DCU, Dublin. 
01/10/2015 Demonstrator for Introductory Chemistry (BMS105) (Oct-December 2015). 
01/10/2015 Roche LC480 Training workshop. 
28/10/2015 Webinar from the UK Data Service 'Data Sources for Research Students.' 
18/11/2015 Adding Value to your Doctoral Training. 
23/11/2015 Workshop at Newcastle University on Bioconductor/RStudio: Microarray 
analysis (4 days). 
10/12/2015 LC480 Training workshop: Part Two held by Roche at Ulster University. 
13/01/2016 Presenting a Bioconductor Workshop Report at the Genomic Medicine 
Research Group lab meeting. 
02/02/2016 Presentation and Focus group leader at a Women in Careers evening at Our 
Lady's Grammar School. Newry. 
05/04/2016 Workshop on R- Advanced Graphics and Programming at Newcastle University 
(4 days). 
21/05/2016 Athena Swan Focus Group Meeting of Female PhD researchers. 
27/05/2016 Oral Presentation at "Shaping Healthier Communities" Conference, Ulster 
University (Coleraine). 
03/06/2016 Attendance at Illumina 450K Methylation Workshop, London. 
22/06/2016 Attendance at a Presentation led by Exiqon on Exosomal Micro RNAs as 
Biomarkers for Prostate Cancer  
25/06/2016 Step up to Science Demonstrator at Ulster University for local schools. 
02/09/2016 Poster Presentation for the "Dolly at 20" Symposium at the Roslin Institute, 
University of Edinburgh. 
09/09/2016 Oral Presentation at Irish Society of Human Genetics Autumn Meeting, City 
Hospital Belfast. 
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21/09/2016 Webinar on the Pipeline Analysis of Methylation Array data in a longitudinal 
study. 
22/09/2016 Published Abstract in Ulster Medical Journal - January 2017.  
22/09/2016 Published Abstract in Ulster Medical Journal - September 2015. 
28/10/2016 An Oral Presentation at 7th C-TRIC Annual Translational Medicine 
Conference, Londonderry.  
09/02/2017 What can you do with a PhD? A Workshop on Planning a Career Outside of 
Academia Workshop. 
27/07/2017 Registered as a STEM ambassador with W5 for Northern Ireland. 
Certificates 
Certified Training from School of Mathematics and Statistics, University of Newcastle (UK) 
for Statistical Modelling, Programming with R, Efficient R Programming, Advanced Graphics 
and Bioconductor. 
Successful certified completion of the CPPD module ‘Introduction to Statistical Programming’ 
Ulster University (2016). 
Conference Presentations 
Oral Presentations 
• 7th Annual Translational Medicine (TMED7) Conference, L/Derry, Northern Ireland-
Big Data and Data Analytics in Precision Medicine (Oct 2015). 
• 19th Irish Society of Human Genetics Annual Scientific Meeting, City Hospital Belfast,
Northern Ireland- Identifying clinically relevant imprinted gDMRs sensitive to a transient loss 
of DNA methylation in human differentiated cells (Sept 2016). 
• Cancer Translational Research Group (CTRG) Annual Symposium, QUB, Northern
Ireland- Does the Acute Myeloid Leukaemia treatment Dacogen act primarily through 
interfering with the enzyme DNA methyltransferase 1? (Oct 2016). 
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• Faculty of Life and Health Sciences Postgraduate Research Conference, Ulster
University, Coleraine- Shaping Healthier Communities. Identifying known and putative 
imprints responsive to restoration of methylation in rescued mouse embryonic stem cells, (May 
2016). 
Poster Presentation 
• 18th Irish Society of Human Genetics Annual Scientific Meeting, DCU, Dublin,
Ireland. Differential responses of clinically important gene classes to transient loss of DNA 
methylation in human differentiated cells. Mackin, S.J., O’Neill, K.M., Walsh, C.P, (Sept 
2015).  
• Coming of Age: The Legacy of Dolly at 20 Symposium, Roslin Institute Edinburgh.
Widespread recovery of methylation at gametic imprints in hypomethylated cells following 
rescue with DNMT3A2. Thakur, A., Mackin, S.J, Irwin, R.E., O’Neill, K.M., Pollin, G., 
Walsh, C.P. (Sept 2016). 
• 50th Anniversary European Society of Human Genetics, Copenhagen, Denmark.
Widespread recovery of methylation at gametic imprints in hypomethylated mouse stem cells 
following rescue with DNMT3A2 Thakur, A., Mackin, S.J, Irwin, R.E., O’Neill, K.M., Pollin, 
G., Walsh, C.P. (May 2017). 
• 19th Irish Society of Human Genetics Annual Scientific Meeting, Croke Park, Dublin,
Ireland. Comparison of DNMT1 inhibitors by methylome profiling identifies unique epigenetic 
signature of Dacogen. Mackin, S.J, Thakur, A., Walsh, C.P (September 2017). 
Grants 
Training Grant from the Genetics Society (UK) £958.47 
Travel Grant from the Genetics Society (UK) £723.58 
Travel Grant from the Irish Society of Human Genetics €600.00 
Awards  
Young Investigator Award for Best Postgraduate Oral at 19th Annual Scientific Meeting of the 
Irish Society of Human Genetics (2016). 
